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Abstract
Wiskott-Aldrich Syndrome (WAS) is a rare X-linked recessive primary 
immunodeficiency characterised by eczema, thrombocytopaenia and 
immunodeficiency. WAS encodes for a haematopoietic restricted protein, WASp, 
involved in transduction of signals from the cell membrane to the actin cytoskeleton. 
Mutations lead to impaired actin dynamics in response to stimuli and are seen as 
defects of receptor capping, chemotaxis, phagocytosis and proliferation. This leads to 
susceptibility to pyogenic, viral and opportunistic infections and increased incidence of 
lymphoproliferative disease and malignancy. Due to the high morbidity and mortality 
associated with mismatched transplantation, WAS is considered a good target for gene 
therapy. We were able to reconstitute a murine model of WAS using a gamma 
retroviral vector, with reconstitution of specialised actin structures, podosomes, as a 
functional readout. Reservations concerning the safety of such vectors, following 
adverse events in a clinical trial, led to the development of third generation self- 
inactivating lentiviral vectors. Under the promotion of CMV, SFFV LTR or short 
sequences of the proximal endogenous Wiskott-promoter, WASp was able to restore 
cytoskeletal abnormalities in dendritic cells in-vitro from WASp-deficient mice. In 
addition we have demonstrated stable expression of WASp in T cell, B cell and 
myeloid lineages following transduction and engraftment of lineage negative murine 
bone marrow (up to 9 months) using both an SFFV LTR and endogenous promoter 
sequences. We have demonstrated the ability to restore cytoskeletal abnormalities and 
proliferative responses from the reconstituted mice. Recently a novel mutation in WAS 
has led to the discovery of a constitutively active WASp, with a novel monocytopaenic 
and neutropaenic phenotype. Here we characterised the patient phenotype of a novel 
constitutively active WASp12941 mutant. In addition to monocytopaenia and 
neutropaenia, there was abnormal cytoskeletal actin, manifesting itself as abnormal 
podosome distribution and an inability to phagocytose or produce an oxidative burst to 
physiological stimuli. There was also increased apoptosis in the bone marrow and 
evidence of genomic instability. Utilising lentiviral vectors, WASpI294T was expressed 
in a cell line to elucidate the possible mechanisms responsible for the patient 
phenotype. These studies demonstrate the efficacy and feasibility of a lentiviral vector- 
mediated gene therapy strategy for WAS using endogenous promoters where a more 
regulated expression level may be achieved.
2
Acknowledgements
I would like to thank the people who have helped me in the completion of this work. 
Firstly my supervisors Adrian Thrasher and Christine Kinnon without whose support 
over the years would have made this impossible. There have been many members of 
the Molecular Immunology Unit past and present who have helped with time, 
discussion, helpful advice, reagents and as drinking partners. There have been many 
over the years but I would like to name Ste, Kate, Doug, Ajay in particular with a 
special mention to Jo for her help (and patience) with the FACS.
I would also like to thank the western lab staff and their help with the in vivo work.
A big thankyou must also go to Anne Galy and Sabine Charrier at Genethon for their 
viral preps and primers as well as useful discussion and Phil Ancliff who supplied the 
patient.
Finally a special thankyou goes to Susie who has had to put up with me whilst writing 
this thesis providing encouragement all the time.
3
Publications
Bums,S., Thrasher,A.J., Blundell JM.P.. Machesky,L., and Jones,G.E. (2001). 
Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, 
and differentiation. Blood 98, 1142-1149.
Jones,G.E., Zicha,D., Dunn,G.A., BlundelKM.. and Thrasher,A. (2002). 
Restoration of podosomes and chemotaxis in Wiskott-Aldrich syndrome macrophages 
following induced expression of WASp. Int. J. Biochem. Cell Biol. 34, 806-815.
Calle,Y., Jones,G.E., Jagger,C., Fuller,K., Blundell.M.P,. Chow,J., Chambers,T., and 
Thrasher,A.J. (2004). WASp deficiency in mice results in failure to form osteoclast 
sealing zones and defects in bone resorption. Blood 103, 3552-3561.
Martin,F., Toscano,M.G., BlundelKM.. Frecha,C., Srivastava,G.K., Santamaria,M., 
Thrasher,A.J., and Molina,I.J. (2005). Lentiviral vectors transcriptionally targeted to 
hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther. 12, 715- 
723.
Ancliff PJ, Blundell MP. Cory GO, Calle Y, Worth A, Kempski H, Bums S, Jones GE, 
Sinclair J, Kinnon C, Hann IM, Gale RE, Linch DC, Thrasher AJ.
Two novel activating mutations in the Wiskott-Aldrich Syndrome protein resulting in 
congenital neutropenia. Blood. 2006 Jun 27; [Epub ahead of print]
4
Table of Contents
Page number
Abstract 2
Acknowledgements 3
Publications 4
Table of Contents 5
List of figures and tables 14
Abbreviations 18
Chapter 1: 20
1 General Introduction 21
1.1 Description of disease 21
1.2 Genetics of WAS 22
1.2.1 Mutations 22
1.2.2 X Inactivation 23
1.2.3 Female WAS 23
1.2.4 Somatic Mosaicism 24
1.3 Domain structure 25
1.3.1 WH1 domain 27
1.3.2 GTPase domain 27
1.3.3 Proline rich domain 28
1.3.4 Carboxy domain 30
1.4 WASp family members 31
1.4.1 N-WASp 31
1.4.2 Scar/WAVE 32
1.4.3 Bee/1 p 33
1.5 Cellular defects 33
1.5.1 T cells 33
1.5.2 B cells 35
1.5.3 NK cells 35
1.5.4 Platelets 36
1.5.5 Myeloid cells 36
1.5.5.1 Chemotaxis 37
1.5.5.2 Phagocytosis 40
1.6 Murine models 42
1.7 Treatments 43
1.8 Stem cells 45
1.8.1 Human stem cells 45
1.8.2 Murine Stem cells 46
1.8.3 Gene transfer into HSC 48
1.9 Gene therapy 49
1.9.1 Viral vectors 50
1.9.2 Requirements for stem cell gene therapy 52
1.9.3 Retroviruses 53
1.9.4 Retrovirus life cycle 53
1.9.5 Principles of vector design 55
1.9.6 Packaging cell lines 56
1.9.7 Limitations of HSC and retroviruses 59
1.9.8 Lentiviruses 59
1.9.9 Development of lentiviral vectors 64
6
1.10 Regulation of gene expression 66
1.11 Aims of the project 68
Chapter 2: Materials and Methods 70
2.1 Cell culture 71
2.1.1 Cell lines 71
2.1.2 Human peripheral blood macrophages 71
2.1.3 Murine dendritic cells 72
2.1.4 Murine stem cells 72
2.2 Immunostaining 73
2.2.1 Human dendritic cells, macrophages and murine
dendritic cells 73
2.2.2 Adherant cell lines 74
2.2.3 Reconstituted mice 74
2.2.4 Cell cycle analysis 74
2.2.5 Apoptosis and cell death 75
2.3 Virus production 75
2.3.1 Amphotropic and ecotropic retrovirus 75
2.3.2 Lentivirus 76
2.4 Viral infection of cells 76
2.4.1 Retrovirus titering 76
2.4.2 Infectious titering of lentivirus 76
2.4.3 Titering of lentivirus by quantitative PCR 76
2.4.3.1 Purification of DNA 77
2.4.3.2 Creation of standard curves 77
7
2.4.4 Titering by p24 ELISA 78
2.4.5 Infection of cell lines 79
2.4.6 Infection of dendritic cells and macrophages 79
2.4.7 Retroviral infection of murine HSC 79
2.4.8 Lentiviral infection of murine HSC 80
2.5 Cloning 80
2.5.1 Digests 80
2.5.2 Blunting 80
2.5.3 Cleaning 80
2.5.4 Dephosphorylating 81
2.5.5 Gels 81
2.5.6 Ligation 81
2.5.7 Bacteria 81
2.5.8 T ransformation 82
2.5.9 Mini-preps 82
2.5.10 Mega-preps 82
2.6 Western 83
2.7 Quantitative PCR 84
2.7.1 Copy number 84
2.7.2 RNA expression levels 84
2.7.2.1 RNA extraction 84
2.12.2 DNA from RNA 85
2.1.23 Expression analysis 85
2.8 T cell Proliferation assay 85
2.9 Granulocyte function assays 86
8
2.9.1 E.Coli phagocytosis 86
2.9.2 Oxidative burst 86
2.9.3 FACS 87
2.9.4 Apoptosis 87
Chapter 3: Oncoretroviral Gene therapy for Wiskott-Aldrich
Syndrome 89
3.1 Introduction 90
3.2 Results 91
3.2.1 Cloning of an EGFP-WASp fusion protein 91
3.2.1.1 Transient transfection of COS-7 cells 92
3.2.1.2 Confirmation of fusion protein expression 93
3.2.2 Transient transfection of human dendritic cells 94
3.2.3 Generation of oncoretroviral cDNA contructs 96
3.2.3.1 Subcloning EGFP-WASp into pBluescript 96
3.2.3.2 Cloning EGFP-WASp into a retrovirus 
backbone 96
3.2.3.3 Production of high titer retrovirus 97
3.2.4 Reconstitution of WAS KO murine model 99
3.2.4.1 Transduction efficiency after reconstitution 102
3.2.4.2 Analysis of phenotypic recovery 104
3.2.4.3 Quality of WASp reconstitution 106
3.3 Discussion 109
Chapter 4: In Vitro Development of Lentiviral vectors 116
9
117
118
118
119
120
124
125
126
128
131
133
136
139
141
145
146
146
10
Introduction
Results
4.2.1 Cloning lentiviral vectors containing viral promoters
4.2.1.1 Transduction of 3T3 cells
4.2.1.2 Restoration of podosomes in WAS KO 
dendritic cells in vitro
4.2.1.3 Quality of reconstitution
4.2.2 Cloning lentiviral vectors containing putative 
endogenous Wiskott promoter sequences
4.2.2.1 Titering lentiviral vectors containing 
endogenous promoter sequences and WASp
4.2.2.2 Reconstitution of podosomes using vectors 
containing an endogenous promoter
4.2.3 Inclusion of the WPRE
4.2.3.1 Quality of reconstitution
4.2.4 Infection of human peripheral blood macrophages 
derived from WAS null patients
4.2.4.1 Quality of podosome reconstitution 
Discussion
Reconstitution of murine model of WAS using
lentiviral vectors
Introduction
Results
5.2.1 Reconstitution of WAS KO model using CMV and
SFFV vectors 146
5.2.1.1 Transduction efficiency of lineage negative
stem cells 148
5.2.1.2 Bone marrow reconstitution levels 149
5.2.1.3 Secondary lymphoid organ reconstitution
levels 150
5.2.1.4 Lineage analysis 151
5.2.1.5 Peripheral Blood 152
5.2.1.6 Spleen 152
5.2.1.7 Reconstitution of podosomes 154
5.2.1.8 Integrated viral copy number and human
WASp expression levels 156
5.2.1.8.1 Copy number 156
5.2.1.8.2 Expression levels 157
5.2.1.9 T cell proliferation assay 158
5.2.2 Reconstitution of WAS KO model using endogenous
promoters 159
5.2.2.1 Immunoblot of spleen lysate from transduced
mice 160
5.2.2.2 Podosome recovery in murine dendritic cells 161
5.2.2.3 Integrated viral copy number and human
WAS expression levels 164
5.2.2.3.1 Copy number 164
5.2.2.3.2 Expression levels 165
5.2.2.4 T cell proliferation assay 166
11
5.3 Discussion 167
Chapter6: Discovery of a novel activating mutation in WAS resulting
in congenital neutropaenia 173
6.1 Introduction 174
6.1.1 Discovery of an activating mutation in WASp 174
6.2 Results 175
6.2.1 Characterisation of patient 175
6.2.1.1 Macrophage morphology 175
6.2.1.2 Granulocyte phagocytosis in WASp12941 patient 179
6.2.1.3 Oxidative burst in WASp12947 patient 179
6.2.1.4 Viability of haematopoietic cells 181
6.2.1.4.1 CH-11 mediated apoptosis levels in
peripheral blood 181
6.2.1.4.2 Spontaneos apoptosis levels in
whole bone marrow 182
6.2.2 Generation of Lentivirus encoding EGFP-WASp12947 183
6.2.2.1 Infection of Bac-1 macrophages with lentiviral 
vectors 185
6.2.2.2Viability of HT1080 cells is diminished 187
6.2.3 Cloning of VCA-domain deleted lentiviral contructs 189
6.2.3.1 Viability of VCA-domain mutant transduced
cells is maintained 191
6.2.4 Cloning of lentiviral vectors containing an SFFV 
internal promoter 194
12
6.2.4.1 Viability of HT1080 cells after transduction is
6.2.5 WASpI294T induces genomic instability and
6.2.5.2 Abnormal cytokinesis is observable in
HT1080 cells 198
6.3 Discussion 200
Chapter 7: General Discussion 206
References 215
Appendix 243
1 FL3/41.5RI:0.5RI. Plasmid containing WASp cDNA 243
2 pEGFP-C2 243
3 pEGFP-WASp-C2 244
4 pBluescript 244
5 PINCO-EGFP retroviral construct 245
6 PINCO-EGFP-WASp retroviral construct 245
7 CMV EGFP WPRE Lentiviral construct 246
8 SFFV EGFP WPRE lentiviral construct 246
9 CMV EGFP-WASp WPRE lentiviral construct 247
10 SFFV EGFP-WASp WPRE lentiviral construct 247
11 Sequence of PCR product for 500bp wiskott promoter 248
12 Wp-EGFP lentiviral construct 248
13 Wp-WASp lentiviral construct 249
13
List of Figures and Tables
Chapter 1 Page
Figure 1.1 Domain structure of WASp 26
Figure 1.2 WASp family members 26
Figure 1.3 Action of PIP2 and Cdc42 on activation state of WASp 29
Figure 1.4 Podosome structure 38
Figure 1.5 Defects in WASp deficient dendritic cells 39
Figure 1.6 Development of the haematopoietic system 47
Table 1.1 Properties of commonly used gene transfer vectors 51
Figure 1.7 Retrovirus replication cycle 54
Figure 1.8 Development of type C retroviral vectors 55
Figure 1.9 Retroviral packaging cell line 58
F igure 1.10 Development of HIV -1 derived gene transfer vectors 61
Figure 1.11 The lentiviral pre-integration complex 63
Chapter 3
Figure 3.1 Creation of EGFP-WASp fusion 92
Figure 3.2 CCD images of transfected COS-7 cells 93
Figure 3.3 Western blot of transduced 293T cell lysates 94
Figure 3.4 Transient transfection of human dendritic cells 95
Figure 3.5 Cloning of retroviral vectors 97
Figure 3.6 FACS of infected 3T3 cells 98
Figure 3.7 Confocal and western blot of infected 3T3 cells 99
Figure 3.8 Schematic of transduction protocol for murine bone
marrow transplant 100
Figure 3.9 Transduction levels in ScaH- cells 101
Figure 3.10 Transduction levels in reconstituted mice 103
Figure 3.11 Transgene expression levels in secondary lymphoid organs 103
Figure 3.12 FACS of murine bone marrow 104
Figure 3.13 Percentage of murine BM DCs with podosomes 105
Figure 3.14 Confocal images of BM DCs 106
Figure 3.15 Podosomes per cell in BM DCs 108
Figure 3.16 Distribution of podosome number in a cell population 109
14
119
120
121
122
123
124
125
126
127
129
129
130
131
132
133
134
135
136
137
138
139
140
147
148
149
150
151
152
153
154
155
15
Lentiviral vectors containing CMV and SFFV promoters
Infection of 3T3 cells
Infection of DCs with lentiviral vectors
Reconstitution of podosomes
Confocal images of EGFP transduced murine DCs
Quality of reconstitution of podosomes
Distribution of podosome number per cell
Lentiviral vectors containing an endogenous promoter
Comparison of titration methods
Recontitution of podosomes
Quality of reconstitution of podosomes in murine DCs 
Distribution of podosome number per cell 
Confocal images of transduced DCs
Cloning of lentiviral vectors containing endogenous promoters 
Reconstitution of podosomes
Quality of reconstitution of podosomes in murine DCs 
Confocal images of transduced DCs 
Infection of primary human macrophages 
Podosome recovery on primary human macrophages 
Confocal images of tranduced macrophages 
Quality of reconstitution of podosomes in macrophages 
Distribution of podosome number per cell
Lentiviral Ex vivo transduction protocol 
Transduction of lineage negative cells 
FACS plots of transduced cells 
Levels of bone marrow reconstitution 
Transduction in secondary lymphoid organs 
Determination of lineage transduction in PBL 
FACS of splenocytes from transduced mice 
Percentage of murine DCs with podosomes 
Podosomes per cell
Figure 5.10 Confocal imgaes of transduced murine DCs 155
Figure 5.11 RT-PCR to determine copy number 157
Figure 5.12 Expression levels of human WASp in murine BM 158
Figure 5.13 Splenic T cell proliferation in transduced mice 159
Figure 5.14 Immunoblot of splenic lysates from transduced mice 160
Figure 5.15 Percentage of murine DCs with podosomes 161
Figure 5.16 Podosomes per cell in DCs 162
Figure 5.17 Confocal Images of BM DCs 163
Figure 5.18 Integrated viral copy number 164
Figure 5.19 Human WASp expression levels 165
Figure 5.20 Splenic T cell proliferation 166
Chapter 6
Figure 6.1 Solution structure of autoinhibited conformation of WASp 176
Figure 6.2 Macrophages from a patient with mutant WASp have abnormal
cytoskeletal structure 177
Figure 6.3 Quantification of cytoskeletal structure in macrophages 178
Figure 6.4 Phagocytosis and oxidative burst in patient neutrophils 180
Figure 6.5 Increased levels of apoptosis in cultured patient lymphocytes 181
Figure 6.6 Spontaneous apoptosis in fresh BM 182
Figure 6.7 Creation of a lentiviral vector containing EGFP-WASp12947 184
Figure 6.8 EGFP-WASp12947 induces the formation ofpodosomes in
BAC-1 macrophages 186
Figure 6.9 Infection of HT1080 cells with EGFP-WASp12947 1 87
Figure 6.10 Apoptosis levels in transduced HT1080 cells are increased 188
Figure 6.11 Generation of AVCA deletion mutant of EGFP-WASp
lentiviral constructs 190
Figure 6.12 The VC A domain is responsible for the toxicity seen in
transduced HT1080 cells 192
Figure 6.13 Apoptosis levels in VC A deletion mutants are not increased 193
Figure 6.14 Cloning of mutant WASp vectors with an internal SFFV LTR 194
Figure 6.15 infection of HT1080 cells with SFFV vectors show less inhibited
growth of EGFP-WASpI294T expressing cells 195
16
Figure 6.16 Analysis of DNA content in EGFP+ and EGFP- cell populations 197
Figure 6.17 Increase of cellular DNA and multinucleate cells during mitosis 198
Figure 6.18 Loss of actin contractile rings in dividing HT1080 fibroblasts 199
17
Abbreviations
7-AAD 7-amino-actinomycin D
AAV Adeno-associated vims
ADA Adenosine deaminase
Bm Bone marrow
BMT Bone marrow transplant
bp Base pair
BSA Bovine serum albumin
CD Cluster of differentiation
Cdc42 Cell division cycle 42
cDNA Complementary DNA
CMV Cytomegalovirus
cPPT Central poly purine tract
CSF-1 Colony stimulating factor-1
Cy-5 Cy-chrome-5
DC Dendritic cell
DMEM Dulbecco’s Modified Eagle Medium
DNA Deoxyribonucleic acid
DNFB Dinitrofluorobenzene
EDTA Ethylenediaminetetraacetic acid
EGFP Enhanced green fluorescent protein
EFl-a Elongation factor-1-alpha
ELISA Enzyme linked immunoabsorbent assay
Env Envelope
ER Endoplasmic reticulum
FACS Fluorescence activated cell sorting
FCS Foetal calf serum
FITC Fluorescein Isothiocyanate
fMLP f-Met-Leu-Phe
Gag Group specific antigens
GM-CSF Granulocyte macrophage colony stimulating factor
HIV-1 Human Immunodeficiency Vims -1
HSC Haematopoietic stem cell
HSV Herpes Simplex Vims
Ig Immunoglobulin
IL-3 Interleukin-3
IL-6 interleukin-6
IRES Internal ribosomal entry site
kD Kilo Daltons
LTR Long terminal repeat
MACS Magnetic Active cell sorting
M-CSF Macrophage colony stimulating factor
MFI Mean fluorescence intensity
MMLV Molony Murine Leukaemia Vims
MMP Matrix Metallo Proteinases
MOI Multiplicity of infection
NK Natural Killer
N-WASp Neural WASp
PAGE Polyacrylamide gel electrophoresis
PBL Peripheral blood leukocytes
PBS Phosphate buffered saline
PCR Polymerase Chain Reaction
PE Phycoerythrin
PFA Paraformaldehyde
PHA Phyto haemagglutinin
PI Propiduim odide
PMA Phorbo-12-myriste-13-acetate
Poly A Poly adenylation
Pgk Phosphoglycerate kinase
RNA Ribonucleic acid
RPMI Roswell Park Memorial Institute
RSV Rous Sarcoma virus
RT-PCR Real-Time PCR
Seal Stem cell antigen 1
Scar Suppressor of cAR
SCF Stem Cell Factor
SCID Severe Combined Immunodeficiency
SFFV Spleen focus forming virus
Spl Spleen
S/NOD SCID/ Non-Obese Diabetic
Thy Thymus
TPO Thrombopoeitin
VSV.G Vasicular stomatitis virus glycoprotein
v/v Volume to volume
WAS Wiskott-Aldrich syndrome
WASp Wiskott-Aldrich syndrome protein
WAVE WASp family Verprolin homologous protein
WIP Wiskott Interacting Protein
Wp Wiskott promoter
WPRE Woodchuck hepatits virus post-transcriptional 
regulatory element
XLT X-Linked Thrombocytopaenia
X-SCID X-linked severe combined immunodeficiency
CHAPTER 1
INTRODUCTION
Chapter 1
1. Introduction
Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive primary 
immunodeficiency. It was first described by Wiskott, in 1936, when patients presented 
with symptoms of thrombocytopaenia, bloody diarrhoea, eczema and recurrent inner 
ear infections. Subsequently in 1954, Aldrich described affected males and concluded 
the disease was X-linked recessive. Since these early diagnoses, the triad of eczema, 
immunodeficiency and thrombocytopaenia with small platelets now describes the 
syndrome. Due to variability of symptoms however, this triad is actually only seen in 
30% of cases, with the thrombocytopaenia the least variable symptom. In addition there 
are recurrent bacterial and viral infections and increased risk of malignancies. Overall 
there is a high level of variability in the symptoms and milder forms of WAS are often 
classified as X-linked thrombocytopenia (XLT) although both have been shown to be 
due to mutations in the WAS gene (Villa et al., 1995; Zhu et al., 1995).
1.1 Description of Disease
Patients have microthrombocytopaenia and as a result have the associated problems of 
bleeding and haemorrhaging, which accounts for approximately 23% of deaths 
associated with disease (Sullivan et al., 1994).
Immunological defects associated with mutations in the WAS gene affect both the 
lymphoid and myeloid compartments of the haematopoietic system. These include an 
impairment of delayed hypersensitivity and mitogen responses and failure to respond to 
polysaccharide antigens (Ochs et al., 1980; Lo et al., 1999a). There is low serum IgM 
and IgG with increased levels of IgA and IgE, and responses to some proteins do not 
show class switching (Ochs et al., 1980). The total numbers of circulating lymphocytes
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in infants is not reduced, but they often develop lymphopaenia by 6-8 years of age, 
which has been attributed to increased levels of apoptosis (Rawlings et al., 1999).
This immune disorder in WAS leads to susceptibility to pyogenic, viral and 
opportunistic infections and an increased incidence of lymphoproliferative disease and 
malignancy, accounting for 44% and 26% of deaths, respectively (Sullivan et al., 
1994). In fact due to improved medical care the median survival is now around 15 
years of age but with this increased life span an increase in malignancies has been 
observed.
1.2 Genetics of WAS
WAS is an X-linked recessive disease affecting 1 in 250,000 live births in Europe 
(Thrasher and Kinnon, 2000b). The gene responsible was cloned in 1994 and found to 
lie on the short arm of the X chromosome at Xpl 1.22-pl 1.23 (Derry et al., 1994). It is 
comprised of 12 exons over 9kb of genomic DNA. The cDNA encodes a 502 amino 
acid protein, WASp, with a molecular weight of approximately 65kD, with expression 
restricted to cells of the haematopoietic lineage (Derry et al., 1994; Stewart et al., 
1996). It is mutations in this gene that lead to Wiskott-Aldrich syndrome.
1.2.1 Mutations in WAS
In addition to Wiskott-Aldrich syndrome, it has subsequently been shown that 
mutations in WAS can also cause X-linked thrombocytopaenia (Villa et al., 1995; Zhu 
et al., 1995). Investigations into the positions of the mutations and the severity of 
disease have revealed mixed results. Schindelhauer et al. found no correlation between 
genotype and phenotype (Schindelhauer et al., 1996), as did others (Greer et al., 1996), 
conflictingly however Zhu et al. found that missense mutations in the first three exons
22
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generally resulted in a mild disease phenotype and reduced WASp expression (Zhu et 
al., 1997), whereas more complex mutations and missense mutations in the remainder 
of the gene result in lower protein levels (if any) and a more severe phenotype. A recent 
more comprehensive study of 262 patients from North America and Europe (Jin et al., 
2004) found five mutational hotspots and a strong association between genotype and 
phenotype. It was found that a less severe disease phenotype was seen in patients with 
mutations which allow some protein expression e.g. missense, whereas patients with 
more complex mutations which lead to no protein expression revealed a more severe 
phenotype.
Recently an incidence of congenital X-linked neutropaenia was caused by a mutation in 
the Cdc42 binding domain of WAS (Devriendt et al., 2001) without the 
thrombocytopaenia associated with classical WAS, further showing the complicated 
link between genotype and phenotype.
1.2.2 X-inactivation
Heterozygous female carriers of a mutated WAS gene have been shown to undergo 
apparent non random X-inactivation in all haematopoietic lineages (Greer et al., 1989), 
even in CD34 positive stem cells (Wengler et al., 1995) from which all mature blood 
cells derive, suggesting WASp expression is critical for survival of mature and 
primitive haematopoietic cells and possibly their development. Similar phenomena 
have been seen in other X-linked diseases and are consistent with a selective advantage 
for cells without the mutation.
1.2.3 Female WAS patients
23
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As with any X-linked disease it is extremely unusual for females to be affected. 
Nevertheless, there have been some females with clinical symptoms of WAS. In one 
case there was skewing of the X inactivation by allowing the spontaneously mutated 
paternal X chromosome to be activated (Parolini et al., 1998), possibly through a XIST 
mutation. In other cases skewing of X inactivation is thought to be the underlying 
reason for a disease phenotype (Kondoh et al., 1997; Luzzatto and Martini, 1998). 
Female XLT phenotypes have been reported (Inoue et al., 2002; Proust et al., 2005) 
showing the type of mutation is still important in determining the severity of disease.
1.2.4 Somatic Mosaicism
Mosaicism occurs when there is the spontaneous reversion from a disease phenotype to 
a normal or mild phenotype by de novo mutations leading to 2 or more populations of 
cells. Because of the variation in the disease phenotype compared to genetic mutations 
discussed earlier, reversions are difficult to diagnose. However there have been three 
cases (Ariga et al., 1999; Ariga et al., 2001; Wada et al., 2003) reported to date; 1. 
Where there is a single nucleotide reversion, 2. An insertion event restoring the open 
reading frame, and 3. A deletion of 6bp reinserted, have been described. Only one case 
(Wada et al., 2001) had a definite improvement of disease phenotype upon reversion of 
the mutation even though all had a partial restoration of the T cell compartment 
showing a selective advantage. The lack of improvement in disease phenotype seen 
may be due to irreversible damage to the body, as the timing of the reversions could not 
be measured. Additionally, normal T cells alone may not alleviate symptoms and 
myeloid cells may be more responsible for the immune dysregulation seen in WAS 
patients. Somatic mosaicism has been seen in other X-linked diseases such as 
Adenosine Deaminase Deficiency (ADA) (Hirschhom et al., 1996) and X-linked
24
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Severe Combined Immunodeficiency (SCID) (Stephan et al., 1996). In the case of X- 
linked SCID a reversion mutation in the common y chain in an early T cell progenitor 
led to a normal phenotype creating a partially restored T cell compartment (Stephan et 
al., 1996) due to a selective advantage. Somatic mosaicism is encouraging for treatment 
of WAS by gene therapy because a selective advantage would be predicted in 
transduced T cells, although B and myeloid cells may need higher levels of 
transduction as there is no selective advantage (Konno et al., 2004). A selective 
advantage seen with transduced T cells in X-linked SCID has aided the correction of 
the disease, even with relatively low levels of transduction.
1.3 Domain Structure of Wiskott-Aldrich syndrome Protein
WASp is a predominately cytosolic protein which is excluded from the nucleus 
(Rivero-Lezcano et al., 1995) and is part of a family of related proteins. Other members 
of the family are more ubiquitously expressed, but all are involved in the transduction 
of signals from the cell surface to the actin cytoskeleton and all can induce actin 
polymerisation in vitro (Zalevsky et al., 2001). WASp can be divided into specific 
domains that have different functions and homology (Figure 1.1). Other members of 
the family include N-WASp, Scar/WAVE, and Beelp as well as WASp homologues in 
different species (Figure 1.2) and can also be divided into similar domains. They all 
possess a VC A (verprolin/cofilin homology, acidic region) domain and a proline rich 
domain at the C-terminus (Figure 1.2). WASp and N-WASp have a GTPase binding 
domain (GBD) although this is not found in Scar/WAVE (Figure 1.2). Another 
difference with WAVE is in the N-terminus, as there is a WAVE homology domain 
instead of a WASp homology domain (Figure 1.2). The main members of the WASp
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family will be discussed in more detail followed by the homologues and their 
differences.
WH1 B ( GBD PPPP c A I 502aa
1
WIP
PIP2
T t t T
Cdc42 PSTPIP Btk Actin/Arp2/3 
Crh2 Nek hindinp
Fyn
Figure 1.1 Domain structure of WASp
Cartoon of Wiskott-Aldrich syndrome protein showing the various domains determined by 
function, homologies, and known protein-protein interactions. The N-terminus WASp 
Homology 1 (WH1) domain binds Wiskott-Interacting protein (WIP) and PrP2. There is a 
central GTPase binding domain (GBD) thought to be important in the regulation of WASp 
and a polyproline domain (PPPP) through which there are protein/protein interactions from 
cytosolic signalling molecules. The C-terminus verprolin-cofilin acidic domain (VCA), 
often also named the WH2 domain, binds p21arc of the arp2/3 complex and monomeric 
actin and has been implicated in the initiation of dendritic branching of filamentous actin.
N-WASp WH1 PPPP C A ■ 505aa
Scar/WAVE
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Figure 1.2 WASp family members
Cartoon representations of other WASp family members showing the domain structure 
defined by function, homologies and known protein/protein interactions. The ubiquitous N- 
WASp and yeast homologue Beelp have an N-terminal WASp homology 1 (WH1) domain, 
whereas the Scar/WAVE proteins (1-3) have a Scar homology domain (SH). N-WASp has a 
GTPase binding domain (GBD) but is absent in WAVE and Beelp. All three proteins contain 
a central polyproline (PPPP) containing domain similar to WASp. Another difference from 
WASp is the presence of additional verprolin homology domains at the C-terminus.
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1.3.1 WH-l Domain of WASp
This is the least understood of all the domains of WASp and has been referred to as a 
pleckstrin homology domain (Imai et al., 1999) although the homology is disputed. 
Similar domains have been identified in other proteins (VASP, Ena/Mena) and these 
too are involved in regulation of the actin cytoskeleton (Gertler et al., 1996). So far the 
only established WH1 domain target is WASp interacting protein (WIP). It was first 
thought to bind via its polyproline domain but has subsequently been shown to wrap 
around the entire WH1 domain (Volkman et al., 2002). The majority of mutations in 
WAS are in the WH1 domain and may alter the binding of WIP and be important in the 
regulation and stability of WASp. However, severity of disease is variable even with 
similar mutations in this domain suggesting transcriptional activating ability through 
this domain may be differently affected (Silvin et al., 2001). The relevance of the WH1 
domain however has yet to be conclusively elucidated, although localisation of WASp 
to the cell membrane through this domain has been postulated (Miki et al., 1996).
1.3.2 GTPase Binding Domain
Cdc42 is known to play key roles in the regulation of the actin cytoskeleton (Hall, 
1998) and along with Rac, albeit with a weaker interaction, Cdc42 has been shown to 
bind to WASp in the active GTP form via the GBD (Aspenstrom et al., 1996). 
Subsequently it was revealed extra WASp sequences outside the GBD are required for 
tight binding (Rudolph et al., 1998). This data along with the abnormal actin 
polymerisation when a dominant negative form of Cdc42 is co-expressed (Symons et 
al., 1996) leads to the conclusion that WASp is a downstream effector of Cdc42.
When activated Cdc42 binds to WASp, in conjunction with PIP2 , there is a change in 
the structure of WASp from an autoinhibited state to an active state (Kim et al., 2000)
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releasing the proline rich domain and VC A domain leading to intracellular changes in 
actin (Figure 1.3). Recently a mutation in WASp was identified in the GBD region, 
and is thought to prevent the autoinhibited confirmation of WASp. This mimics binding 
of the GTP form of Cdc42, resulting in severe neutropaenia and constitutive actin 
polymerisation in vitro (Devriendt et al., 2001).
Although a key role for Cdc42 binding to WASp thus subsequently affecting the 
activity of WASp seems likely, there is evidence of actin clustering and recruitment of 
WASp to an immunological synapse independent of Cdc42 (Kato et al., 1999; Cannon 
and Burkhardt, 2004; Cannon et al., 2001), suggesting there are other influences and 
possibly other mechanisms for WASp activation (Badour et al., 2003b).
1.3.3 Proline Rich Domain
WASp has a proline rich domain that has been shown by many groups to be capable of 
binding the SH3 domains of other cytosolic proteins. These proline rich domains are 
found in all members of the WASp family and are thought to provide a scaffold to 
allow interactions between signalling molecules. Amongst the proteins found to bind in 
vivo are tyrosine kinases and adaptors including Nek (Rivero-Lezcano et al., 1995), 
PSTPIP1 (Wu et al., 1998), Grb 2 (She et al., 1997), Fyn (Banin et al., 1999) and Btk 
(Baba et al., 1999). These binding partners have been found to be involved in the 
regulation of the actin cytoskeleton, either upon growth factor stimulation (Matuoka et 
al., 1993) or in cytokinesis (Spencer et al., 1997).
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Figure 1.3 Actin of PIP2 and Cdc42 on activation state of WASp
Cdc42 and PIP2 bind to WASp causing the release of the inhibited WASp conformation 
This allows the binding of SH3 containing proteins and the phosphorylation of tyrosine 
291 stabilising the active conformation and allowing response to specific stimuli. 
Unmasking of the VC A Arp2/3 binding domain allows polymerisation of actin 
monomers to actively progress allowing membrane protrusions e.g filopodia and 
phagocytic cups to form.
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Therefore binding to WASp may allow compartmentalisation within the cell. This is 
supported by data showing a proline rich domain-deleted WASp was not translocated 
to an immunological synapse (Cannon et al., 2001). Other influences of binding of Src 
family kinases to the proline rich domain can be seen with Hck which induces 
phosphorylation of Y291 in WASp altering the physical properties and stabilising the 
active confirmation (Cory et al., 2002) and PST-PEST which induces 
dephosphorylation thus destabilising the active confirmation (Cote et al., 2002). 
Interactions with the endocytic proteins syndapin and intersectin via the polyproline 
domain show how WASp may be recruited to sites of membrane remodelling (Simpson 
et al., 1999; Kessels and Qualmann, 2002).
1.3.4 Carboxy Terminus Domains
The carboxy terminus of WASp contains an actin binding domain, a cofilin homology 
domain and a highly negatively charged acidic region and is thought to be where the 
effector function of WASp resides. The verprolin homology or WH2 domain of WASp 
and N-WASp have been shown to bind actin monomers (Paunola et al., 2002; Miki and 
Takenawa, 1998) whereas the acidic domain interacts directly with actin related 
proteins of a cytoskeletal organiser named the Arp2/3 complex (Machesky and Insall,
1998). The Arp2/3 complex is comprised of seven proteins, Arp2, Arp3, p41-Arc, p34- 
Arc, p21-Arc, p20-Arc and pl6-Arc and has been shown to be localised to regions of 
dynamic actin polymerisation such as filopodia and lamellipodia in cells (Welch et al., 
1997).
Overexpression of the C-terminus domain of WASp results in dysregulation of the 
actin cytoskeleton (Symons et al., 1996) and it is thought that WASp acts as a cellular
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actin nucleation promoting factor (Higgs et al., 1999). This nucleation activity provides 
a molecular explanation for the role of WASp in transduction of signals from the cell 
surface by holding together cytosolic proteins leading to actin remodelling within a 
cell.
In addition to binding Arp2/3, the acidic domain of WASp interacts with the basic 
domain to hide the VCA and proline rich domain (Figure 1.3). This results in an 
inhibitory confirmation, which is released upon PIP2 and Cdc42 binding (Kim et al.,
2000). This releases the C terminus to allow actin remodelling and in fact the mutant of 
WASp, which results in an active protein conformation, polymerises actin 
constitutively (Devriendt et al., 2001).
The lack of transduction of signal mediated by WASp may be the cause of some of the 
defects seen in patients that lack WASp. The amelioration of phenotype in XLT may be 
due the presence of low levels of cellular WASp allowing some signalling to occur.
1.4 WASp Family Members
1.4.1 N-WASp
As has been discussed earlier, WASp expression is restricted to cells of the 
haematopoietic lineage, whereas N-WASp (Neural-WASp) (Figure 1.2), although first 
found in the brain, has a more widespread distribution (Miki et al., 1996). There is 50% 
homology between the two proteins with N-WASp possessing an extra verprolin 
homology domain. N-WASp is thought to be involved in the formation of filopodia 
(Miki et al., 1998a) acting downstream of tyrosine kinases and Cdc42. N-WASp is 
found in an inhibitory confirmation that is activated upon binding of PIP2 and Cdc42,
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releasing the VCA domain to interact with its cellular partners (Rohatgi et al., 2000), 
and this inhibited confirmation was subsequently also found to be the case with WASp 
(Kim et al., 2000). Over expression of N-WASp in a cell causes co-precipitation of N- 
WASp and actin in the cell cytoplasm (Miki et al., 1996) showing it has a potent actin 
polymerisation ability, more potent than WASp or WAVE in fact (Zalevsky et al.,
2001), which is diminished when the WH2 domain is deleted (Yamaguchi et al., 2000; 
Yamaguchi et al., 2002). This actin polymerisation ability could be important in neural 
cells, where it is highly expressed, for the formation of neural growth cones (Banzai et 
al., 2000). In addition the intracellular pathogen Shigella, utilises N-WASp to move 
through the cytoplasm generating an actin tail to propel it along (Suzuki et al., 1998). 
There are no reported human cases of N-WAS deficient patients. Interestingly when a 
knockout mouse was made it was embryonic lethal suggesting that neither WASp nor 
WAVE could compensate for N-WASp. Therefore there may be different signalling 
events regulating the different proteins (Snapper et al., 2001).
1.4.2 Scar/WAVE Proteins
Originally discovered in Dictyostelium as Scar (suppressor of cAR) (Bear et al., 1998) 
but subsequently were also isolated as three mammalian homologues WAVE 1, 2 and 3 
(WASp family Verprolin homologous protein) (Miki et al., 1998b; Suetsugu et al.,
1999). They have a similar C-terminus to WASp but the N-terminus has a 
SCAR/WAVE homology domain rather than a Wiskott homology domain and do not 
possess a GTPase binding domain (Figure 1.2). Consequently, unlike WASp, they are 
not associated with Rho GTPases and may be regulated through different mechanisms. 
Mechanisms found so far include Abl interacting protein, which is involved in Ras to 
Rac signalling (Blagg and Insall, 2004).
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Dominant negative mutants of WAVE1 lack Rac-dependant ruffling and neurite 
extension (Miki et al., 1998b). In Dictyostelium, loss of Scar leads to reduced F actin 
content and impaired cell motility and chemotaxis (Bear et al., 1998). WAVE1 
knockout mice have severe brain impairments (Soderling et al., 2003) and WAVE2 
knockouts are embryonic lethal (Yan et al., 2003), again showing little or no overlap of 
function with WASp or N-WASp.
1.4.3 Bee/1 p
Bee/lp is the yeast homologue of WASp but lacks a GTPase binding domain (Figure 
1.2). It has been shown to be a component of the cortical actin cytoskeleton in yeast, 
playing an essential role in the organisation of actin filaments. When Beelp is knocked 
out there are defects in cytokinesis and budding (Li, 1997).
1.5 Cellular Defects of WASp
This section will discuss some of the cellular defects seen in patients with WASp, how 
they can be explained with respect of the protein structure and how the lack of a 
functional actin polymerisation response to a stimulus can lead to some of the clinical 
features seen.
1.5.1 T Cells
There is overwhelming evidence from the multiple defects seen in patient T cells that 
WASp is crucial for effective regulated T cell function. Patient T cells have been 
shown to be defective in their proliferative capability in response to various stimuli, 
including antigenic and allogenic (Ochs et al., 1980) and impaired IL-2 secretion upon
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cross-linking of CD3e (Molina et al., 1993). The lymphocytes are reduced in number 
(Ochs et al., 1980) and have been shown to exhibit morphological defects by having a 
reduced number of microvilli on the cell surface (Kenney et al., 1986), however 
recently this has been disputed (Majstoravich et al., 2004) and is possibly related to T 
cell activation states. There is a defect in receptor capping upon stimulation (Molina et 
al., 1993), which previously had been shown to be dependant upon actin polymerisation 
(Ryser et al., 1982). The immunological synapse is impaired without WASp, 
preventing optimisation of cell signalling, and therefore subsequent signalling events, 
such as cytokine secretion and proliferation (Badour et al., 2003a). Following TCR 
ligation WASp is recruited to lipid rafts that allow lateral movement of the TCR. In 
WAS patients and knockout mice there is a reduction in the number and upregulation 
of lipid rafts following T cell activation, preventing efficient responses to stimuli 
(Dupre et al., 2002). When WASp was re-introduced using a retroviral vector the lipid 
raft clustering and subsequent T cell activation was restored (Dupre et al., 2004).
T cell trafficking may also be impaired and contribute to the disease phenotype as the T 
cell chemoattractant SDF-la has been shown to induce phosphorylation of WASp 
(Okabe et al., 2002) thus directing migration and diapedesis.
The defects shown in the T cells ability to respond to stimuli, ultimately due to an 
inability to polymerise actin, and therefore a lack in helper function, have been argued 
to be the main cause of immune dysregulation seen in WAS patients. This however 
usually reflects the specific interests of the investigators concerned, as other groups 
have identified major defects in other lineages e.g DC homing (de Noronha et al., 
2005), that have also been theorised to be the main cause of the symptoms in WAS.
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1.5.2 B Cells
B cells are not thought to be as severely affected in WAS as cells from other lineages. 
However B cells from WAS patients have been found to have defective transmembrane 
signalling (Simon et al., 1992) with reduced numbers of microvilli on the cell surface 
(Zhang et al., 1999). EBV transformed B lymphoblastic cell lines from patients have 
defective actin polymerisation and chemotaxis (Facchetti et al., 1998). Defects in 
migration may explain the aberrant splenic architecture seen in patients and mice 
(Vermi et al., 1999; de Noronha et al., 2005). The abnormal immunoglobulin levels 
seen in patients may in part be due to lack of T cell help as well as inherent problems 
with the B cells. Further evidence that WASp is not as important in B cells was shown 
in a patient that had somatically mutated a lymphoid progenitor so that both B and T 
cells expressed normal WASp. A selective advantage was seen in the T cell lineage but 
not the B cell lineage (Konno et al., 2004). This data supports that seen in murine 
knockout models (Snapper et al., 1998; Zhang et al., 1999) where T cells but not B 
cells are affected.
1.5.3 Natural Killer cells
As in T cells, NK cell activation relies on the formation of an immunological synapse 
and lipid raft clustering. Activation is reliant upon efficient actin polymerisation, as 
WASp and F-actin have been shown to be present in the immunological synapse of 
activated NK cells (Orange et al., 2002). In WAS patients although there are increased 
numbers of NK cells (Morio et al., 1989) their cytotoxicity is impaired (Gismondi et 
al., 2004). Introduction of IL-2 can correct the cytotoxicity (Gismondi et al., 2004) 
suggesting a lack of signal transduction is responsible for the defects, which is similar
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to that observed in T cells. This lack of signalling and therefore cytotoxicity also 
probably partly explains the susceptibility of WAS patients to viral infections.
1.5.4 Platelets
Although thrombocytopaenia and small platelets are classical symptoms of WAS 
(Semple et al., 1997), the exact role of WASp in their development and function is still 
not known. In vitro experiments have shown WAS megakaryocytes to have abnormal 
cytoarchitecture, but platelets formed in this system were of a normal size (Haddad et 
al., 1999). Lack of WASp has been implicated in failure of maintenance of platelet 
integrity and aggregation at sites of haemorrhage with circulatory damage proposed as 
a reason for small platelets (Thrasher and Kinnon, 2000b). However WASp deficient 
platelets can activate Arp2/3 to form filopodia (Falet et al., 2002) making the reasons 
for the defects unclear.
1.5.5 Myeloid Cells
The ability of neutrophils, dendritic cells and monocytes to respond to a stimulus, 
whether through migration, efficient antigen presentation or through phagocytosis, is 
reliant upon quick and specific de novo actin polymerisation. As actin polymerisation 
has been shown to be defective in other cell types it would be reasonable to assume 
these myeloid cells, which rely heavily upon actin regulation for their function would 
also have defective actin polymerisation and therefore associated defects in their 
function. Specific defects of myeloid cells are discussed in more detail below.
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1.5.5.1 Chemotaxis
Macrophages and dendritic cells have to be able to migrate through tissues when they 
are stimulated to go to a site of inflammation or to secondary lymphoid tissues to 
stimulate other cells of the immune system. Cell locomotion is controlled by 
protrusions of the cell membrane and is reliant upon spatial and temporal regulation of 
actin polymerisation. WAS macrophages have been shown to have abrogated 
chemotactic responses to fMLP, MCP-1 (Badolato et al., 1998), and CSF-1 (Zicha et 
al., 1998) compared to normal cells. Dendritic cells from WAS patients also have 
intrinsic defects in their actin regulation. When stimulated with fMLP or RANTES 
WAS DCs were non-motile. In addition, they did not polarise or extend dendritic 
processes (Binks et al., 1998).
Both macrophages (Linder et al., 1999) and DCs (Bums et al., 2001b) from WAS 
patients are lacking in specialised actin structures called podosomes. Podosomes are 
highly dynamic actin based structures with a half-life of 2-12 minutes that are in close 
contact with the substratum (Figure 1.4).
As can be seen in Figure 1.4, there is a basic actin core with actin regulatory proteins 
surrounded by a ring of vinculin and other cellular adhesion molecules (Marchisio et 
al., 1984). The regulation of podosome assembly and disassembly has been 
investigated in both macrophages and DCs and has been shown to be tightly regulated 
by WASp and Cdc42. They both associate in the podosome, and expression of the 
dominant negative form of Cdc42, V12Cdc42, in these cells leads to podosome 
disassembly (Bums et al., 2001b; Linder et al., 1999). Podosomes are thought to be 
involved in cell motility through adhesion to extra cellular matrix proteins and localised 
release of proteases allowing the cells to migrate through the substratum.
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Figure 1.4 Podosome
Cartoon representation of a podosome present on the apical surface of a cell with 
structure components and associated proteins. The podosome is comprised of a 
central core of filamentous actin, Arp2/3 and WASp surrounded by adhesion 
molecules such as vinculin and integrins amongst others shown. Matrix 
metalloproteinases are thought to be secreted from the centre of the podosome (pink 
arrow). Figure adapted from (Linder and Kopp, 2005).
Release of MMPs has been shown in osteoclasts (Delaisse et al., 2000) and vascular 
smooth muscle cells (Burgstaller and Gimona, 2005). In fact WAS DCs do not adhere 
as strongly to ICAM-1 and do not assemble integrins around podosomes confirming 
podosomes are involved in adhesion (Bums et al., 2004). Chemotactic defects in 
macrophages and DC are therefore due to at least two defects. Firstly there is an 
abrogation in filopodia mediated by Cdc42 and WASp, shown to be crucial for 
chemotaxis (Allen et al., 1997; Allen et al., 1998). Secondly abnormal polarisation and 
adherence to substrata leads to an inability to direct movement in a regulated manner.
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In addition to the chemotaxis defects in vitro, migration and homing defects of 
Langerhan cells have been demonstrated in vivo in a WAS KO mouse model (de 
Noronha et al., 2005). In deletion experiments, the minimal region of WASp required 
for chemotaxis is the VCA region. This is also the minimal region needed to stimulate 
actin nucleation, further linking the defects in WAS with dysregulation of actin 
polymerisation (Yarar et al., 1999). Figure 1.5 shows how the defects in WASp 
deficient dendritic cells affect a normal immune response.
B cell zone
mature 
dendritic cell
periphery Secondary lymphoid tissue
Incomplete localisation to 
T cell areas in lymphoid 
organs
cellular
interactions
phagocytosis 
of antigen
immature 
dendritic cell
migration out of 
periphery
Figure 1.5 Defects in WASp deficient dendritic cells
WASp deficient dendritic cells fail to phagocytose some antigen and then show 
delayed migration from the periphery to secondary lymphoid organs. Upon arrival 
there is abnormal distribution within the T cell zones in secondary lymphoid tissue and 
failure to form an immunological synapse with T cells. (All deficiencies marked by an 
X).
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1.5.5.2 Phagocytosis
In addition to chemotactic defects there have been several demonstrations of 
phagocytic defects in WAS patient macrophages. Phagocytosis is the active engulfment 
of particles by macrophages or DC. This can be in response to infections where bacteria 
are the target, virally infected cells, tumour cells for antigen presentation, or in the 
resolution of an inflammatory response where apoptotic cells are removed thus 
preventing chronic inflammation. Studies of phagocytosis have revealed two distinct 
mechanisms of phagocytosis involving different GTPases. One involving the 
complement receptor CR3 was mediated by Rho. The other mechanism was via the 
immunoglobulin receptor FcyR, and was mediated by Cdc42 and Racl (Caron and 
Hall, 1998). Phagocytosis can also be mediated through scavenger receptors for the 
clearance of apoptotic cells (Platt et al., 1996; Savill et al., 1990; Devitt et al., 1998) 
and mannose receptors which recognise mannans on bacterial cell walls (Stahl and 
Ezekowitz, 1998).
In experiments with immunoglobulin coated beads it has been shown that WAS patient 
macrophages have a defect in phagocytosis and fail to efficiently assemble a 
phagocytic cup (comprised of F-actin and phosphorylated proteins including WASp) 
although binding to the cell surface was normal (Lorenzi et al., 2000b). Similarly when 
phagocytosis of apoptotic cells was investigated WAS macrophages exhibited a defect 
in vitro and in vivo. In control macrophages there was localisation of WASp to the 
phagocytic cup supporting a role for WASp in phagocytosis (Leverrier et al., 2001b). 
So far there has been no association of CR3-mediated phagocytosis with WASp. As 
this is directed through Rho and there is little or no binding of Rho to WASp, this 
suggests that there is some redundancy where other WASp family members may play a 
role.
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Another cell type of the myeloid lineage, the osteoclast, has been shown to be lacking 
in podosomes and does not form sealing zones, shown to be important in bone 
resorption, in WASp deficient mice (Calle et al., 2004). When WASp was reintroduced 
into these cells using a retrovirus, podosomes were restored along with normal 
cytoarchitecture (Calle et al., 2004).
These intrinsic defects in phagocytosis and chemotaxis in WAS macrophages and 
dendritic cells may contribute to the pathology seen in WAS. There is abnormal antigen 
presentation thereby adding to the immunodeficiency, and ineffective removal of EBV- 
driven lymphoproliferative disease increasing the susceptibility to autoimmune disease. 
A failure to remove apoptotic cells may also result in unchecked inflammatory 
responses and in Clq-deficient mice has been linked to systemic lupus erythematosus 
(Taylor et al., 2000). Thus it is possible that the increased autoimmunity seen in WAS 
patients is due to a breakdown of normal mechanisms of inflammatory suppression and 
maintenance of peripheral tolerance (Leverrier et al., 2001a). The abnormal dendritic 
cell migration to lymphoid organs in response to antigen may contribute to the 
immunodeficiency by not coming into contact with T cells in the correct environment 
and surveillance of the periphery for antigen or virally infected cells would therefore be 
impaired (Thrasher and Kinnon, 2000a).
Importantly when a normal copy of WAS is introduced into WASp null macrophages 
(Jones et al., 2002) and osteoclasts (Calle et al., 2004), podosomes are restored, as is 
chemotaxis showing the importance of WASp in these cytoskeletal defects. 
Additionally introduction of WASp into WAS null DCs leads to normal polarisation 
and podosome formation (Bums et al., 2001a). This is encouraging for gene therapy
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protocols, as introduction of a functional copy of the gene leading to expression of 
WASp appears to correct the cellular cytoskeletal defects.
1.6 Murine Models of WASp
Generally murine models of human diseases are important to elucidate mechanisms of 
pathology and often mimic the human form of the disease. There are two murine 
models of Wiskott Aldrich syndrome based on Sv/129 backgrounds (Snapper et al., 
1998; Zhang et al., 1999). Both are knockouts, caused by an insertion of a neo cassette 
in exon 7 and exon 4, respectively, resulting in a lack of protein expression and both 
reveal a reduction in the total number of lymphocytes in the periphery. However, the 
model by Zhang et al. reveals a defect in lymphocyte development (Zhang et al., 1999) 
not seen in the Snapper model. Both models reveal defects in T cell proliferation and 
receptor capping in response to CD3e and have been used to elucidate the function of 
WASp in T cell responses. B cells in both models respond normally to antigen receptor 
stimulation with receptor capping and normal levels of proliferation. In addition they 
have normal levels of immunoglobulin.
Platelets in knockout mice are present in reduced numbers, although they are of normal 
size (murine platelets are smaller than human platelets), which mimics the defect seen 
in humans.
Mice in this study were kindly donated by S. Snapper. Dendritic cells and osteoclasts 
from the Snapper mouse model have a defect in the number of podosomes (Bums et al., 
2001b; Calle et al., 2004) and exhibit defects in chemotaxis (Bums et al., 2001a) and 
homing (de Noronha et al., 2005) similar to that observed in human cells. 
Haematopoietic stem cells isolated from knock out mice are defective in their migration 
compared to normal cells (Lacout et al., 2003) and this has been suggested to be the
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mechanism through which skewing of X inactivation is observed. Stem cells expressing 
WASp can home to the bone marrow preferentially, thus the WASp null cells (which 
express from a mutant X) do not survive as well.
WASp mice do not develop eczema or haematological malignancies, although this may 
be related to age and maintenance in a pathogen free environment. They do however 
develop chronic colitis with lymphocyte infiltrations, which is not seen in humans, but 
is often seen in mouse models with defects in T cell function (Snapper et al., 1998).
In conclusion, WASp deficient mice are a relevant model for use in further explaining 
the defects seen in WAS and for further elucidating WASp function. This is 
emphasised in experiments where WASp has been introduced into WAS null cells and 
function has been restored (Dupre et al., 2004; Calle et al., 2004; Charrier et al., 2005).
1.7 Treatments for Wiskott-Aldrich Syndrome
If left untreated, patients with typical WAS have a poor prognosis and often die in early 
childhood. A variety of treatments have arisen in the years since WAS was first 
characterised, in an effort to improve the survival rate. Prophylactic antibiotics and 
immunoglobulins are given in an effort to reduce infections and therefore inflammation 
(Litzman et al., 1996). A splenectomy can be effective at increasing platelet numbers 
reducing the risk of haemorrhaging (Lum et al., 1980) as the platelets are not removed, 
however it does increase the risk of infection. This has increased the life expectancy of 
children but a significant proportion of patients still die before 10 years of age (Sullivan 
et al., 1994).
The only effective curative treatment so far is a bone marrow transplant (BMT). In a 
recent study of worldwide treatment, 61.8% of all centres and 95% of centres that treat 
10 or more patients recommend a bone marrow transplant if a HLA matched sibling
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donor is available. This is reduced to 55.2% and 77.7%, respectively, for matched 
unrelated donors (Conley et al., 2003). The survival rate for allogeneic transplants 
performed below the age of 5 years is 80% whereas above 5 years this fell below 50% 
(Thrasher and Kinnon, 2000b). In a study of WAS patients who had received a BMT 
some sustain full chimerism whereas others have mixed chimerism with a high 
proportion of WAS negative cells in the myeloid lineage and thrombocytopaenia. Due 
to the reduced survival rates without a matched donor, a lack of donors and 
complications arising from conditioning patients to accept the graft, alternative 
treatments are sought.
One alternative treatment to bone marrow transplantation is somatic gene therapy. With 
the increase in understanding of the function and regulation of WASp and improved 
gene therapy vectors, coupled with gene therapy successes for other primary 
immunodeficiencies, WAS is an attractive target for ex vivo stem cell gene therapy for 
several reasons. Firstly there is good characterisation of WASp expression and 
function, including murine models allowing safety and efficacy testing. Normally there 
is WASp expression from early in haematopoietic development, therefore there should 
be no abnormal reaction to WASp expression and it has been shown to be crucial in 
homing (Lacout et al., 2003) in the murine model. Somatic mutations have revealed a 
selective advantage, thus low expression and low transduction levels may not be a 
problem. These benefits are emphasised by the restoration of cytoskeletal actin 
structures and cell signalling when WAS is introduced into WAS null cells (Candotti et 
al., 1999; Wada et al., 2002; Bums et al., 2001b; Dupre et al., 2004; Calle et al., 2004; 
Strom et al., 2003b; Strom et al., 2003a; Charrier et al., 2005) and when normal cells 
are introduced into knock out mice (Strom et al., 2002; Charrier et al., 2005).
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1.8 Stem Cells
Stem cells are defined as being pluripotent cells that are capable of self-renewing. They 
have been discovered deriving from various tissues e.g neural (Reynolds and Weiss, 
1992) mesenchymal (Pittenger et al., 1999) and haematopoietic (Ogawa, 1993; Orlic 
and Bodine, 1994). Until recently, it was thought stem cells from one tissue could only 
give rise to cells of that tissue. Subsequently stem cells have been shown to be able to 
“trans-differentiate” into cells of tissues other than their origin through undefined re­
programming pathways e.g. muscle to blood (Jackson et al., 1999) blood to liver 
(Lagasse et al., 2000) and blood to muscle (Ferrari et al., 1998) although this is still 
controversial.
1.8.1 Human Haematopoietic Stem Cells
Haematopoietic stem cells (HSC) can be derived from bone marrow, mobilised 
peripheral blood and umbilical cord blood and are able to give rise to all the cells in 
blood and the immune system, as outlined in Figure 1.6, and have been discovered in 
most vertebrate species, with human and mice being the most widely characterised. 
They have none of the lineage markers found on more mature cells, however various 
cell markers have been used to define human stem cells, with one of the first being 
CD34 (Strauss et al., 1991).
Experiments using murine xenograft models which allow human haematopoietic cell 
engraftment e.g. SCID, S/NOD, common y-chain/RAG knock out, subsequently 
showed that the most primitive cells with the highest repopulating capacity are CD34+ 
CD38' (Larochelle et al., 1996; Bhatia et al., 1997). The frequency of scid repopulating 
cells, and therefore pluripotency, varies depending on the source, with mobilised
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peripheral blood having the lowest (1 in 6xl06 total cells), then bone marrow (1 in 
3xl06) and finally cord blood (1 in 9.3xl05) having the highest (Wang et al., 1997). 
More recently CD 133 (also known as AC 133) has been shown to be a stem cell marker 
(Yin et al., 1997), as has CDCP1 (Cub-domain containing protein) (Conze et al., 2003) 
and KDR (Ziegler et al., 1999). Although these markers along with others have been 
found on stem cells they may not be definitive markers as their expression levels can 
change with cell cycle status.
1.8.2 Murine Stem Cells
Murine stem cells are also characterised by the lack of lineage markers (Spangrude et 
al., 1988) and the presence of cell surface markers such as Sca-1, thy-1 and c-kit, 
although expression levels can be strain dependant (Uchida and Weissman, 1992; 
Spangrude and Brooks, 1993). As has been observed in humans these populations are 
not pure stem cell populations with other cells expressing some of these markers. 
Although CD34 is expressed on foetal haematopoietic stem cells in mice by adulthood 
-90% do not express CD34, with the CD34‘/low subset of Sca-l+c-kit+ cells having a 
greater stem cell frequency (Osawa et al., 1996). So unlike humans, CD34 is not a 
marker for murine stem cells.
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Figure 1.6 Development of the haematopoietic system
Pluripotent stem cells undergo division and commitment to multipotent progenitors or 
renewal. They in turn give rise to common lymphoid precursors (CLP) or common 
myeloid precursors (CMP). Further division and commitment lead to all the lymphoid 
and myeloid lineages of the blood. Granulocyte monocyte precursor (GMP), 
megakaryocyte erythrocyte precursor (MEP), erythrocyte progenitor (ErP), 
megakaryocyte progenitor (MkP). Adapted from (Reya et al., 2001)
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1.8.3 Gene Transfer into HSC
Haematopoietic stem cells (HSC) are an attractive target for gene therapy because they 
are long lived and have a large capacity for self-renewal and, due to their pluripotency, 
if transduced would repopulate the blood with transduced progeny. In fact the plasticity 
of haematopoietic stem cells may allow correction of non-haematopoeitic tissues 
(Theise, 2004). They are easily accessible from different sources (bone marrow, cord 
blood and mobilised peripheral blood) with standard large-scale purification (typically 
immunomagnetic separation) and readily delivered back to patients by established 
transplantation techniques. However due to their quiescence and lack of receptors on 
their cell surface they are generally difficult to transduce.
The main focus of HSC gene transfer is to acheive high efficiency transduction whilst 
maintaining the repopulating ability and pluripotency. Many groups have focused on 
using cytokine cocktails that allow maintenance and even expansion of stem cells ex 
vivo without losing the pluripotency and engraftment potential as extended culture 
results in loss of the stem cell phenotype and homing potential (Blundell et al., 1999; 
Ahmed et al., 2004). Combinations of Stem cell factor (SCF), interleukins 3 and 6 (IL- 
3, IL-6), Flt-3 ligand (Flt-3L) and thrombopoeitin (Tpo) have been used successfully to 
culture and expand primitive HSC in humans (Bhatia et al., 1997; Conneally et al., 
1997b; Conneally et al., 1998; Demaison et al., 2000; Cavazzana-Calvo et al., 2000a; 
Gaspar et al., 2004), and mice (Moreau-Gaudry et al., 2001; Strom et al., 2003b; Klein 
et al., 2003; Uchida et al., 2003) whilst maintaining engraftment potential enabling ex 
vivo transduction to take place.
In addition to cytokine stimulation other methods of maintaining the self-renewal 
properties of HSC have been investigated by deconstruction and manipulation of the
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molecular pathways normally regulated in HSC (reviewed in (Stein et al., 2004)). 
These include transcription factors such as homeobox genes e.g. HoxB4 which is 
expressed in primitive but not lineage specific cells. When HoxB4 was over expressed 
in murine HSC it lead to a repopulation advantage over untransduced cells whilst still 
able to fully reconstitute the HSC compartment (Thorsteinsdottir et al., 1999). Other 
pathways looked at include cell cycle regulators. Entry into cell cycle in stem cells is 
governed by the cyclin-dependant kinase inhibitors p21 and p27, and when they are 
absent in mice there is an increase in the stem cell pool size (Cheng et al., 2000; Cheng 
et al., 2001). It is hoped that further understanding of the molecular pathways through 
which stem cell commitment and self-renewal is regulated may allow transduction ex 
vivo whilst maintaining pluripotency.
1.9 Gene Therapy
Gene therapy is the complementation or replacement of a defective copy of a gene by 
the addition and expression of a correct copy, in trans, via recombinant DNA 
technology thus restoring a normal phenotype.
Somatic gene therapy has been used as a therapeutic tool for over ten years and 
although originally developed for single-gene defects (Kay and Woo, 1994), it has now 
been developed for a wide range of diseases such as cardiovascular disease (Isner,
2002), neurodegenerative disorders (Baekelandt et al., 2000), infectious diseases 
(Bunnell and Morgan, 1998) and cancer therapies (Kay et al., 2001). In fact cancer 
therapies make up the majority of all gene therapy clinical trials, comprising over 63% 
with varied efforts to fight cancer, approaches include delivering anti-angiogenic 
factors, tumour suppressor genes and immunostimulatory genes (Mccormick, 2001).
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Generally, gene therapy strategies would require high levels of transduction of the 
target cells, that is sustained at therapeutic levels as long as is needed without the need 
for repeat procedures. These criteria have been tackled in many different ways with 
different vectors comprising of two main types. Firstly there are vectors derived from 
viruses where the virus has been modified through removal of genes involved in 
replication, toxicity and immunogenicity to become safe and to allow packaging and 
delivery of the transgene ready for expression in the target cell.
The other types of vectors are synthetic and termed non-viral. After initial experiments 
with naked DNA they now encompass a multitude of different approaches to deliver 
DNA efficiently and safely. Both approaches have their advantages and disadvantages 
for different diseases and are summarised in table 1.1.
1.9.1 Viral Vectors
Viruses are highly evolved to infect cells, and to deliver and replicate a genetic package 
using the host cell machinery. Viral vectors for gene therapy utilise the efficient 
infection pathways but are replication defective and have reduced toxicity. Many 
different viruses have been adapted to make them into vectors suitable for gene 
therapy. These include adenovirus, adeno-associated virus, herpes simplex virus, 
gamma retroviruses and lentiviruses (Table 1.1).
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Table 1.1 Properties of Commonly used Gene Transfer vectors (adapted from (Nathwani et al., 2005)
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1.9.2 Requirements for stem cell gene therapy
Due to the inefficiency of non-viral vectors a viral vector is preferred. Ideally the viral 
vector most suited for use in correction of immunodeficiencies by gene therapy would 
be one with a good tropism for haematopoietic stem cells. Efficient infection and 
therefore delivery of the transgene would make use of the current techniques in stem 
cell culture without losing the pluripotent potential of the HSC. Additionally 
integration of the transgene into the host chromosome would be beneficial for long­
term gene expression and for correction of all lineages. The viral vectors would ideally 
be non-immunogenic, as an immune response could hinder the efficacy of the treatment 
as well as be harmful to the patient. Finally the vector would need to be able to carry a 
relatively large sized transgene, in the order of 9kb, to enable most single gene genetic 
defects to be treated and the vector should be easily prepared with large scale 
preparation a necessity for a clinical trial.
As can be seen in Table 1.1, although adenovirus and herpes simplex virus (HSV) can 
package DNA constructs of large length and can infect non-dividing cells, they do not 
have good tropism for HSC (Wickham et al., 1993) and do not integrate into the host 
genome. Additionally even though they have had many immunogenic genes removed 
they can still elicit host immune responses. Adeno-associated virus (AAV) can only 
package a small transgene, has low integration and poor tropism for HSC. There is a 
high incidence of host antibodies to AAV although no symptoms or disease is known to 
result from AAV infection. Utilisation of alternative serotypes may overcome these 
problems however (Nathwani et al., 2005).
Retroviral vectors, including simple type C and complex lentiviruses, can infect HSC 
and integrate their DNA (once reverse transcribed) into the host genome. They can 
package relatively large transgenes and are non-immunogenic. There are packaging cell
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lines available enabling easy preparation and scale up for clinical trials. Therefore 
gamma retroviral and lentiviral vectors may be the best suited for use in the treatment 
of single gene defect immunodeficiencies.
1.9.3 Retroviruses
Retroviruses are enveloped viruses consisting of 2 copies of single stranded RNA and 
are so named due to their ability to transcribe RNA to DNA. The main feature 
promoting them to the forefront of viral gene therapy vectors is their ability to integrate 
into the host genome. They can be classified simply into three groups: spumaviruses 
e.g. foamy virus, lentiviruses e.g. HIV-1, with all the others classed as onco- 
retroviruses e.g. Murine leukaemia virus.
All retroviruses contain at least three coding domains: gag, pol and env within long 
terminal repeats (LTR) responsible for integration of the provirus into the host genome. 
The LTR also has promoter and enhancer functions thus regulating the expression of 
the viral proteins, gag encodes for the matrix, capsid and nucleoproteins; pol encodes 
the viral protease {pro), reverse transcriptase and integrase and finally env encodes the 
envelope glycoprotein. Complex retroviruses such as lentivirus and spumavirus have 
additional accessory genes that encode regulatory elements effecting transcription, 
infectivity/virulence and RNA splicing.
1.9.4 Retrovirus Life cycle
A simplified model of the infection of a cell followed by budding of new viral progeny 
is shown in Figure 1.7. The virus particle binds to the cell via a cell surface receptor 
and this initiates the entry of the virus through fusion of the two membranes resulting in
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the insertion of the viral core. The single stranded RNA is reverse transcribed to double 
stranded DNA and is transported to the nucleus. Entry to the nucleus allows the 
pro viral DNA to integrate into the host genome. Translation by the host cellular RNA 
polymerase II allows transcription of spliced mRNA, for expression of viral proteins, 
and of full length RNA for packaging into new virus particles. New virus particles are 
assembled at the cell membrane and new infectious virions are released by budding
from the host membrane.
Translation Assembf
Figure 1.7 Retrovirus replication cycle
1. The parental virus attaches to a specific receptor on the surface of a permissive cell. 2. The 
virion and cell membrane fuse leading to entry of the core. 3. The RNA is reverse transcribed 
to generate a double stranded DNA copy. 4. The pro virus DNA is transported to the nucleus 
and integrated into host chromosomal DNA. 5. Translation by host cell RNA polymerase II 
generates RNA copies of full length and spliced messenger RNAs. 6. Messenger RNA is 
translated in the cytoplasm to form viral proteins. These are assembled together at the plasma 
membrane with full length RNA to form progeny virus. 7. Budding releases progeny virus able 
to infect other cells.
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1.9.5 Principles of Retroviral Vector Design
The basic principles of retroviral design involve making the virus safe and replication 
defective whilst maintaining their ability to efficiently transduce target cells. Synthetic 
retroviral vectors were first produced in the early 1980s using replication-competent 
helper virus but this was not acceptable, as the replication competent virus could not be 
separated. The development of packaging cell lines that provided retroviral proteins in 
trans eventually lead to the production of replication defective retroviral vectors. 
Because early steps in the retroviral life cycle, infection, reverse transcription and 
integration do not depend on viral protein synthesis, retroviral vectors have been 
improved by eliminating all viral coding regions and reducing viral elements to a 
minimum allowing more space for the transgene, up to 9kb, and reducing any problems 
associated with transfection with viral proteins (Figure 1.8).
Figure 1.8 Development of type C Retroviral Vectors
1/. Proviral genome structure of murine leukaemia virus (size 8.8kb). 2/. Genome structure 
of a MLV based viral vector. Gag, pro, pol and env have been removed and replaced with 
the transgene but the essential packaging sequence (vj/), primer binding site (PBS), poly 
purine tract (PPT) and poly adenylation sites are retained. An internal promoter is optional 
if there are is an intact U3 region on the 3’ LTR but necessary in SIN vectors where the U3 
region has been deleted. The transgene and promoter can be in either orientation between 
the viral LTRs. Adapted from (Hu and Pathak, 2000)
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Most of the vectors used in gene transfer are derived from mammalian type-C viruses 
such as Moloney murine leukaemia virus (MMLV), although other types have been 
used. The simplest vectors have a transgene with the expression controlled through the 
viral LTR and a packaging signal to incorporate the viral RNA correctly within the 
virion. More complex vectors have internal promoters, alternative splicing, multiple 
promoters and internal ribosomal entry sites to enable multiple gene expression often 
including selectable markers. An additional safety feature is the deletion of the U3 
region of the 3’ LTR. This deletion is transferred to the 5’ LTR during reverse 
transcription making transcription after integration impossible without an internal 
promoter, but maintains the poly A signal and PPT. Use of tissue or cell specific 
promoters can therefore provide some regulation of the transgene expression when 
compared to the ubiquitous LTR driven expression. This will be discussed in more 
detail later.
1.9.6 Packaging Cell Lines
Various packaging cell lines have been developed from adherent cell lines such as 
NIH3T3, 293T and HT1080, which provide the helper function necessary for 
production of replication deficient virus. They constitutively express the virus 
packaging genes on separate plasmids, to reduce the probability of recombination, 
under the control of drug resistance genes to maintain expression. Some packaging cell 
lines e.g. the 293T based Phoenix cell line used in this study also express markers 
which are linked to gag, pol and env expression thus allowing selection of high 
expressers and ultimately high titer virus producing cells (Kinsella and Nolan, 1996; 
Grignani et al., 1998b). Without the addition of the transfer vector packaging cells 
secrete empty particles, but upon transfection with a transfer vector, virus particles
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containing the transgene are secreted (figure 1.9). As vector design has improved so 
have packaging cell lines. There are many different packaging cell lines available 
including those that are pseudotyped with different envelopes compared to the original 
virus. This allows the tropism of the virus to be broadened and to increase the 
efficiency of transduction in cells that are lacking in certain viral receptors. An 
ecotropic envelope packaging cell line allows production of virus able to infect mouse 
cells only. The receptor is a cationic amino acid transporter, CAT-1 (Albritton et al., 
1989). For production of virus able to infect both human and mouse there is the 
amphotropic envelope whose receptor is Pit 2, a phosphate transporter (Kavanaugh et 
al., 1994; Miller et al., 1994). Other popular envelopes pseudotyped with MLV based 
retroviruses are Gibbon-Ape Leukaemia Virus (GALV) which binds Pit 1, another 
phosphate transporter (Kavanaugh et al., 1994; Miller et al., 1994), RD114 which binds 
RDR, a neutral amino acid transporter (Rasko et al., 1999) and Vesicular Stomatitis 
Virus-G (VSV-G) which binds the cell membrane component phosphatidylserine 
(Mastromarino et al., 1987).
Virus with the ecotropic envelope is able to infect murine stem cells, as there are high 
levels of the receptor on the cell surface. The amphotropic receptor is present at lower 
levels on both murine and human stem cells, therefore resulting in low transduction 
efficiency. Improved transduction efficiency in these cells has been seen with GALV 
and RD114 pseudotyped vectors, when compared to amphotropic and this has been 
directly linked to increased amounts of receptor (Thomsen et al., 1998).
Furthermore the RD114 and VSV-G envelopes stabilise the virus particles. This allows 
concentration of the virus by centrifugation, allowing for higher titers, and therefore 
higher multiplicity of infection leading to improved transduction efficiency (Gatlin et 
al., 2001).
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Figure 1.9 Retroviral packaging cell lines
The transfer vector containing the gene of interest (in this case WASp) in between 2 LTRs 
and a packaging signal (y) is transfected into a packaging cell stably transfected with Gag-Pol 
and Env to provide all elements in trans necessary for formation of intact viral particles 
(Pheonix cells are the packaging cells shown). The packaging cell can have various Env genes 
to enable pseudotyping of the virus particle. Upon infection of the target cell the viral RNA is 
reverse transcribed to double stranded DNA and integrated randomly into the host genome. 
The strong expression from the viral LTRs gives rise to cellular expression of the transgene.
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1.9.7 Limitations of Haematopoietic Stem cell Transduction with Retroviruses
Murine stem cells have been efficiently transduced with retroviral vectors and 
correction of murine models of human primary immunodeficiencies has been observed 
with relative ease (Bunting et al., 1998; Lo et al., 1999b; Yates et al., 2002; Otsu et al., 
2002). However human stem cells have proved to be more problematic. Inefficient 
gene transfer can be ascribed to the quiescent nature of the cells under normal 
conditions. Most of the stem cells are in GO and G1 with very few actively dividing 
(Cheshier et al., 1999). As retroviral integration requires the breakdown of the nuclear 
envelope (Miller et al., 1990b; Miller et al., 1990a; Roe et al., 1993), these cells can be 
activated and induced to divide using cytokine cocktails as previously described, 
making them susceptible to transduction (Dao et al., 1997; Conneally et al., 1997a; 
Demaison et al., 2000; Cavazzana-Calvo et al., 2000b). The use of Retronectin™, a 
synthetic fragment of fibronectin, has increased the efficiency of transduction by co­
localisation of virus and stem cells (Hanenberg et al., 1996; Moritz et al., 1996), 
however optimal transduction takes 3-4 days, during which time the repopulating 
ability in S/Nod mice is severely impaired (Gothot et al., 1998; Blundell et al., 1999). 
Although this has not stopped retroviral gene therapy vectors being developed for 
clinical use, with some success, it has fuelled the development of other novel retrovirus 
based vectors.
1.9.8 HIV-1 Lentivirus
The lentivirus is a complex retrovirus consisting of six additional genes to the 
previously described three for simple retroviruses (Figure 1.10), however they do not 
have oncogenic potential. They have an advantage over simple retroviruses in that they 
can infect non-dividing cells (Lewis and Emerman, 1994). Vectors for use in gene
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therapy are mainly derived from HIV-1 (Naldini et al., 1996), but have also been made 
from HIV-2 (D’Costa et al., 2001), SIV (Schnell et al., 2000) and EIAV (Yamada et al., 
2001). The most widely used and most advanced complex retrovirus based vectors are 
HIV-1 derived.
In addition to gag, pol, and env found in simple retroviruses, HIV-1 has four accessory 
proteins; vif, vpu, vpr and nef and two regulatory elements; tat and rev. The accessory 
proteins found in complex retroviruses enhance the efficiency of the viral life cycle 
such as mRNA production, protein production and transport to and from the nucleus, 
but unfortunately they also add to the virulence and pathology associated with the 
virus. In wild type virus vpr is required for replication of the virus and targeting virus to 
the nucleus in non dividing cells via its nuclear localisation sequence (Heinzinger et al., 
1994b). In addition it can induce cell cycle arrest in infected cells (Trono, 1995). vif is 
important for the production of highly infectious mature virions through unknown 
mechanisms (Gabuzda et al., 1992). vpu encodes for a small integral membrane protein. 
In T cells it acts upon CD4 accelerating its destruction in the endoplasmic reticulum 
(ER) therefore down regulating it on the cell surface. The subsequent release of env 
from CD4 binding in the ER promotes transport of env to the cell surface and enhances 
release of virus from the cell membrane (Willey et al., 1992; Gottlinger et al., 1993). 
The product of the nef gene is membrane associated, has complex effects on signal 
transduction within the cell and it too down regulates CD4, but from the cell surface 
(Greenberg et al., 1997). nef also has an effect on reverse transcription as virus particles 
without nef are less infective and have reduced viral DNA synthesis (Schwartz et al., 
1995).
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Figure 1.10 Development of HIV-1 derived gene transfer vectors
1/. Wildtype HIV-1 genome showing the full-length proviral DNA, the open reading 
frames (ORFs) and viral proteins. 2/. First-, 3/. Second-, 41. Third generation HIV-1 based 
lentiviral vectors showing the progressive loss of viral genes and the replacement of the 
LTRs with a CMV promoter and the addition of a poly A signal. All the structural and 
accessory proteins and maintained in the first generation vectors but are lost in the second 
generation. The third generation further splits rev onto another plasmid for increased 
safety. 5/. The transfer vector contains the gene of interest flanked between the LTRs. The 
3’ LTR is U3 deleted, which is duplicated during reverse transcription, for increased 
safety but therefore requires an internal promoter. Additional features include a central 
poly purine tract and the woodchuck post-transcriptional response element. 6/. The 
envelope plasmid allows pseudotyping viral particles with the VSV-G envelope, altering 
the tropism compared to wildtype. (Adapted from (Brenner and Malech, 2003).
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Finally the remaining two genes tat and rev are responsible for activating transcription 
and regulating splicing and RNA transport respectively, tat binds to a region in the viral 
LTR called TAR (Tat activation region) and is a potent activator of HIV-1 gene 
expression from the viral LTR (Laspia et al., 1989). rev binds to a cis-acting RNA 
target, the Rev Responsive Element (RRE) (Figure 1.10), present in all unspliced viral 
transcripts and targets them for nuclear export thus allowing alternative splicing 
necessary to generate the array of mRNAs required for expression of all viral genes 
(reviewed in (Pollard and Malim, 1998)). These two genes are necessary for virus 
replication, whereas the other four are associated with virulence.
The infection and replication cycle of HIV-1 is similar to that of simple retroviruses in 
that once the virus has entered the cell there is reverse transcription of the RNA to 
DNA followed by integration and translation. The subsequent differences in 
transcriptional activation and regulation have been discussed, as have the effects of the 
virulence factors. The main difference driving vector development is the ability to 
infect non-dividing cells. This is by actively transporting the pre-integration complex 
through the nuclear membrane pore via a nuclear localization signal in an energy 
dependant manner (Bukrinsky et al., 1992) even though the pre-integration complex is 
larger than the nuclear pores. The pre-integration complex is comprised of nucleic acid, 
the matrix protein p i7, reverse transcriptase, integrase and vpr (Figure 1.11). The 
matrix protein and vpr can be removed without loss of integration as vectors have been 
made without either suggesting some redundancy (Heinzinger et al., 1994a). However a 
non-classical nuclear localisation signal has been found in the catalytic domain of 
integrase and seems to be critical for transport across the nuclear membrane (Bouyac- 
Bertoia et al., 2001). In addition, subsequent studies have revealed the triple stranded
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DNA flap created by reverse transcription of the central polypurine tract (cPPT) is 
important for nuclear localisation (Zennou et al., 2000).
Critically for development of lentiviral vectors the pathogenic features need to be 
removed and the risk of generation of replication competent virus eliminated whilst 
maintaining the specific feature of transduction of non-dividing cells.
Figure 1.11 The lentiviral pre-integration complex.
The viral cDNA, complete with DNA flap, forms a complex with Vpr, matrix 
protein p i7 (MA) integrase (IN) and reverse transcriptase (RT) in the cell 
cytoplasm. This complex is transported through the nuclear pore into the nucleus 
where the cDNA is able to integrate into the host genome. Adapted from 
(Sherman and Greene, 2002)
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1.9.9 Development of Lentiviral Vectors
The development of lentiviral vectors can be grouped into ‘generations’ where each 
subsequent generation reveals a major change and/or improvement from the last (figure 
1.10), although this nomenclature is not specifically defined in the literature.
The first generation of vectors consisted of breaking the viral genome into three 
plasmids similar to the process first developed for retroviruses (Naldini Science 1996), 
to reduce the chance of a replication competent virus being produced. The three 
plasmids produced were: a transfer vector containing the ‘gene of interest’ (either a 
marker or therapeutic gene) located in-between the viral LTRs, a packaging construct 
containing the helper functions and the envelope containing construct. The helper or 
packaging construct (pCMVA8.9) contains gag and pol with all the accessory virulence 
factors apart from vpu but has no LTR sequences or packaging signal. A CMV promoter 
controls expression in place of the 5’LTR and a poly A signal derived from the insulin 
gene replaces the 3’LTR (Naldini et al., 1996). The transfer vector (pHR’) containing 
the viral LTRs has most of the viral gag and pol sequences removed, as is the env and 
all of the accessory genes, whilst retaining the rev and tat responsive elements (RRE 
and TAR). The RRE allows complex expression elements including introns and 
genomic sequences to be included by taking advantage of the nuclear export function of 
rev. Removal of the RRE results in a dramatic reduction in the titer. With the removal of 
most of the wild-type genome, up to lOkb can be inserted between the LTRs. The third 
plasmid contains the env gene under the control of the CMV promoter. HIV-1 normally 
has the narrow tropism of macrophages and T cells, but will tolerate pseudotyping. 
Therefore the original envelopes used were either the VSV-G envelope, which confers a
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broad based tropism due to its ability to bind to phosphatidylserines in the plasma 
membrane or the MLV amphotropic envelope.
Virus is made by transiently transfecting all three plasmids into an adherent cell line 
such as 293T cells and harvesting the supernatant 48-72 hours later. VSV-G 
pseudotyped particles can be concentrated by ultracentrifugation due to their stability 
(Naldini et al., 1996). This allows the production of replication defective infectious 
virus that can integrate into cells not undergoing mitosis. Unfortunately there are few 
HIV-1 packaging cell lines possibly due to the toxicity associated with the VSV-G 
envelope (Klages et al., 2000) or HIV-1 protease (Ikeda et al., 2003).
Second generation vectors have further changes in the packaging plasmid. The 
accessory genes (vif vpu, vpr, nef) are removed with the regulatory elements tat and rev 
retained. The efficiency of virus production was not affected by the extra deletions 
however there was a reduction in efficiency of transduction in some cell types e.g. 
macrophages (Zufferey et al., 1997). This was thought to be due to dependence upon 
vpr and vif and is cell type dependant, as irradiated 293T cells did not have a reduced 
infectivity. Further modifications include the manipulation of the 3’LTR by partially 
deleting the U3 region. This creates a self-inactivating (SIN) vector due to both U3 
regions of the cDNA created from the 3’LTR during reverse transcription. Deletion of 
the U3 region eliminates transcriptional activity of the viral LTR, and prevents synthesis 
of viral RNA, therefore an internal promoter was required (Zufferey et al., 1998). The 
creation of SIN vectors improved the safety of the vectors by minimizing the risk of 
creating replication competent virus and abnormal expression of cellular genes mediated 
by the viral LTR. In addition the removal of the enhancer sequences prevents distant 
promoters being activated and interference between specific promoters and the viral 
LTRs (Zufferey et al., 1998).
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Third generation vectors further split and deleted the lentivirus genome for additional 
safety, whilst maintaining the titers obtained and the transduction efficiencies, tat was 
made redundant, and therefore removed, by the placement of a constitutive promoter in 
place of the U3 portion of the 5’LTR. rev was separated from the helper plasmid onto a 
new non-overlapping construct under the control of an RSV promoter (Dull et al., 
1998). This created a four plasmid system available for use in a similar manner to the 
three plasmid system. These additional safety features render the plasmids non­
functional outside of the producer cells and further decreases the likelihood of 
recombination events leading to replication competent viral particles being produced 
whilst removing as much of the wild type HIV-1 genome as possible.
Enhanced expression from SIN vectors has been achieved through the incorporation of 
the central polypurine tract (cPPT) and the posttranscriptional regulatory element of the 
woodchuck hepatitis virus (WPRE). The cPPT acts by enhancing nuclear transport and 
increasing the amount of integrated vector DNA promoting higher transduction 
(Follenzi et al., 2000) especially in stem cells (Sirven et al., 2000). The inclusion of the 
WPRE enhances transport of vector RNA from the nucleus (Schambach et al., 2000) 
and increases the efficiency of transduction (Zufferey et al., 1999).
1.10 Regulation of Gene Expression
Historically one of the main problems associated with gene transfer, especially into 
haematopoietic cells, is long term maintenance of high levels of expression of the 
transgene. Many vectors utilise the CMV promoter which works well in vitro but can 
often be silenced in vivo by de novo methylation (Challita and Kohn, 1994a). This has 
led to the use of other promoters such as phosphoglycerate kinase (pgk) (Zufferey et al.,
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1998; Follenzi et al., 2000) and elongation factor l a  (EFla) (Salmon et al., 2000). Use 
of different retroviral 3’ LTR sequences such as those from the spleen focus forming 
virus (SFFV) have also shown increased levels of expression in haematopoietic lineages 
(Baum et al., 1995) and with the WPRE and cPPT have vastly improved the expression 
levels in haematopoietic cells (Demaison et al., 2002).
Although high transgene expression is often required there may be some problems 
associated. Dissemination of particles, although not a problem ex vivo, could lead to 
transduction of non-target cells in vivo raising the possibility of germ-line transmission. 
Over expression of transgenes and expression in cells that do not normally express a 
protein may lead to adverse effects. Therefore the regulation of transgene expression 
through inducible promoters or tissue specific promoters has been investigated with the 
aims of improving the efficiency, safety and duration of expression possibly regulated 
within the cell in a normal manner.
Regulation of gene expression by inducible promoters has been achieved by systems 
such as the tet on/off system (Vigna et al., 2002) or ecdysone (Galimi et al., 2005). This 
allows regulation of the amount of protein expressed, cessation of expression and 
repeated treatment cycles if needed. These systems are however reliant upon the easy 
administration of the inducer/repressor and reliable activation leading to expression of 
the transgene.
Tissue specific promoters would allow promiscuous infection whilst stopping unwanted 
expression in undesirable cell types. They have been described for brain (Hwang et al., 
2001), muscle (Li et al., 1999), bone (Hou et al., 1999), and liver (Nash et al., 2004). In 
addition to tissue specific expression, cell or lineage restricted expression has also been 
investigated. These include T cells (Indraccolo et al., 2001), macrophages (Gough and 
Raines, 2003) megakaryocytes (Yasui et al., 2005) and red blood cells (May et al.,
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2000) amongst others. These promoters whilst maintaining specificity often do not give 
expression levels comparable to constitutively active promoters and therefore are not 
always optimal.
Critically primary immunodeficiencies such as WAS often have defects in multiple 
lineages therefore a haematopoietic specific promoter would be required. There is some 
evidence to suggest that the putative promoter sequence 3’ of the start codon of WAS 
shows some haematopoietic restriction (Petrella et al., 1998; Martin et al., 2005) thus 
making it an attractive promoter for use in retroviral or lentiviral gene therapy protocols.
1.11 Statement of Aims
The aims of this study were:
• To develop a fusion protein of EGFP and WASp to elucidate the role of 
WASp in cells using direct fluorescence and for use in gene therapy 
protocols.
• To restore WASp expression to therapeutic levels in a WAS KO mouse 
model by transducing bone marrow derived stem cells using this fusion 
protein in a retrovirus
• Establish the efficiency of HIV-1 based lentiviral vectors encoding EGFP- 
WASp and WASp to restore functional activity in murine dendritic cells and 
human WASp null macrophages, using a podosome based assay. This 
includes a comparison of internal promoters including constitutive, derived 
from viruses, and tissue specific, derived from the region immediately 5’ of 
the WAS start codon to determine the best efficacy.
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• Further comparison of the HIV-1 based vectors ability to restore WASp 
expression, and therefore phenotype in vivo, by introduction of WASp in a 
WASp KO mouse model.
• Investigate constitutively active WASp12947 in patient primary cells and 
induced expression in a cell line to determine possible mechanisms of patient 
phenotype.
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All reagents from Sigma, unless otherwise stated. All primers from Invitrogen.
2.1 Cell Culture
2.1.1 Cell Lines
293T cells, Phoenix Eco, HeLa cells, HT1080 cells and NIH 3T3 cells were purchased 
from the European Collection of Cell Cultures (ECCC) and cultured in Dulbecco’s 
MEM- Glutamax (Life Technologies) supplemented with 10% FCS (Sigma) lOOIU/ml 
penicillin and lOOug/ml streptomycin (Life Technologies).
Jurkat cells and Cos-7 cells were purchased from ECCC and were maintained in RPMI- 
glutamax supplemented with 10% FCS and lOOIU/ml penicillin and lOOug/ml 
streptomycin (complete). All the cultures were maintained at 37°C with 5% CO2 and 
split every 3-4 days when approaching confluency. Adherent cells were detached by 
incubating with trypsin-EDTA for 5-10 min prior to splitting.
Bac-1 macrophages (a gift from G Jones, Kings College, London) were cultured in 
complete RPMI supplemented with 30ng/ml of rhuM-CSF were split every 3-4 days. 
Incubation with Accutase at 37°C for 5-10 min was used to detach adherent cells.
2.1.2 Human Peripheral Blood Macrophages
10ml human blood from patient or a normal control was venisected into heparinised 
tubes, diluted 1:1 with RPMI and layered onto Ficol-Hypaque (Pharmacia, Sweden) and 
centrifuged at 2300rpm, without brake, for 20 min. The peripheral blood mononuclear 
cells were aspirated from the ficol/serum interface and washed in RPMI (Life
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Technologies) twice. These cells were then plated into 25cm flasks in complete RPMI 
and incubated at 37°C for 2 hours to allow the monocytes to adhere. After 2 hours the 
non-adherent cells were removed and fresh complete RPMI was added supplemented 
with lOng/ml rHu-MCSF (R+D Systems, Oxon, UK). The media was refreshed every 2 
days until day 5 or 6 when the macrophages were harvested for use. Purity was 
determined by CD 14+ staining.
2.1.3 Murine Dendritic Cell Culture
Bone marrow was obtained by flushing the femur and tibia of mice with RPMI. The
•j
single cell suspension was plated into 75cm flasks in HEPES-buffered RPMI 
Glutamax-1 supplemented with 10% FCS, lOOIU/ml penicillin and lOOug/ml 
streptomycin, and 25ng/ml rmuGM-CSF (Peprotech). After 48 hours the media was 
replaced with complete RPMI containing 25ng/ml rmuGM-CSF and lOng/ml rmuIL-4 
(Peprotech). The cells were further grown for 72-96 hours prior to the non-adherent 
cells being harvested for use. Purity was determined by CD1 lc+ staining.
2.1.4 Purification of murine stem cells
Bone marrow was flushed from the femur and tibia of WASp KO or control Sv/129 
mice with RPMI and washed in PBS/1%BSA (w/v). The scal+ve cells were either 
positively selected using MACS seal microbeads (Miltennyi Biotech) or lineage 
negative cells obtained by negative selection to enrich progenitor cells (Stem Cell 
Technologies).
For positive selection, lOOul of MACS beads were added to lxl 08 cells in 400ul 
PBS/1%BSA and incubated at 4°C for 20 minutes. Unbound beads were diluted out
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with lOmls of PBS/1%BSA and the cells pelleted before resuspension in 1ml of 
PBS/1%BSA. A MACS MS column was equilibrated with 1ml PBS/1%BSA and the 
cells applied to the column. The column was washed with 1ml PBS/1%BSA before the 
bound cells were released by adding 1ml RPMI 30% FCS (v/v) and forcing off the 
column using the syringe plunger. The cells were counted, an aliquot tested for purity 
by flow cytometric analysis of the Scal+ population, and cultured at concentrations of 
5x105-1x106 in lOOng/ml SCF, lOng/ml Flt-3L and 20ng/ml IL-6 (Peprotech).
For negative selection cells were resuspended at 2-8x10 /ml in PBS 1%BSA. Cells were 
then incubated with rat serum (final concentration 5%) at 4°C for 15 minutes, followed 
by addition of the antibody cocktail at the indicated concentration and further incubation 
for 15 minutes at 4°C. Cells were washed and lOOul/ml of anti-biotin tetrameric 
complexes was added, incubated at 4°C for 15 minutes and finally 60ul/ml of magnetic 
colloid added followed by a further 4°C incubation for 15 minutes. The sample was 
loaded onto a prepared column and the enriched progenitors collected as flow through. 
Cells were counted and cultured as described previously for Scal+ selected cells.
2.2 Immunostaining of Cells
2.2.1 Human dendritic cells, macrophages and murine dendritic cells
On day 6, 104 macrophages or dendritic cells were transferred to 13mm diameter glass 
cover slips coated with fibronectin, where stated, and allowed to adhere. Prior to 
immunostaining, the cells were fixed in 4% paraformaldehyde (PFA), permeabilised 
with 0.1% Triton X-100 and blocked with PBS/1 % BSA for 30 minutes. Cells were 
incubated with rhodamine phalloidin (Molecular Probes, Leiden, Netherlands) for 20
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min to visualise F-actin and then with anti-vinculin antibody (hVIN-1 mouse IgGl 
monoclonal, ascitic fluid used at 1:100 dilution). Antibody binding was detected with a 
goat anti-mouse IgG conjugated to Cy-5 (Jackson Immunoresearch, West Grove, PA, 
USA). Images were recorded digitally using either a charge coupled device (CCD) 
camera or a confocal Leica (TCS-SP2) microscope to obtain composite images or 
projections of 8-12 z sections. Images were processed with Adobe Photoshop®.
2.2.2 Adherent Cell Lines
Cells were plated onto 13mm diameter or 22mm coverslips at densities between 10 - 
105 in their respective media, allowed to adhere overnight, before fixing and staining as 
described previously.
2.2.3 Reconstituted Mice
Murine bone marrow, axial and brachial lymph nodes, spleen and thymus were excised 
from mice and a single cell suspension made in PBS/1%BSA. lxlO6 cells were washed 
twice in PBS/1%BSA before incubating with antibody at 1:100 dilution against CD3, 
CD1 lb or B220 at 4°C for 20 minutes. The cells were washed twice in PBS/1%BSA 
and once in PBS before fixing in 4% PFA.
2.2.4 Cell Cycle analysis
HT1080 cells were grown as previously described. At intervals between days 2-15 cells 
samples were harvested, washed in PBS and fixed in PFA overnight. After 24 hours 
they were washed with PBS and incubated on ice in 70% ethanol for 2-3 hours. The 
cells were washed again and resuspended in PI buffer, (1 mg/ml Na3 Citrate, 0.1% 
triton), PI added at 50ug/ml and analysed by flow cytometry within 15 minutes for
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DNA and EGFP levels. The data was collected using Expo32 software (Beckman 
Coulter). Doublet discrimination was used to include only single cells. 100,000 events 
were collected to permit cell cycle analysis of both the GFP-negative and GFP-positive 
fractions. Linear gates were set to quantify cells at each phase of the cell cycle. 
Additional analysis was performed using Multicycle software (Phoenix Flow Systems). 
The aggregate model was applied to the data to exclude doublets and a curve fitted to 
model DNA distribution within the cell cycle.
2.2.5 Apoptosis and Cell Death Analysis
HT1080 cells were maintained as previously described and at intervals between day 2- 
28 samples were harvested, washed in PBS and resuspended in annexin buffer prior to 
staining for annexin V PE (Pharmingen) and 7AAD to determine the levels of apoptosis 
and cell death. The cells were analysed within 20 minutes of staining and 20,000 cells 
collected to allow both the GFP positive and negative fraction to be analysed.
2.3 Virus Production
2.3.1 Ecotropic and Amphotropic Retrovirus
Phoenix retrovirus producer cells containing either the ecotropic (a gift from Garry 
Nolan), were plated at 70% confluency and transfected with PINCO constructs 
containing EGFP, EGFP-WASp or WASp by the calcium phosphate precipitation 
method. The cells were treated with puromycin at lug/ml for 1-2 weeks until a highly 
selected population was obtained. The cells were removed from selection washed and 
plated at high confluency with just enough media to cover (5ml in 75cm2 flask) and the
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supernatant containing the virus harvested twice daily for 2-3 days. Virus was stored at 
-80°C.
2.3.2 Lentivirus Production by Ultracentrifugation
Viral stocks were produced by co-transfecting 3 plasmids into 10-15xl06 293T cells: the 
envelope plasmid pMD.G (lOug), the helper plasmid pCMVR8.91 (30ug) and one of 
the transfer vectors encoding EGFP, EGFP-WASp or vector containing WASp (40ug) 
After 48 hours the resulting viral supernatant was concentrated by ultracentrifugation at 
100,000g in a Beckman centrifuge to pellet the virus, followed by resuspension in 
RPMI or Stemspan (Stem Cell Technologies) and stored at -80°C until used.
2.4 Viral infection of cells
2.4.1 Retrovirus Titering
50.000 3T3 cells were seeded in dilutions of viral supernatant from 1:1 to 1:250. After 
72 hours the cells were harvested and analysed by flow cytometry to determine the 
percent positive cells. The titer was then be calculated by multiplying the number of 
cells seeded by the dilution and the percent of positive cells.
2.4.2 Lentivirus Titering by Infectious method
50.000 HeLa cells were seeded in dilutions of viral supernatant from 1:100 to 1:106.
After 72 hours the cells were harvested as previously described and the titer calculated 
as before.
2.4.3 Lentiviral Titering by Quantitative per
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2.4.3.1 Purification of genomic DNA from Cultured cells
Cultured cells were pelleted and 20ul of NP40 lysis buffer containing proteinase K was 
added. This was incubated at 56°C for 2 hours, briefly pulsed at 13,000 rpm, before 
further incubation for 15minutes at 95°C to inactivate the proteinase K. The solution 
was again pulsed at 13,000rpm and 180ul of distilled DNAse free water added. 
Following centrifugation at 13,000rpm for 10 minutes the supernatant was collected and 
transferred to another tube. This was either used immediately or frozen at -20°C until 
needed.
50,000 HT1080 cells were seeded and dilutions of viral supernatant added as described 
previously. After 72 hours the cells were harvested, pelleted and genomic DNA purified 
from the cell pellet. Two separate PCR reactions were run for each sample in triplicate 
using a fluorescently labelled probe (ABI) against the lentiviral vector primer binding 
site and against p actin. The probes are fluorescent labelled on the 5’ end and have a 
quencher on the 3’ terminus. The endonuclease activity of taq releases the 5’ fluorescent 
label from the fret activity of the quencher thus increasing the fluorescence in the well 
with each cycle of the per, which can be detected. This would allow a value to be 
obtained for the number of viral copies present and the number of cell genomes in the 
reaction. By comparing the cycle threshold values, an arbitrary value where all the 
samples are in log phase expansion and are increasing without converging, obtained 
against a standard curve for the lentiviral vector and p actin, the number of copies of 
integrated virus could be calculated per cell. The viral titer can then be calculated by 
multiplying the integrated copy number by the number of cells plated and the dilution of 
virus added initially.
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2.4.3.2 Creation of standard curves
A standard curve of known copies of lentiviral plasmid was generated from 1 copy to
100,000 copies/5ul added to the PCR reaction. The number of lentiviral vector genomes 
was calculated using the following formulae.
Plasmid size (bp) x 330 Daltons x 2nt/bp = No of Daltons or g/mole
e.g. for SEWW. 11371 x 660 = 7504860
g/mole -5- Avagadro’s constant = g/molecule
e.g. 7504860 + 6.023x10“  = 1.246xl017
Therefore, 8.9ug/ml of plasmid (actual concentration) has
0.0089g/ml -5- 1.246xl0"17 = 7.1429xl014 molecules/ml
The plasmid DNA can then be diluted to the appropriate concentration per 5ul.
A plasmid was generated containing p actin and dilutions were made in a similar 
manner and normalised against known dilutions of cells (a gift from D King and S 
Howe, ICH).
2.4.4 p24 ELISA
The quantity of p24 in viral supernatants was calculated using a commercially available 
HIV-1 p24 antigen ELISA (Beckman Coulter). The assay was performed as per 
instructions. Briefly viral supernatant was diluted l:lx l0 6 and l:5xl06 and added to the 
antibody pre-coated wells. The samples were lysed and biotinylated human anti HIV-1 
IgG added followed by incubation at 37°C. After washing a streptavidin horseradish 
peroxidase is added followed by tetramethylbenzidrine (TMB) and hydrogen peroxide 
to form a blue colour. This reaction is stopped by addition of acid and the intensity of 
the colour developed is directly proportional to the amount of HIV-1 in the sample. This 
can then be calibrated against p24 antigen standards at known dilutions.
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2.4.5 Viral Infection of Cell Lines
Retroviral infection of cell lines was performed by seeding cells at a low confluency to 
induce cell division followed by addition of viral supernatant diluted 1:1 with fresh 
media. Multiple rounds of infection were performed to increase transduction levels if 
needed.
For lentiviral infection the concentrated virus was directly added to the cells in culture 
at the required MOI in small culture volumes with no conditioning.
2.4.6 Lentiviral Infection of Macrophages and Dendritic cells
Macrophages and dendritic cells were prepared as described previously and transferred 
to 13mm diameter coverslips, coated with fibronectin where stated. After 2-3 hours in 
culture to allow adherence lentivirus was added at the required MOI. The media was 
refreshed 24h later and the cells incubated for a further 48h before fixing and staining as 
previously described. Podosome restoration was determined by counting random fields 
of view captured as images by confocal microscopy (Leica). Images were manipulated 
in Adobe Photoshop® and 100-200 cells were scored for each condition. These images 
were further used to determine the number of podosomes per cell.
2.4.7 Retrovirus Infection of Murine Stem Cells For Reconstitution
Seal positive cells were harvested as previously described placed into culture in 30% 
FCS RPMI (v/v) supplemented with lOOng/ml SCF, 20ng/ml IL-6 and lOng/ml Flt-3L 
for 48 hours. Non-tissue culture plates were coated with retronectin (Takara) and virus 
supernatant was preloaded by centrifugation at 4000g for 20 minutes. Cultured Scal+ 
cells were added to the retronectin coated wells and more viral supernatant added
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diluted 1:1 with fresh media supplemented with cytokines. The cells underwent 4 
further rounds of infection over the next 72 hours. Finally after 5 days the cells were 
washed and either plated out in semi-solid media as previously described or re-infused 
into lethally irradiated (1000 RADS) recipients at doses of 2-4x105/mouse.
2.4.8 Lentivirus Infection of Murine Stem Cells for Reconstitution
Seal positive cells or lineage negative cells were harvested and plated out as previously 
described overnight in media containing cytokines with the addition of the lentiviral
7  Qsupernatant at the stated MOI at an optimised concentration of 10 -10 /ml. After 24 
hours the cells were washed and infused into lethally irradiated recipients at doses of 2- 
3xl05/mouse.
2.5 Cloning
2.5.1 Restriction Endonucleases
l-4ug of DNA was digested for 1-2 hours with excess enzyme present. All digests were 
performed in 40-50ul in the optimal buffer and temperature recommended by the 
manufacturer (Promega or NEB unless stated).
2.5.2 Blunting 5’ ends
After digestion if needed the DNA was blunted by addition of DNA polymerise I 
(Klenow Fragment) and 2mm dNTPs buffered as required. This was performed at room 
temperature for 15 minutes before heat inactivating the enzyme at 65°C for 15 minutes.
2.5.3 DNA cleaning
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Digested and blunted DNA was cleaned using a Qiagen Nucleotide Clean up Kit. This 
removed all salts and previously added enzymes which could inhibit further 
manipulation.
2.5.4 Dephosphorylating DNA
Where required DNA was dephosphorylated using shrimp alkaline phosphatase. This 
required incubating the DNA with lul of enzyme in the supplied buffer at 37°C for 1 
hour before heat inactivating for 15 minutes at 65°C.
2.5.5 Resolving digested DNA
After manipulation the DNA was run on a 1% agarose gel for 1-2 hours depending on 
the size of fragment to be resolved. The band was excised and purified from the agarose 
using a gel extraction kit (Qiagen)
2.5.6 Ligation
Suitably compatible digested and purified DNA fragments were mixed with DNA ligase 
and ligase buffer as per the manufacturers instructions and incubated overnight at 14°C.
2.5.7 Preparation of Chemically Competent Bacteria
50ml LB was inoculated with JM109 E.coli and incubated at 33°C with agitation for 4-8 
hours. At regular intervals a sample was tested to determine the optical density at 
650nm. When the density was between 0.6-0.7 the culture was spun down at 5000rpm 
for 15 minutes at 4°C and the resulting pellet resuspended in 10ml sterile 2M CaCb for
81
Chapter 2
15 minutes. The bacteria were spun again and resuspended in 4ml of fresh 2M CaCL 
lml of sterile glycerol added and snap frozen in aliquots of lOOul in liquid nitrogen.
2.5.8 Transformation of Competent Bacteria
20-30ul of ligated DNA was incubated on ice with lOOul of competent bacteria for 30 
minutes. The DNA bacteria mix was then incubated at 42°C for 90 seconds before 
returning to ice for 5 minutes. Then lml of LB without antibiotics was then added to the 
transformed bacteria and incubated at 33°C for lhour. After incubation the bacteria 
were pelleted and spread onto an LB agar plate with the appropriate antibiotic selection 
and incubated overnight at 33°C until colonies derived from single bacteria could be 
observed.
2.5.9 Mini-preps
5-10ml LB containing the appropriate antibiotic (either 50ug/ml kanamycin or lOOug/ml 
ampicillin) was inoculated from a single colony and incubated overnight. Multiple 
colonies were picked and the resulting cultures were pelleted and the plasmid DNA 
extracted using a mini-prep kit (Qiagen). This DNA was digested to confirm the 
presence of the correct plasmid DNA construct within the bacteria.
2.5.10 Large Scale Plasmid DNA Production
500ml LB with the appropriate antibiotic was inoculated 1/1000 and incubated for 12- 
14 hours at 33°C with agitation. The bacteria were pelleted by centrifugation at 5000g 
for 15 minutes and the plasmid DNA extracted by alkaline lysis using a Mega-Prep Kit 
(Qiagen). The resulting DNA was resuspended in lml water and stored at -20°C.
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2.6 Immunoblot
Cells from culture or primary cells were harvested and pelleted at 1200rpm for 5 
minutes. They were then resuspended in 200ul of lysis buffer containing protease 
inhibitors and incubated on ice for 5 minutes. The sample was then spun at 14000rpm 
for 5 minutes at 4°C and 200ul of the supernatant added to 200ul of 2 X SDS loading 
buffer. This was then heated at 85°C for 5 minutes before loading onto gel or stored at -  
20°C until required.
Glass plates were cleaned and a gel poured. The plates were filled to 3A full with a 
separating gel of 8% and allowed to set. The remaining % was filled with a stacking gel 
of 12% (see appendix) and allowed to set. The gel was loaded with all wells filled in 
order to get straight running and a voltage of 150-250 volts applied for 1-3 hours 
depending on the size of the gel. The gel was transferred to nitrocellulose using a semi 
dry blotter at 12 volts for 20 minutes.
Before probing with antibodies the nitrocellulose was incubated for lA hr-1 hr in a 5% 
milk solution in PBS-T to block non-specific binding. The nitrocellulose was probed 
with a solution of antibody in 5% milk PBS-T for 1-2 hours before being washed 5 X in 
PBS-T. A secondary antibody conjugated to HRP was added for Vz -% hour in 5% milk 
solution in PBS-T, then the blot was again washed in PBS-T. Protein bands were 
visualised by incubating the nitrocellulose with ECL for 1 minute and exposing on 
photographic film or digitally captured using a gel documentation system (UVITEC) 
and software (UVISOFT).
Where necessary the nitrocellulose had the bound antibody stripped off by washing in 
0.2M glycine, 0.5M NaCl for 5-10 minutes before rinsing in 0.1 M NaOH for 10 
minutes. The nitrocellulose could then be re-probed for p-actin to enable loading of the 
gel to be checked.
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2.7 Quantitative PCR
2.7.1 Determination of Viral Copy Number in Transduced murine cells
Quantitative per was used to determine integrated viral copy number and has been 
described previously (Towers et al., 1999). The transduced murine cells were pelleted 
and genomic DNA extracted as previously described. Two separate per reactions were 
run in triplicate for each sample using a fluorescently labelled probe against the 
lentiviral vector primer binding site and against murine titin (a gift from A Galy, 
Genethon, Paris, France(Charrier et al., 2005)). This would allow a value to be obtained 
for the number of viral copies present and the number of murine cell genomes in the 
reaction. By comparing the cycle threshold values obtained against a standard curve for 
the lentiviral vector and murine titin, the number of copies of integrated virus could be 
calculated per cell. Standard curves were created by diluting plasmid as previously 
described. The value for murine titin was normalised for copy number per cell. After 
obtaining a value for copy number the value was normalised to that of another 
laboratory (A.Galy, Genethon, France) performing the same per on the same sample.
2.7.2.1 Extracting mRNA from cell pellets
thCell pellets were resuspended in Tri-reagent and 1/5 total volume of chloroform 
(stabilised with amylenes) was added. This was centrifuged at 13,000rpm in a 
microfuge to separate the RNA, DNA and protein into specific layers. The clear top 
layer containing RNA was removed and an equal volume of isopropanol added. This 
was incubated at -20°C for at least 2 hours before centrifugation at 13,000rpm to pellet 
the precipitated RNA. The RNA pellet was washed in 70% ethanol, spun at 13,000rpm
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for 5 minutes and air dried. The dry pellet was resuspended in 10-20ul of water and 
stored at -20°C until needed.
2.122  Making cDNA from RNA
5ul of RNA was incubated with 0.5ul RNAse inhibitor (Applied Biosystems), lul of an 
oligo dT and lul of 2.5mM each dNTPs at 70°C for 10 minutes followed by placing on 
ice for 5 minutes, lul of 25mM MgC12, lul of per buffer 2 (Applied Biosystems) and 
0.5ul MMLV reverse transcriptase (Applied Biosystems) was added and the mixture 
incubated at 42°C for 1 hour to allow reverse transcription. The resulting cDNA/mRNA 
hybrid could then be used in a per to determine mRNA levels in the cells.
2.1.23 WAS mRNA expression analysis
Two separate per reactions were performed in triplicate using the cDNA/mRNA hybrid 
as template to determine the expression levels of WAS (Assay by Demand, ABI). These 
were a human WAS specific per and a murine PGK per. By directly comparing the cycle 
threshold (CT) value obtained from the WAS per relative to the housekeeping gene the 
expression levels of human WAS can be compared across samples using one sample as 
the reference to which all others can be compared. The fold increase or decrease in 
expression levels are calculated in the following way.
WAS CT -  PGK CT = ACT for each sample 
ACT sample -  ACT reference = AACT 
2-mct _ jncrease between samples
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2.8 T Cell proliferation Assay
Murine splenocytes, (2xl05 cells/well in 200ul), were stimulated in triplicate for 72 
hours in DMEM with 10%FCS with anti-CD3e antibody (Pharmingen) coated onto 96 
well flat bottomed microtiter plates. Cultures were pulsed with [methyl-3H] thymidine 
(luCi/well) for the last 16 hours. Incorporated radioactivity was measured using a 
scintillation counter.
2.9 Patient Leukocyte Functional assays
2.9.1 E.Coli Phagocytosis (Kit phagotest Orpegen)
lOOul whole blood was added to separate FACS tubes containing 20ul FITC labeled 
opsonised e.coli (lxlO9 bacteria/ml). A control tube was kept a 4°C, the test tube was 
incubated at 37°C for 10 mins. The tubes were then put on ice and lOOul quench 
solution added to strip the FITC labeled bacteria which are outside of the cell. 2ml PBS 
was added and the tubes centrifuged at lOOOxg for 5 mins, the supernatant was 
discarded and lml lysing solution added at room temp for 10 mins to remove 
erythrocytes. The tubes were centrifuged at lOOOxg for 5 mins, cells resuspended in 
PBS and recentrifuged. Once the supernatant had been dicarded the cells were 
resuspended in 300ul PBS with lOOul DNA staining solution. The samples were kept on 
ice and analysed within 20 mins.
2.9.2 Oxidative Burst Response in Granulocytes (Kit phagoburst Orpegen)
lOOul whole blood was added to separate FACS tubes containing 20ul PBS, 20ul of 
unlabelled opsonised e.coli (lx l09 bacteria/ml), 20ul 5uM PMA solution, or 20ul 
400nmol/l fMLP for which the blood has been preincubated for 3 minutes with 3ug/ml
86
Chapter 2
cytochalasin B. The tubes were incubated for 10 mins at 37°C, 20ul working solution of 
DHR is added, and the tubes were returned to 37°C for a further 10 mins. 
lml lysing solution was added at room temp for 10 mins to remove erythrocytes. Then 
the tubes were centrifuged at lOOOxg for 5 mins, the supernatant discarded, cells 
resuspended in PBS and recentrifuged. Once the supernatant had been dicarded the cells 
were resuspended in 300ul PBS with lOOul DNA staining solution. The samples were 
kept on ice and analysed within 20 mins.
2.9.3 Flow cytometry
All samples were analysed on a Beckman Coulter XL flow cytometer using Expo2 
software. A live gate was enabled on the DNA stain (675nm) to eliminate debris and 
bacteria. 10,000 events were collected in the granulocyte gate identified by forward 
scatter side scatter analysis. Oxidative burst was observed using the FL1 (525nm) signal 
to detect the oxidation of DHR from a non fluorescent to fluorescent compound to 
evaluate the percentage and MFI above the PBS control response. Phagocytosis was 
observed using the FL1 (525nm) signal to detect the percentage of cells which had 
phagocytosed FITC labelled bacteria compared to the 4°C control. The MFI was 
evaluated as a guide to the amount of bacteria within each cell.
2.9.4 Apoptosis in Patient Lymphocytes and Bone Marrow
Apoptosis in lymphocytes was measured by incubating the mononuclear cell fraction 
from density-centrifugation separated peripheral blood for 48 hours in RPMI / 10% FCS 
containing IL-2 (60IU/ml) and PHA (lOpg/ml). For the induction of apoptosis, cells 
were transferred to a 48 well plate (1 x 105 cells/ml). Apoptosis restricted to the fas 
pathway was induced by the addition of 1 pg/ml IgM anti CD95 antibody (CHI 1 clone
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Kamiya Biomedical, Seattle, WA). Non specific cell death was induced by 0.1 pg/ml 
camptothecin. A negative control, medium only, was included to assess spontaneous 
cell death. After a further 48 hour culture, cells were washed and resuspended in 
annexin buffer (Pharmingen, Oxford, UK) prior to staining with annexin-V FITC and 
7AAD/propidium iodide (PI) to determine apoptosis and death levels. 10000 cells were 
read by Beckman Coulter XL FACS within 30 minutes of staining (Vermes et al., 1995; 
van Engeland et al., 1998). Spontaneous apoptosis in bone marrow was measured by 
incubating density-centrifugation separated cells for 15 minutes at room temperature 
with Annexin V FITC and PI to a final concentration of 1 |ig/ml for each. The signal 
was then quenched in Annexin buffer and analysed immediately. Cells had been pre­
labelled by incubation with one of CD34, CD33 or CD 15 for 30 minutes and then 
washed with PBS. Samples were analysed on the flow cytometer as previously 
described.
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3.1 Introduction
In order to elucidate the functional role of WASp in cells it is necessary to have an easy 
and reliable method of detection. A lack of suitable antibodies against WASp has 
required solutions such as FLAG tagging (Symons et al., 1996). Unfortunately this 
requires fixation of the cells and tagging on the conformationally sensitive C-terminus. 
Tagging the N-terminus with EGFP to create a fusion of EGFP and WASp was 
considered a viable option to detect WASp in live cells and to determine where in the 
cell WASp is located. Use of fluorescence is also useful for determination of 
transduction efficiencies, promoter activity and protein levels.
Viral somatic gene therapy for primary immunodeficiencies such as Wiskott-Aldrich 
syndrome would be best achieved using retroviral vectors due to the ease of virus 
production, transduction of cells and insertion of the transgene as has been discussed 
earlier. In fact retroviral gene therapy has been very successful in clinical trials 
involving X-linked SCID (Cavazzana-Calvo et al., 2000a; Hacein-Bey-Abina et al., 
2002; Gaspar et al., 2004), clearing a pathway for other primary immunodeficiency 
diseases to be tackled.
The aims of this chapter were to firstly to make a fusion of EGFP and human WASp 
with evaluation to determine function in vitro. EGFP and EGFP-WASp were then 
cloned into an oncoretroviral vector for use in an in vivo gene therapy protocol to 
reconstitute a WASp KO murine model (Snapper et al., 1998).
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3.2 Results
3.2.1 Creation of an EGFP-WASp fusion cDNA construct
WASp has a natural auto inhibited conformation which is released upon binding of PIP2 
and the GTP form of Cdc42 (Higgs and Pollard, 2000; Kim et al., 2000). Any large 
additions to the C-terminus to make a fusion could theoretically inhibit this inactive 
conformation and subsequently alter the properties. Previous attempts to detect WASp 
have been by tagging the C-terminus with small markers, which can then be detected 
with antibodies (Symons et al., 1996). As EGFP has a size of 25kDa, it may also be too 
large to add to the C-terminus without altering the properties of WASp. It was decided 
therefore to create a fusion protein where EGFP was added to the less conformationally 
active N-terminus of WAS thus theoretically allowing normal protein folding and thus 
normal regulation of activation upon stimulation.
The complete WAS cDNA was excised from FL3/41.5RI:0.5RI (a gift from J.Derry) 
(appendix 1) with SacII and EcoRV and ligated, in frame, into pEGFP-C2 (Clontech) 
(appendix 2) which had been linearised with SacII and Sma-I before the stop codon 
(Figure 3,1a). This created an EGFP-WASp fusion open reading frame with the two 
proteins sequences separated by 75bp due to the continued presence of the multiple 
cloning sites from the pEGFP-C2 vector. For ease of further sub-cloning a 60bp 
fragment between the two proteins containing the multiple cloning site, was removed by 
digestion with Xma III followed by re-ligation of the fragments (appendix 3). The open 
reading frame was maintained whilst removing the multiple cloning sites between the 
two protein sequences (Figure 3.1b). Digestion with EcoRI followed by separation of 
the DNA fragments on an agarose gel confirmed the cloning as WAS contains extra 
recognition sequences compared to EGFP (not shown).
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pEGFP- FL3/41.5RI:0.
Xmalll ,  BgHI, Xhol, HindHI, EcoRI, PstI, Kpnl, Notl, XmalH
EGFP WAS
Xmalll digest and re-ligation
start
EGFP WAS
Figure 3.1 Creation of EGFP-WASp fusion
a) Plasmid maps showing position of restriction enzymes used to create fusion, b) 
Superfluous cDNA containing a MCS was removed by digestion with Xmalll whilst 
maintaining the fusion protein in frame.
3.2.1.1 Transient transfection of COS-7 cells
Confirmation that a fluorescent protein could be expressed and that it was a fusion of 
EGFP and WASp was next determined by transfecting a readily available cell line. 
COS-7 cells were seeded onto coverslips and transiently transfected with lug of DNA 
per well using an integrin binding peptide and lipofectin technique (LID) (Hart et al., 
1997) at a ratio of 1:4:0.75, of DNA:peptide:lipofectin. The pattern of fluorescence 48 
hours post transfection observed when cells were transfected with EGFP is diffuse and 
present throughout the cell (Figure 3.2a,b). EGFP-WASp transduced cells revealed a 
markedly different pattern of expression (Figure 3.2c,d). There was predominantly 
expression in the cytoplasm with exclusion from the nucleus. Expression even seemed 
to be sequestered to form aggregates within the cytoplasm. To confirm the expression 
pattern was the result of expression of a fusion protein and not an artefact of
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transfection it was repeated using calcium phosphate precipitation as the transfection 
mediator, where an identical pattern of expression was seen (data not shown).
The differences in the expression patterns seen suggested WASp was altering the 
staining pattern usually seen with EGFP. Revealingly, the pattern of cytoplasmic EGFP- 
WASp expression, with nuclear exclusion, was identical to that already observed for 
cells transfected with FLAG tagged WASp (Symons et al., 1996) and by other groups 
(Rivero-Lezcano et al., 1995).
Figure 3.2 CCD images of transfected COS-7 cells
a+b) pEGFP and c+d) pEGFP-WASp transiently transfected into COS-7 cells using 
lipid and integrin binding peptide. Cells were fixed 48 hours post transfection and 
images captured using a CCD digital camera. Scale bar = lOum
3.2.1.2 Confirmation of expression of a fusion protein
To confirm there was expression of a fusion of EGFP and WASp an immunoblot was 
performed on transfected 293T cells. 293T cells are a human kidney epithelia cell line, 
which does not normally express WASp. Cells at 70% confluency were transiently
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transfected with 20ug EGFP or EGFP-WASp using PEI as the transfecting agent 
harvested after 48 hours to allow protein expression, and the protein lysate separated on 
an acrylamide gel. When probed with an anti-WASp antibody a protein of ~90kDa was 
revealed (Figure 3.3) whereas a band of 65kD is normally seen for wt WASp in 
haematopoietic cells. The cells transfected with EGFP alone did not expose a band on 
the gel. The western confirms that the visible green fluorescent protein being expressed 
is recognised by an anti-WASp antibody and is the predicted size of a fusion of EGFP 
and WASp.
— 105
< EGFP-WASp
— 75
— 50
Figure 3.3 Western Blot of 293T cell lysates
Cell lysates prepared from EGFP (lane 1) and EGFP-WASp (lane 2) transfected 
293T cells were separated by SDS-PAGE and probed for WASp using an anti-WASp 
antibody.
3.2.2 Transient transfection of human dendritic cells
WASp expression is restricted to cells of the haematopoietic lineage, so a readily 
available source of haematopoietic cells were transfected to see how the fusion protein 
would be expressed and what effects it would exert on the cell. Normal human dendritic 
cells derived from peripheral blood (a gift from S.Bums, ICH) were plated onto 
coverslips and transfected with EGFP or EGFP-WASp using LID (Hart et al., 1997) 
Fixed and permeabilised cells were stained for filamentous actin (F-actin) and nuclear 
staining. Overlaid colour images were captured on a CCD digital camera. Low-level
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transfection was achieved with both constructs, which although was not quantified was 
clearly visible. Cells transfected with pEGFP-C2 expressed EGFP throughout the cell 
with distinct actin staining. Clearly visible in red were specialised actin structures, 
podosomes (Figure 3.4a,b). However when dendritic cells were transfected with EGFP- 
WASp there was no distinct EGFP or actin staining alone. There were however large 
aggregates within the cytoplasm that were yellow, showing co-localisation of actin and 
EGFP (Figure 3.4c,d). This shows that overexpression of the EGFP-WASp fusion 
protein is leading to dysregulation of actin in normal WASp containing haematopoietic 
cells, where previously control over actin polymerisation was tightly regulated. This 
ability to influence the normal distribution and regulation of F-actin within cells 
suggests the fusion is therefore active.
4
X
Figure 3.4 Transient transfection of human dendritic cells
Peripheral blood derived human dendritic cells were transiently transfected with 
EGFP (a+b) or EGFP-WASp (c+d) (green) using a lipid and integrin binding peptide 
complex. Cells were counterstained with rhodamine phalloidin (red) and DAPI 
(blue) to show F-actin and nuclei, respectively. Arrows point to podosomes in (b) 
and areas of co-localisation in (c) and (d). Overlaid images of all 3 colour channels 
were captured using a CCD digital camera. Scale bar is 20um
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3.2.3 Generation of oncoretroviral cDNA constructs
The initial experiments proving expression of a fusion protein led us to further our 
approach towards a gene therapy protocol. Oncoretroviruses have the ability to integrate 
their genome into an infected cell, which is particularly useful to correct primary 
immunodeficiencies. A pluripotent stem cell can be permanently transduced which can 
divide to repopulate the immune system without the loss of transgene.
3.2.3.1 Subcloning EGFP-WASp into pBluescript
EGFP-WASp was removed from pEGFP-WASP-C2 with Nhe-I and BspMI, and 
blunted using the Klenow large fragment. This was then inserted into pBluescript 
(appendix 4), linearised with Smal, a blunt cutter, and dephosphorylated to prevent re­
closure. This had three benefits. Firstly it increased the number of restriction sites at 
either end of the EGFP-WASp expression cassette available for further subcloning, 
secondly as it was a blunt ligation, constructs in both orientations were obtained further 
increasing the restriction sites available for future use if needed. Thirdly, the poly A site 
was removed. This is necessary for full-length expression of the retrovirus mRNA 
needed for packaging and production of infective virus. This created two constructs 
designated pB-EW and pB-EWrev.
3.2.3.2 Cloning EGFP-WASP into a retrovirus backbone
The retroviral construct of choice was PINCO (Introna et al., 1998; Grignani et al., 
1998a; Gasperi et al., 1999) (appendix 5) This retroviral construct was chosen for 
several reasons. It has a Molony Murine Leukaemia virus LTR and an internal CMV 
promoter, previously been shown to generate high levels of transgene expression, often 
an important requirement for gene therapy. In addition there is an EBV EBNA-1 ori
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site. When the plasmid is transfected into producer cells this allows it to divide 
episomally with the cells without loss of plasmid, and therefore easy creation of a stable 
producer cell line without cloning of single cells. Thirdly, a puromycin resistance 
marker allows selection of transduced cells with puromycin in 3 days. Therefore, high 
titer viral producer cells to be made quickly and efficiently, again removing the need for 
cell cloning.
pB-EW was digested with Hindlll and Notl and the fragments separated on a gel to 
remove EGFP-WASp. This fragment was sticky end ligated into PINCO-EGFP also 
digested with Hindlll and Notl to replace the EGFP cassette (Figure 3.5) creating 
PINCO-EGFP-WASp (appendix 6). Cloning was confirmed by digestion with EcoRI, as 
extra recognition sequences are introduced, and separation on a 1% agarose gel (not 
shown).
5’ MoMuLTR CMV EGFP 3’ MoMuLTR
EGFP
________  EGFP WASp ___________
^ 1  EGFP-WASp
Figure 3.5. Cloning of retroviral PINCO vectors
EGFP-WASp was removed from pEGFP-WASp-C2 and blunt ligated into an 
intermediate pBluescript removing the poly A tail and increasing the potential number 
of cloning sites. EGFP-WASp was then ligated between the LTRs of the retroviral 
vector PINCO EGFP.
3.2.3.3 Production of high titer retrovirus
When Phoenix cells, a retrovirus producer cell line, are transfected with the PINCO 
retroviral vector construct a replication deficient oncoretrovirus is made. Ecotropic 
Phoenix cells, previously selected for 2 weeks in Diptheria toxin and hygromycin, to 
select for GAG and POL were transiently transfected by calcium phosphate 
precipitation with either PINCO-EGFP or PINCO EGFPWASp constructs and selected
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with puromycin to give a high virus titer producing cell line. These cells were EGFP 
positive after 24 hours and the pattern of expression was identical to that previously 
seen in COS-7 cells (data not shown). After 5 days puromycin selection was halted and 
the viral supernatant harvested and titered on the permissive NIH 3T3 cell line. A 
representative flow cytometric plot showing the percent transduction at a dilution of 
1:250 of PINCO EGFP-WASp is shown (Figure 3.6) from which a titer could be 
obtained. An infectious titer was calculated by multiplying the number of cells by the 
dilution, and dividing by the percentage positive for the transgene, in this case EGFP 
and EGFP-WASp. This gave a consistent titer of ~lx 106 for both EGFP and EGFP- 
WASp vectors.
a b 1/250 dilution of virus
-►   ►
ssc EGFP
Figure 3.6 Flow cytometric plots of Infected 3T3 cells
50,000 3T3 cells were infected with increasing dilutions of retrovirus in a total 
volume of lml and harvested 72 hours later for flow cytometry, a) The forward (fsc) 
and side scatter (ssc) show the cell population, b) Percent EGFP expression was 
measured and used to calculate virus infectious titer.
When the pattern of EGFP-WASp expression was examined in the infected cells a 
similar cellular distribution of cytoplasmic staining was observed to transduced cells 
seen earlier (Figure 3.7a). An immunoblot of EGFP-WASp infected 3T3 cell lysate 
probed with an a-WASp antibody revealed a 90kDa band (Figure 3.7b), also observed 
previously, showing EGFP-WASp could be successfully packaged in a retrovirus and
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subsequently expressed under the control of a viral LTR. The band in lane 3 at 60kDa is 
an artefact and appeared across 2 wells (Figure 3.7b).
EGFP-WASp ►
WAS ►
Figure 3.7 Confocal image and western blot of infected 3T3 cells
a) Infected cells were trypsinised and plated onto coverslips prior to fixation. Samples 
were mounted and z sections captured to reveal the pattern of EGFP staining, b) 
Lysates were prepared from Ficolled peripheral blood (lane 1) and 3T3 cultures 
infected with EGFP (lane 2) or EGFP-WASp (lane 3) and separated by SDS-PAGE 
followed by probing with an anti-WASp antibody.
3.2.4 Reconstitution of a WAS KO mouse model
An in vivo model for optimisation of gene therapy is essential before transfer to a 
clinical setting. An in vivo model mirrors protocols that could be utilised in a clinical 
setting, albeit in a murine environment, and successful recovery of a murine model is a 
pre-requisite before clinical trials can start. This allows optimisation of vectors, 
transduction protocols and efficiencies and meaningful analysis of successful 
reconstitution. Although our retroviral constructs contained human WASp fused to 
EGFP, it was thought that because of the high homology (-86%) between human and 
murine WASp (Derry et al., 1995) there would be cross-reactivity and human WASp 
would be able to reconstitute the mouse model.
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The basic protocol used in the generation of an in vivo model is outlined in Figure 3.8. 
Briefly scal+ murine stem cells from WASp KO mice were harvested from the bone 
marrow, infected ex vivo in the presence of cytokines on retronectin coated plates in a 
method adapted from Demaison et a I, (Demaison et al., 2000) and infused into a lethally 
irradiated recipient to allow the donor cells to repopulate the haematopoietic system. 
After a period of incubation of 2-3 months to allow engraftment and repopulation of the 
immune system with the transfused cells, the mice were sacrificed and analysed for the 
presence of transgene and for reconstitution of WASp function.
Day 1
Day 3
Day 5
Figure 3.8 Schematic of transduction protocol for murine bone marrow 
transplant
Sea 1+ cells were harvested from the bone marrow of donor WASp KO mice and 
placed into culture for 48 hours in the presence of cytokines. The cells were then 
infected twice daily with retroviral supernatant in 24 well plates precoated with 
retronectin which had been pre- loaded with retrovirus. After 72 hours the cells were 
washed and injected intravenously into lethally irradiated WASp KO recipients. A 
sample of the cells was kept in culture for 72 hours to determine expression levels.
Harvesting of 
Sea 1+ cells
WASp KO
48 hrs prestimulation with 
cytokines (SCF, Flt3-L and IL-6)
c> o cu ao oO O O  O Q O
WASp
Co-localisation of cells and 
. virus with multiple rounds 
of infection over 72 hours
Injection of transduced cells 
into lethally irradiated 
recipient (1000RADS)
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Sea 1 positive cells recovered from WAS KO mice were cultured in the presence of 
cytokines for 48 hours to induce mitosis before infection with ecotropic retrovirus. 
Virus was preloaded onto retronectin-coated plates and sea 1+ cells added before 
additional virus was added diluted 1:1 with fresh media and the relevant cytokines. The 
stem cells underwent a further 4 rounds of infection over a 48 hour period after which 
the cells were either infused into mice or kept in culture for a further 72 hours to asses 
the level of gene marking. As many cells as possible were re-introduced into lethally 
irradiated recipients to increase the chance of successful reconstitution. In general, the 
sea 1+ cells recovered from 2 mice were infused back into 1 recipient with the total 
number infused being 2-3x105 per mouse. From the 2 experiments performed, similar 
levels of gene marking after 72 hours ranging from 15-25% and 10-15% for EGFP and 
EGFP-WASp respectively (Figure 3.9) was attained using virus previously titered on 
3T3 cells at lx l0 6 for both.
30
25
£  20 
U 15
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Expt 1
EGFP
EGFP-WASp
Expt 2
Figure 3.9 Transduction levels in Sea 1+ cells
Bar chart of EGFP transduction levels 72 hours after transplant of retrovirally infected 
Sea 1+ cells, determined by flow cytometry. Two experiments are shown where EGFP 
and EGFP-WASp containing vectors were used
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3.2.4.1 Transduction efficiency after reconstitution
Reconstituted mice were sacrificed 2-3 months after infusion of transduced cells. Bone 
marrow, spleen, thymus and lymph nodes were removed and analysed for the presence 
of either EGFP or EGFP-WASp. The presence of transduced cells was first confirmed 
by flow cytometry of the bone marrow. Bone marrow from mice in experiment 1 
revealed that mice reconstituted with EGFP still had 1-8% EGFP positive cells whereas 
those reconstituted with EGFP-WASp had no transduced cells detectable (Figure 3.10). 
Upon repetition of the experiment greater success was achieved with both EGFP and 
EGFP-WASp able to be detected in the bone marrow. The levels of EGFP were 7-33% 
and EGFP-WASp 0.4-5.9% (Figure 3.10). It is unclear why EGFP levels were retained 
close to the input levels whereas EGFP-WASp levels were significantly reduced 
compare to the input percent. It has been reported that there is a selective advantage in 
the homing capabilities of stem cells that express WASp (Lacout et al., 2003) and 
revertant mutations in patients has resulted in somatic mosaicism and partial recovery of 
the immune system (Wada et al., 2003; Wada et al., 2001) predicting an increase in 
EGFP-WASp transduced cells. When spleen, thymus and axiliary and brachial lymph 
nodes were analysed, EGFP was detectable, albeit at lower levels than was seen in the 
bone marrow (Figure 3.11). However there was no EGFP detectable by flow cytometry 
in the mice that were transduced with EGFP-WASp in any tissue other than the bone 
marrow.
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Figure 3.10 Transduction levels in reconstituted mice
Bone marrow was removed 2-3 months after mice were transplanted and the levels of 
transgene expression were assessed by EGFP flow cytometry. Two experiments are 
shown and each point represents an individual mouse. P value is from students T test
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Figure 3.11 Transgene expression in secondary lymphoid tissue
2-3 months post transplant mice were sacrificed and the levels of transgene expression 
determined by flow cytometry detecting EGFP levels in bone marrow (BM), spleen 
(Spl), thymus (Thy) and lymph node (LN) single cell suspensions. E = EGFP and EW = 
EGFP-WASp. Numbers shown are the percentages represented in the bar chart.
103
Chapter 3
3.2.4.2 Analysis of phenotypic recovery
To assess the quality and quantity of recovery of phenotype, bone marrow from the 
reconstituted mice was put into culture with GM-CSF followed at day 3 by addition of 
IL-4 which, by day 7, would generate dendritic cells (de Noronha et al., 2005). These 
cells were then positively sorted for transduced cells by FACS on the basis of EGFP 
level. After sorting the positive cell population was increased from 5% to >95% (Figure 
3.12). Sorted cells were plated onto coverslips, allowed to adhere, then fixed and stained 
with phalloidin to assess the F-actin distribution and podosome levels in the cells. 
Murine dendritic cells from WAS KO mice are largely deficient in clearly defined 
podosomes (~5%) compared to 50-60% we have observed in Sv/129 normal control 
mice.
a b
98%33%
EGFP
Figure 3.12 Fluorescence Activated Cell Sorting of murine bone marrow
Representative FACS plots showing purification of EGFP positive cells from murine 
bone marrow derived dendritic cells from transplanted mice 2-3 months post transplant. 
Cells pre-sort (a) were purified to >95% purity (b) post sort, based on EGFP levels.
Restoration of podosomes was therefore a functional test of recovery of phenotype in 
addition to EGFP-Wasp expression. Confocal images of dendritic cells made from mice 
transduced with EGFP revealed high levels of EGFP but podosomes were found in only 
4.4% of all cells counted (Figure 3.13). In EGFP-WASp expressing dendritic cells the
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percent of cells with podosomes ranged from 8.1-20.5% with an average of 16.6% 
(Figure 3.13). An increased level of transduced cells present in the bone marrow did not 
necessarily correlate with an increase in the percent of podosomes (e.g. mouse 4 had 0.4 
% transduced cells, but 19.6% of those had podosomes). Reconstitution of podosomes 
observed was up to a third of that seen in normal Sv/129 controls, but may be sufficient 
for a beneficial therapeutic effect. In addition to having podosomes there was co­
localisation between EGFP and the F-actin core of the podosomes showing that the 
introduced EGFP-WASp, as has been seen in human macrophages (Jones et al., 2002) 
and dendritic cells (Bums et al., 2001a), was integral to de novo podosome formation 
(Figure 3.14).
Figure 3.13 Percent of murine bone marrow derived dendritic cells with podosomes
Bone marrow derived dendritic cells from experiment 2 were positively sorted for EGFP 
and plated onto coverslips for 24 hours to allow cells to adhere. Cells were then fixed and 
counterstained with rhodamine phalloidin to visualise F-actin. Confocal images of the 
cells were obtained and maximal projections of 6-12 z sections were used to score for the 
presence or absence of podosomes on the basal surface. Each point represents an 
individual mouse with 50-100 cells counted for each. P value is from a students T test.
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Figure 3.14 Confocal images of bone marrow dendritic cells
Bone marrow dendritic cells from EGFP (a + b) and EGFP-WASp (c + d) transduced 
mice were positively sorted on the basis of EGFP before being plated onto coverslips 
overnight. Cells were fixed and counterstained with rhodamine phalloidin to visualise F 
actin. Images are maximal projections of 6-12 z sections. An overlaid image of EGFP 
(green) and phalliodin (red) (e) shows co-localisation in yellow.
3.2.4.3 Quality of WASp reconstitution
Although successful transduction and subsequent reconstitution in the bone marrow 
could be observed in 6/6 mice in experiment 2, the quality of this reconstitution needed 
to be assessed. Although few WASp null cells have podosomes, it has been shown 
recently that in XLT, a mild form of WASp where there is reduced WASp expression 
levels, there are podosomes present but in reduced numbers per cell compared to normal 
(Linder et al., 2003). Therefore the number of podosomes per cell in dendritic cells from 
transduced mice could relate to the amount of WASp expressed and subsequently the 
quality of reconstitution compared to normal and whether the levels we achieve are 
sufficient to correct the phenotype.
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The number of podosomes per cell for normal dendritic cells averaged 30.4 compared to 
15 for WAS KO, when only the cells with podosomes are included (Figure 3.15). 
Dendritic cells from EGFP transduced cells had an average of 12 podosomes per cell 
again when only scoring those containing podosomes. When dendritic cells from EGFP- 
WASp reconstituted mice were compared, the average number of podosomes per cell 
ranged from 14-40 for the 6 mice, with 5/6 mice showing the quality of reconstitution to 
be at normal levels. When the podosomes per cell data from all 6 EGFP-WASp 
transduced mice was pooled to increase the numbers the average number per cell was
30.9 (Figure 3.15).
The number of podosomes per cell was divided into groups of 0, 1-20, 21-50, 51-100 
and >100 and the percent of cells in each increment plotted as previously shown in 
(Linder et al., 2003) to analyse the natural range and distribution of podosome number 
in the whole population. Due to the low numbers of cells counted for each mouse all 6 
EGFP-WASp transduced mice were again pooled to give an average.
107
Chapter 3
120
100
oo
k.0)a 80
a>
|  60
3
C
<D1 40 
o (0 o
U 20a
pcQ.Ol
O av = 30.1
O
X
O u  O 
OpO 
o g  8  °
o09av = 15 O ooW rO  
3)0C.
00i5vOO
p<0.01
o
av = 30.9
O
av = 12
WASp KO wild-type EGFP EGFP-WASp
Figure 3.1S Podosomes per cell in dendritic cells
Cells were stained with phalloidin to visualise actin and therefore podosomes. 
Positive cells had the number of podosomes per cell scored and plotted. Each point 
represents a single cell with podosomes present. Where necessary values are pooled 
from similar treated mice (EGFP n=2, EGFP-WASp n=6). P values shown are from 
a students T test
When plotted against normal and EGFP transduced mice the range of podosomes per 
cell was very similar to normal (Figure 3.16) again suggesting the quality of 
reconstitution was approaching normal.
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Figure 3.16 Distribution of podosome number in a cell population
Bar chart representing the distribution of podosomes in EGFP+ sorted murine bone 
marrow dendritic cells from transplanted mice compared to normal Sv/129 mice. 
EGFP-WASp and normal values are for cells positive for podosomes only. Bar chart 
values are from 50-150 cells and are the combined values from similar treated mice. 
EGFP (n=2) EGFP-WASp (n=6). Error bars shown are +1 SD
3.3 Discussion
The aim of this work was to firstly make a fusion protein of EGFP and human WASp 
that would enable direct visualisation of WASp expression in live cells, providing a 
useful tool for molecular investigations into the activity of WASp. Secondly it would be 
of use in optimising a gene therapy protocol, as EGFP is readily detectable using 
fluorescence microscopy and flow cytometry. Although WASp has been FLAG tagged 
previously at the C-terminus (Symons et al., 1996), the important protein inhibitory 
folding structure meant an N-terminal EGFP fusion was needed. A fusion of EGFP and 
WASp was cloned and when transfected into cell lines expressed a protein, which was 
detected with anti-WASp antibodies at a size of 90kDa compared to the usual 65kDa
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seen for wild-type WASp. The expression pattern of WASp has been described as 
predominately cytosolic (81%) with some membrane bound (16%) and very little in the 
nucleus (3%) (Rivero-Lezcano et al., 1995). The pattern of fluorescence seen in 
adherent cells transfected with EGFP-WASp mimicked this pattern of expression 
suggesting a functional fusion was being expressed and that the EGFP was having little 
or no effect upon the function of WASp.
WASp is haematopoietic restricted (Derry et al., 1994) so EGFP-WASp was transfected 
into normal human dendritic cells, a haematopoietic cell available at the time to observe 
any effects. This had a major effect on the actin structure of transfected cells. Normal 
dendritic cells express specialised actin structures, podosomes, whose assembly are 
dependant upon the presence of WASp (Linder et al., 1999; Bums et al., 2001a). When 
EGFP-WASp was transfected into dendritic cells there was a loss of podosomes and an 
aggregation of the actin. Changes in the regulation of WASp can dramatically alter the 
appearance and the number of podosomes in dendritic cells. Use of the constitutively 
active V12Cdc42 leads to dismption of podosomes in human macrophages, as does 
overexpression of the VCA domain (Linder et al., 2000). Thus overexpression of an 
EGFP-WASp fusion protein may be acting in a similar manner, showing the fusion is 
active.
EGFP-WASp was cloned into a retroviral vector for use in ex vivo gene therapy 
protocols and infectious titers of lxl06 regularly obtained. The pattern of expression of 
EGFP-WASp in retrovirally-infected cells was similar to that observed in transfected 
cells and immunoblots revealed a 90kDa band when probed for WASp. This shows viral
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vectors encoding for EGFP-WASp are capable of infecting cells and the cells 
subsequently capable of expressing a functional fusion protein.
When PINCO EGFP-WASp cDNA was microinjected into normal human dendritic 
cells it co-localised to the site of podosomes. Furthermore when human WASp null 
dendritic cells were microinjected with EGFP-WASp they made podosomes where 
previously they did not (Bums et al., 2001b). Again there was co-localisation of EGFP 
and actin in these newly formed podosomes. This confirms other groups’ work (Linder 
et al., 1999) that WASp is required for podosome assembly and disassembly and the 
EGFP-WASp fusion is active.
Retrovirus infection and integration of the transgene is limited because of the need for 
the breakdown of the nuclear membrane, which occurs when cells undergo mitosis 
(Miller et al., 1990b; Roe et al., 1993). Although expression was confirmed in fibroblast 
cell lines, WASp is normally haematopoietic restricted. This limits the use of a 
retrovirus in vitro due to the lack of an available WASp null cell line in which to show 
reconstitution and restoration of function when WASp is introduced. There has been 
some limited success in vitro where WASp null BLCL’s have been transduced with 
retrovirus particles containing WASp and had restoration of microfilopodia on the cell 
surface (Candotti et al., 1999; Wada et al., 2002) and in T cells where CD3 mediated 
proliferation has been restored (Wada et al., 2002).
Because of a lack of available haematopoietic WAS KO cells to use in vitro an ex vivo 
gene therapy protocol was devised where transduced murine stem cells from WAS KO 
mice were introduced into lethally irradiated WAS KO recipients and allowed to
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repopulate the haematopoietic system, with the intention of correcting the defects seen 
in WAS KO mice. Murine scal+ stem cells could be transduced at levels up to 25% 
measured by EGFP expression, which is comparable to levels found by other groups 
(Strom et al., 2003b; Klein et al., 2003), which has lead to recovery of a normal 
phenotype.
After 3 months there was significant gene marking with EGFP in 6/6 mice. There was 
also expression of EGFP-WASp in the bone marrow in 6/9 mice although it was lower 
in EGFP-WASp transduced mice. There was higher initial gene marking in the second 
experiment that led to a higher level after 3 months in mice when compared to the lower 
transduction efficiency in the first experiment. This would suggest the higher the initial 
transduction the better the reconstitution with transduced cells. It is unclear why there 
are lower expression levels in EGFP-WASp transduced cells compared to EGFP when 
the starting populations had similar levels of transduction. It has been previously shown 
that there is a selective advantage for homing in cells that express WASp compared to 
WASp null cells and somatic mosaicism has revealed a growth advantage for T cells. 
The results here do not confirm or dispute any growth advantage.
As expression of EGFP-WASp in normal dendritic cells leads to aggregation of actin 
and loss of normal cytoskeletal architecture, a similar effect may be exerted on WASp 
KO cells with high expression levels. The combined effect of a viral LTR and the 
internal CMV leads to high expression in vitro and these promoters may lead to too 
much WASp expression leading to abnormal actin regulation and the death of cells. In 
fact the EGFP-WASp mean fluorescence intensity (MFI) was less than EGFP (MFI) in 
transduced bone marrow and confocal images of dendritic cells from transduced mice
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were generally less bright, suggesting only cells that express EGFP-WASp at a 
relatively low level have survived, whereas high level EGFP expressing cells are viable.
Analysis of the transduction levels in secondary lymphoid organs showed that there was 
a significant decrease in the levels of transduced cells for EGFP and undetectable for 
EGFP-WASp. This seems to be linked to levels in the bone marrow as mice with higher 
levels here have increased levels in other organs. It is unknown why the levels in other 
lymphoid organs are reduced. There may not have been enough time to repopulate or 
there could be physical barriers preventing repopulation. Transduction levels similar or 
lower may be expected for EGFP transduced cells where there is no selective advantage 
compared to untransduced WAS KO cells, however if there is a selective advantage in 
cells that have WASp as has been previously shown from somatic mosaicism (Wada et 
al., 2001; Wada et al., 2003; Wada et al., 2004) it is not yet materialising in the 
reconstitution of the bone marrow or secondary lymphoid tissues. In addition it has been 
shown that the proposed selective advantage is cell type dependant with the presence of 
WASp more advantageous to T cell survival than B cell (Konno et al., 2004).
Bone marrow derived dendritic cells from EGFP-WASp transduced mice had 
podosomes restored in their cytoplasm and co-localisation of actin and EGFP-WASp 
showed the introduced WASp was crucial in this. Although the selected cells were 
<95% positive for EGFP-WASp there was only a third of the restoration of cells with 
podosomes compared to normal and there was no correlation with percent of cells 
transduced and podosome number. This may be sufficient for beneficial recovery of 
some actin regulation as low level WASp expression compared to no expression results 
in the less severe XLT phenotype (Linder et al., 2003).
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Encouragingly when the quality of the reconstitution was measured by counting 
podosome numbers within the cells it was found to be of similar level to that seen in 
normal controls even though the levels of transduction were low. Furthermore the 
distribution of podosome number in cells was similar to that seen in normal mice 
showing there was no skewing of results due to a small population of highly transduced 
cells. This suggests there is a normal regulation of WASp in the cells and EGFP is not 
affecting the binding partners of WASp.
Using a retroviral vector we have shown that it is possible to reconstitute a WAS KO 
mouse model with EGFP-WASp and gain restoration of podosomes, an actin structure 
dependant on the presence of WASp, to normal numbers within dendritic cells. This 
was achieved with relatively low levels of transduction, upon analysis after 3 months.
If a greater percentage of stem cells could be transduced initially then there is the 
potential for higher levels of reconstitution which could lead to detection of transduced 
cells in spleen, thymus and lymph nodes thus potentially correcting all the defects seen 
in WAS.
There are two main problems associated with the use of retroviral vectors. The first is 
retroviral integration only occurring in dividing cells (Roe et al., 1993; Miller et al., 
1990b), coupled with the relatively short half-life of the virus (Andreadis et al., 1997). 
There is a limited opportunity to infect true multipotent progenitor cells, as they have to 
be stimulated into cycle. The second problem relates to the favoured sites of integration 
of retroviruses. It has been shown that retroviruses prefer to integrate at gene promotor 
sites (Laufs et al., 2003; Wu et al., 2003) thus leading to the potential for oncogenic
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events due to gene over or under expression. Such serious adverse events have occurred 
in a clinical trial in France where SCID-X1 trials using retroviral vectors (Hacein-Bey- 
Abina et al., 2003b). In that study 3 of 11 patients developed T cell leukaemia. In the 
first 2 patients, the T cell clones were shown to have retroviral insertions in the LMO-2 
proto-oncogene promoter which lead to abnormal LMO-2 protein expression (Hacein- 
Bey-Abina et al., 2003b), the third patient is still being analysed. The abnormal LMO-2 
expression was thought to be a direct result of the LTR enhancer activity in close 
proximity to the LMO-2 promoter. The LMO-2 integrant clones are thought to be 
selected via a growth advantage. The leukaemia may be partly due to the capacity of the 
T precursors to expand to fill the empty compartment and the age of the recipients as 
they were the youngest of the patients treated. This means improved strategies may be 
required. The use of retroviral vectors with improvements in vector design relating to 
self-inactivation and promoters and use of post transcription regulatory elements could 
lead to improved transduction efficiencies and higher levels of correction. It was 
decided however, although success was obtained with oncoretroviral vectors, to use 
lentiviral vectors to try and optimise and possibly improve a gene therapy protocol for 
WASp. This has the benefit of allowing in vitro experiments on WAS KO primary non­
dividing cells to improve vector design and transduction protocols prior to proceeding to 
an in vivo setting.
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CHAPTER 4
IN VITRO DEVELOPMENT OF 
LENTIVIRAL VECTORS
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4.1 Introduction
As lentiviral vectors do not require the breakdown of the nuclear envelope to integrate 
its genome (Naldini et al., 1996) we have used self-inactivating lentiviral vectors 
containing strong viral promoters or putative endogenous WAS promoter sequences to 
transduce murine WAS KO dendritic cells and human WASp null patient macrophages 
in vitro with EGFP, EGFP-WASp and WASp in order to determine which is the most 
suitable for use in a murine stem cell reconstitution model (described in Chapter 3) and 
subsequent possible clinical trials.
Additional modifications to enhance transgene expression have been included in the 
lentiviral vector. A central poly-purine tract (cPPT) has been added to increase the 
stability of the mRNA and therefore increase titer. It has been shown that introduction 
of the cPPT element leads to higher transgene expression (Demaison et al., 2002). In 
addition some vectors have the woodchuck post-transcriptional regulatory element 
(WPRE) added 3’ of the transgene, again thought to increase the stability of the mRNA 
(Zufferey et al., 1999). For additional safety this has been mutated to remove the start 
codon of the X-protein encoded by this sequence, which could be linked to oncogenesis 
(Kingsman et al., 2005). The WPRE has also been shown to increase the expression of 
the transgene in transduced cells (Zufferey et al., 1999; Demaison et al., 2002).
It has been shown that two sequences 5’ of the WAS start codon, one of 500bp and a 
larger one of 1600bp, have been shown to have some promoter activity (Hagemann and 
Kwan, 1999; Petrella et al., 1998) in haematopoietic cell lines and is theorised to lead to 
a more physiologically regulated level of WASp expression compared to strong viral
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promoters. Regulation of WASp expression could be important as high cellular levels of 
EGFP-WASp so far has lead to dysregulation of the actin cytoskeleton (Chapter3). The 
haematopoietic restriction of WASp (Martin et al., 2005) could also be in part due to 
this promoter sequence and could be useful for future work and other applications 
where lineage restriction may be important.
4.2 Results
4.2.1 Cloning lentiviral vectors containing viral promotors
Lentiviral vectors containing EGFP as the transgene were obtained (from K. Parsley 
Molecular Imunology Unit ICH) under the transcriptional control of either a CMV 
promotor or the 3’ LTR from Spleen Focus Forming Virus. Briefly, because of a lack of 
suitable restriction sites in the lentivirus vectors and in EGFP-WASp-C2 to allow 
further cloning, EGFP-WASp was subcloned into a bluescript vector containing a SFFV 
LTR-EGFP-WPRE cassette (pB-SEW)(a gift from K.Parsley, Molecular Immunology 
Unit, ICH), originally made to clone SEW (Figure 4.1b). EGFP-WASp was excised 
from pB-EWrev an intermediate vector made when cloning PINCO EGFP-WASp (see 
chapter 3) via BamHI and Hindlll and sticky end ligated into pB-SEW also digested 
with BamHI and Hindlll to replace EGFP with EGFP-WASp to create pB-SEWW. 
Then, the EGFP-WASp-WPRE cassette from pB-SEWW was excised via BamHI and 
Kpnl and sticky end ligated into the lentiviral vectors pHR’sincpptCEW (Figure 4.1a) 
(appendix 7) or pHR’sincpptSEW (Figure 4.1b) (appendix 8), also digested with 
BamHI and Kpnl to replace EGFP-WPRE. The lentiviral vectors created were 
designated CEWW and SEWW depending on the promoter (Figure 4.1a, Figure 4.1b 
and appendix 9 and 10). Hindlll digestion and separation on an agarose gel confirmed 
the cloning (not shown).
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Figure 4.1 Lentiviral vectors containing CMV and SFFV internal promoters
Cartoon of intermediate pBluescript subcloning vectors containing a) EGFP and 
EGFPWASp. Cartoon depiction of lentiviral transfer vectors containing a) CMV 
promoter or b) SFFV as the internal promoter.
Also shown are the major features. EGFP-WASp-WPRE was cloned from the 
intermediate pBluescript vector using BamHI and Kpnl. LTR = Long Terminal Repeat, 
cPPT = central Poly Purine Tract, WPRE = Woodchuck Post Transcriptional Regulatory 
Element.
4.2.1.1 Transduction of 3T3 cells with Lentivirus
Although during transient transfection during virus production, the producer cells 
expressed EGFP, in order to confirm there was infectious virus, 3T3 cells were infected. 
Confocal microscopy showed expression of EGFP and EGFP-WASp (Figure 4.2a) with 
a pattern of expression similar to that seen previously with retrovirally transduced cells 
(Chapter 3). Furthermore there was substantial disruption of the actin cytoskeleton with 
large aggregates of actin and EGFP-WASp not seen with EGFP (Figure 4.2a) also 
previously seen and has been reported with over expression of WASp in other cell lines 
(Symons et al., 1996). When an immunoblot of the cell lysate from transduced cells was 
probed with an anti WASp antibody there was a large protein revealed at 95kD 
compared to a band at 65kD seen for wild-type WASp in peripheral blood (Figure 
4.2b).
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Figure 4.2 Infection of 3T3 cells
3T3 cells seeded onto coverslips were infected with lentiviral constructs containing 
EGFP (SEW) or EGFP-WASp at an MOI of 10. After 72 hours the cells were fixed 
and stained for F-actin. a) Images shown are representative confocal maximal 
projections of 8-12 Z sections. Green = EGFP, red = rhodamine phalloidin. b) 
Immunoblot of 3T3 cell lysate probed with anti WASp antibody showing EGFP- 
WASp expression. Lane 1 PBL, lane 2 SEW, lane 3 SEWW
4.2.1.2 Restoration of podosomes using lentiviral vectors in vitro
The lentiviral vectors were tested in vitro on WASp KO primary dendritic cells. 
Reconstitution of podosomes was used as a measurement of vector efficacy. Firstly a 
comparison of CMV and SFFV promoter driven vectors was performed to provide data 
based upon high expression levels.
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Bone marrow derived dendritic cells were plated onto fibronectin coated glass 
coverslips and infected with CEW or SEW at an MOI of 100. Transfection levels were 
measured by flow cytometry, or by eye under a fluorescence microscope, and were 
consistently up to 50% positive for EGFP for both CMV (Figure 4.3) and SFFV (not 
shown) containing vectors
Untransduced CEW
GFPLog 10= 10» GFP Log
Figure 4.3 Infection of DC’s with lentiviral vectors
Murine dendritic cells were infected on coverslips at an MOI of 100 and incubated 
for 72 hours to allow transgene expression. Cells were harvested and transduction 
efficiency determined by flow cytometry. CEW = CMV EGFP WPRE, SEW = 
SFFV EGFP WPRE
Normal murine dendritic cells in vitro make podosomes on the ventral surface in 50- 
70% of cells, whereas WASp KO dendritic cells have severely reduced numbers (>5%) 
(Figure 4.4). When WASp KO dendritic cells are transduced with EGFP there is no 
increase in the number of cells with podosomes whereas transduction with EGFP- 
WASp from vectors containing either CMV or SFFV showed a marked increase in 
podosome levels to 36% and 25%, respectively (Figure 4.4).
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Figure 4.4 Reconstitution of podosomes
Bone marrow derived dendritic cells were seeded onto glass coverslips and infected at an 
MOI of 100 with EGFP (CEW, SEW) or EGFP-WASp (CEWW, SEWW). The cells were 
then fixed and permeabilised before staining with rhodamine phalloidin to visualise F 
actin. Confocal images of the cells were scored for the presence or absence of podosomes 
on the basal surface. 100-200 cells were scored. Error bars represent + 1 SD. * p<0.001 
compared to value obtained for WAS KO cells.
Normal dendritic cells make podosomes that have a characteristic ring of vinculin 
around an actin core, whereas WASp KO dendritic cells do not. Although podosomes 
could be identified by the actin staining, the vinculin staining was often weak and was 
often only visible as a co-localising stain (Figure 4.5a) Infection with vectors 
expressing EGFP does promote podosome formation (Figure 4.5b). In EGFP-WASp 
transduced cells the fluorescence was reduced and was predominantly co-localised with 
F-actin at the sites where podosomes were located, often at the leading edge of the cell. 
There was vinculin staining at the podosome sites as seen in normal dendritic cells, 
suggesting normal assembly within the cell (Figure 4.5c,d)). The assembly of 
podosomes when EGFP-WASp is introduced has also been observed in human WASp 
null dendritic cells where DNA was microinjected (Bums et ah, 2001b) supporting the 
findings here.
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Figure 4.5 Confocal images of EGFP transduced murine dendritic cells
Bone marrow derived dendritic cells from WASp wild-type or WASp KO mice were 
plated onto glass coverslips and infected at an MOI of 100 with (a+b) SEW, (c) CEWW or 
(d) SEWW. After 72 hours the cells were fixed in PFA and permeabilised before staining 
for F-actin and vinculin. Cells represented are the maximal projections from 8-12 Z 
sections showing EGFP (green), F-actin (white) and vinculin (blue). Podosomes are visible 
in control and EGFP-WASp transduced cells (yellow arrows) but not WASp KO cells.
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4.2.1.3 Quality of reconstitution
To assess how well the expression of WASp from either promoter corrected the 
phenotype of WASp KO dendritic cells, the number of podosomes present in each 
transduced cell with podosomes was counted. It has been previously shown that XLT 
patients have reduced levels of WASp and correspondingly reduced numbers of 
podosomes (Linder et al., 2003). Normal cells were found to have an average of 30.9 
podosomes per cell compared to 15 in WASp KO cells (Figure 4.6). Only cells that 
have podosomes present were included in this average. WASp KO dendritic cells 
transduced with CEWW had an average of 37.7 and with SEWW had an average of 
36.6 showing that the transduced cells were reconstituted to levels that were above 
normal (Figure 4.6).
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Figure 4.6 Quality of reconstitution of podosomes in dendritic cells
Bone marrow derived dendritic cells transduced with EGFP-WASp were stained 
with phalloidin to visualise F-actin and therefore podosomes. Positive transduced 
cells had the number of podosomes per cell scored and plotted. Each point 
represents a single cell. CEWW = CMV EGFP-WASP WPRE, SEWW = SFFV 
EGFP-WASp WPRE. * p<0.001 students T test
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There were some cells transduced with either CEWW or SEWW that contained very 
high numbers of podosomes that were not seen in normal cells, which may be the reason 
for this high average. When the distribution of podosome number was calculated based 
upon the percentage within specific groups it was found to be almost identical to that 
seen in normal cells with little or no skewing of the populations towards high or low 
numbers of podosomes (Figure 4.7).
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Figure 4.7 Distribution of podosome number per cell
Dendritic cells were transduced with EGFP-WASp (CEWW or SEWW) and were 
scored into groups according to podosome content. For transduced and WASp+/+ 
dendritic cells only the cells with podosomes were included whereas all cells are 
included for WASp-/- cells.
4.2.2 Cloning of Putative Endogenous Wiskott Promoter Sequence
A 500bp sequence upstream of the WAS start codon is one sequence shown in 
luciferase reporter assays to have good promoter activity in haematopoietic cell lines 
(Hagemann and Kwan, 1999). This endogenous promoter sequence was amplified by
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PCR from genomic DNA derived from Ficolled normal peripheral blood lymphocytes. 
As well as amplifying the endogenous wiskot promoter these primers incorporated 
EcoRI and BamHI restriction sites 5’ and 3’ of the 500bp sequence for use in 
subsequent cloning. A band corresponding to 500bp was excised from an agarose gel 
and purified. The band was gel extracted. Sequencing confirmed the correct sequence 
was amplified (appendix 11). The EcoRI and BamHI sites were used to replace the 
SFFV LTR with the endogenous regulatory sequence in an EGFP containing vector, 
pHR’sincpptCE, which contained the cPPT element but not the WPRE (a gift from 
K.Parsley) (Figure 4.8). WAS was subsequently cloned into the resulting WpE vector 
(appendix 12) in place of EGFP using an intermediate bluescript cloning vector 
containing WASp (pB-W) through common BamHI and Kpnl sites to make WpW 
(Figure 4.8)( appendix 13).
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Figure 4.8 Cloning of lentiviral vectors containing an endogenous promoter
Cartoon depictions of lentiviral constructs containing a 500bp endogenous promoter 
sequence (Wp) and a construct with an SFFV LTR with WASp only. Also shown are 
the major features.
4.2.2.1 Titration of lentiviral vectors containing endogenous promoter sequences 
and WASp
Titration of virus particles is easiest when there is a direct way to visualise the 
percentage of transduced cells e.g. EGFP, and was part of the rationale behind creating 
a fusion protein of EGFP and WASp. When WASp was the transgene there was no
126
Chapter 4
reliable way of determining the percent of transduced cells and therefore a titer. In 
addition it was found that the level of EGFP expression obtained from the endogenous 
WASp promoter sequence was not as high as that observed from cells transduced with 
CEW or SEW, although this is probably in part due to the lack of the WPRE. Therefore 
other reliable methods of titration were used. One such method is calculation of the 
concentration of HIV-1 capsid protein p24 in the viral supernatant. It has been 
calculated that lpg of p24 equates to 104 physical particles with 10-100 transducing 
units per pg of p24 allowing the total number of particles to be calculated 
(http://tronolab.com/TUvsp24.php). Table 4.1 shows representative data comparing 
infectious titres where applicable and the values obtained by p24 ELISA. It appears that 
p24 ELISA titres give values that are about 10 fold higher than those observed by 
infectious titration methods suggesting that there are uninfectious particles present.
Sample Infectious titer by flow 
cytometry
p24 amount 
(ng/ml)
p24 titer Molecular titer by 
per
SEW 5x10s 46000 5x1 0° 4.1x10°
CEWW 2xl08 nd nd nd
SEWW 1.75x10* 19500 1.9x10° 4.9x10°
SWW nd 87100 8.7x10° 8.7x10°
WpE 2.8x10s 75300 7.5x10° 1x10'“
WpW nd 450000 4.5x10'° 4.6x10°
Table 4.1 Comparison of titration methods
Viral titers were calculated by infectious titer on a permissive cell line judged by the percent 
positive for the transgene, p24 ELISA, where the amount of capsid protein relates to virus 
quantities or quantitative per, where total copies of integrated viral genomes is calculated 
compared against a known standard, nd = not determined
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An alternative method used to titre virus was using quantitative real time PCR. 
Although titres can be obtained direct from vector supernatant RNA (Lizee et al., 2003) 
we calculated the titer based upon the number of integrated proviral DNA. This is 
because they are least likely to be influenced by factors such as empty or defective 
particles (a problem when using p24 ELISA), or expression levels (a problem for 
infectious titres and supernatant RNA) and has been shown to be reproducible and 
reliable compared to other methods (Sastry et al., 2002b).
Using plasmid DNA to generate standard curves for viral genomes and p-actin (to 
determine cell number), infected cells had their genomic DNA purified, followed by 
real-time quantitative PCR analysis to determine the copy number within the cell 
population. Thus the copy number multiplied by the dilution factor of the virus upon 
infection multiplied by the cells infected gives a titer. When the infectious titer and Q- 
PCR titer were compared there was a consistent 10-fold increase in Q-PCR titer (Table 
4.1). This result was similar to that previously reported (Sastry et al., 2002c) therefore 
molecular titers were used for vectors containing WASp alone or where endogenous 
promoters were used to allow accurate comparison between vectors.
4.2.2.2 Reconstitution of podosomes using vectors containing an 
endogenous promoter
Bone marrow derived dendritic cells were plated onto coverslips and infected with WpE 
WpW and SW at an MOI of 1000 (molecular titer) and incubated for 72 hours. The cells 
were then fixed and counterstained with phalloidin and vinculin to enable scoring of 
cells with podosomes as described previously. As expected cells transduced with WpE 
did not restore podosomes. Cells transduced with WASp from either WpW or SW
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however had podosomes restored to 15% and 25% respectively (Figure 4.9), which is 
up to half of normal levels. Counting the number of podosomes per cell assessed the 
quality of restoration. There was again high quality reconstitution. Normal cells were 
found to have an average of 30.9 podosomes per cell compared to 15 in WASp KO 
dendritic cells, when only positive cells were included (Figure 4.10).
+/+ WpE WpW SW
Figure 4.9 Reconstitution of podosomes
Bone marrow derived dendritic cells were seeded onto glass coverslips and infected at 
an MOI of 1000 determined by molecular titer with EGFP (WpE) or WASp (WpW, 
SW). The cells were then fixed and permeabilised before staining with rhodamine 
phalloidin to visualise F actin. Confocal images of the cells were scored for the presence 
or absence of podosomes on the basal surface. * p<0.005 students T test
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Figure 4.10 Quality of reconstitution of podosomes in dendritic cells
Bone marrow derived dendritic cells transduced with WASp were stained with phalloidin to 
visualise F-actin and therefore podosomes. Positive transduced cells had the number of 
podosomes per cell scored and plotted. Each point represents a single cell. WpW = endogenous 
promoter WASp, SW = SFFV WASp. * p<0.001 students T test compared to WAS KO
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Cells transduced with SW and WpW had an average of 21.5 and 28.6 podosomes per 
cell which is higher than WASp KO cells and in the case of WpW transduced cells is 
approaching normal levels. Again the distribution of podosomes within the dendritic 
cell population was measured by calculating the percentage in defined groups. Cells 
transduced with SW had a higher proportion of cells with lower amounts of podosomes 
when compared to normal cells, which is suggested by the lower average podosome 
number, whereas cells transduced with WpW had a near normal distribution again 
reflecting the near normal average podosome number (Figure 4.11) The podosomes 
seen by confocal microscopy in transduced cells were often present at leading edges and 
either had a ring of vinculin surrounding the actin core, or vinculin in close proximity to 
actin, showing correct podosome assembly for both WpW and SW transduced cells 
(Figure 4.12).
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Figure 4.11 Distribution of podosome number per cell
Dendritic cells were transduced with WASp (WpW or SW) and were scored into 
groups according to podosome content. For transduced and WASp+/+ dendritic 
cells only the cells with podosomes were included whereas all cells are included 
for WASp-/- cells.
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Figure 4.12 Confocal images of transduced dendritic cells
Bone marrow derived dendritic cells from WASp -/- mice were plated onto glass 
coverslips and infected at an MOI of 100 with WpE (EGFP), and WpW or SW (WASp). 
After 72 hours the cells were fixed in PFA and permeabilised before staining for F-actin 
and vinculin. Cells represented are the maximal projections from 8-12 Z sections showing 
EGFP (green), F-actin (white) and vinculin (blue or green). Podosomes are visible (yellow 
arrows) in both WpW and SW infected cells.
4.2.3 Lentiviral vectors containing Endogenous promoter sequences, WASp and 
the WPRE.
In addition to the 500bp sequence 5’ of the WAS start codon having promoter activity 
the sequence 1600bp has also been shown to be active in human haematopoietic cells 
(Petrella et al., 1998) as well as having 2 conserved regions between the proximal and 
distal promoter sequences (Ann Galy. personal communication). Both the 500bp and 
1600bp sequences were cloned into a pRRL based lentiviral vector containing WAS, 
which included the mutated WPRE sequence. These vectors were used in transduction
lb .00  Mill II, 0 0  111
H Mil inn
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experiments in conjunction with an SFFV 5’LTR containing vector (Figure 4.13). All 3 
vectors were a gift from Ann Galy, Genethon, France and were titered based upon a 
molecular quantitative PCR method.
5*-LTR cPPT SFFV WASp WPRE A3’-LTR
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S’-LTR cPPT ^ L 6 VVi j ^  WASp WPRE A3’-LTR
—  1.6WpWW
Figure 4.13 Cloning of lentiviral vectors containing various internal promoters
Cartoon depictions of lentiviral constructs containing WASp alone that contain the
WPRE. Three different promoters were cloned 500bp endogenous promoter sequence
(0.5Wp), a 1600bp endogenous promoter sequence (1.6Wp) and a construct with an
SFFV LTR. Also shown are the major features present in the backbone.
These vectors ability to reconstitute podosomes in murine dendritic cells was used to 
determine which vector is the most efficient and therefore most suitable for use in a 
clinical trial. Dendritic cells were infected at a low MOI (100) and a high MOI (1000) 
and the number of cells with podosomes reconstituted counted. Normal dendritic cells 
were 52% positive for podosomes compared to >5% in WASp KO cells (Figure 4.14). 
There was an increase in the number of cells with podosomes when cells were infected 
with SWW, 0.5WpWW and 1.6WpWW at an MOI of 100 to 21.1%, 13.7% and 18.6%, 
respectively (Figure 4.14). Podosome recovery was increased further by an increase in 
the MOI to 1000. Cells infected with SWW, 0.5WpWW and 1.6WpWW all showed an 
increase in the percentage recovery to 36.9%, 40.2% and 29%, respectively (Figure 
4.14).
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Figure 4.14 Reconstitution of podosomes
Bone marrow derived dendritic cells were seeded onto glass coverslips and infected at 
an MOI of 100 and 1000 determined by molecular titer with WASp under the control of 
a 500bp endogenous promoter sequence, a 1600bp endogenous promoter sequence and 
an SFFV LTR. The cells were then fixed and permeabilised before staining with 
rhodamine phalloidin to visualise F actin. Confocal images of the cells were scored for 
the presence or absence of podosomes on the basal surface. 100-200 cells were scored. 
Error bars shown are +1 SD * p<0.002 students T test compared to WAS KO.
4.2.3.1 Quality of Reconstitution
When the quality of reconstitution, determined by the number of podosomes per cell 
was determined there was again an increase in quality with a corresponding increase in 
MOI. The average number of podosomes per cell for normal cells was 31.7 compared to 
15 for WASp KO cells, in those cells that contained podosomes. The number of 
podosomes per cell increased from 24.6 to 30.7 in SWW infected cells, remained 
relatively similar at 24 and 25 in 0.5WpWW cells and increased from 19.3 to 30.1 in 
1.6WpWW infected cells (Figure 4.15). Confocal images, used to score the presence 
and number of podosomes, revealed podosomes were present in normal cells and WASp
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KO cells transduced with WASp but not EGFP ( F i g u r e  4 . 1 6 ) .  No vinculin staining was
performed on these samples.
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Figure 4.15 Quality of reconstitution of podosomes in dendritic cells
Bone marrow derived dendritic cells transduced with WASp were stained with 
phalloidin to visualise F-actin and therefore podosomes. Positive transduced cells 
had the number of podosomes per cell scored and plotted. Each point represents a 
single cell. O.SWpWW = 500bp endogenous promoter WASp, 1.6WpWW =
1600bp endogenous promoter WASp, SWW = SFFV WASp. f p<0.001, * p<0.05, 
* *  p <i.s_ p .  o j i  1 .students T test compared to values obtained for WAS KO.
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Figure 4.16 Confocal images of transduced dendritic cells
Bone marrow derived dendritic cells from WASp -/- mice were plated onto glass 
coverslips and infected at an MOI of 1000 with 0.5WpWW, 1.6WpWW or 
SWW (WASp). After 72 hours the cells were fixed in PFA and permeabilised 
before staining for F-actin. Cells represented are the maximal projections from 8- 
12 Z sections showing EGFP (green) and F-actin (white). Podosomes are visible 
(yellow arrows) in all infected cells.
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which were similar in appearance to that observed with transient transfections in 
dendritic cells (Chapter 3). Confocal images revealed co-localisation of actin and 
EGFP-WASp in podosomes of transduced cells that was not observed in EGFP 
transduced normal or WASp null cells; although no vinculin staining was performed on 
these samples. The podosome cluster was often present at the leading edge of the cell 
reminiscent of the position in normal cells (Figure 4.19).
I
Figure 4.18 Podosome recovery in primary human macrophages
Primary human macrophages were seeded onto glass infected at an MOI of 100 with 
a) EGFP-WASp (CEWW) or b) EGFP (SEW and WpE) or WASp (SW and WpW). 
The cells were fixed and stained with phalloidin to reveal F-actin. Cells were scored 
for the presence or absence of podosomes. Error bars shown are +1 SD
WASp null cells were also infected with vectors containing WASp alone under the 
control of an SFFV LTR or the 500bp endogenous WASp promoter at a molecular titer 
of 1000. Cells transduced with SW and WpW restored podosomes in 19% and 47.5% of 
cells respectively (Figure 4.18b). These cells also had their podosomes often present at 
the leading edge mimicking that seen in normal macrophages (Figure 4.19).
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Figure 4.19 Confocal images of transduced macrophages
Peripheral blood derived macrophages from WASp null patients were plated onto glass 
coverslips and infected at an MOI of 100 with EGFP (SEW), EGFP-WASp (CEWW) 
or WASp (SW+WpW). After 72 hours the cells were fixed in PFA and permeabilised 
before staining for F-actin. Cells represented are the maximal projections from 8-12 Z 
sections showing EGFP and EGFP-WASp (green) and F-actin (white). Podosomes are 
visible (yellow arrows) in normal cells and in WASp null cells infected with EGFP- 
WASp and WASp.
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4.2.4.1 Quality of Podosome Reconstitution
Again the quality of reconstitution was measured by counting the number of podosomes 
in reconstituted cells and comparing to normal. The average number of podosomes per 
cell in normal controls is 40.4 whereas WASp null cells with podosomes were greatly 
reduced at an average of 7.2 podosomes per cell (Figure 4.20). Macrophages infected 
with CEWW had an average number of podosomes of 56.6 showing there was high 
quality reconstitution that is similar to that observed in normal cells (Figure 4.20a). 
Cells transduced with WASp alone also showed high quality reconstitution. The average 
number of podosomes per cell was 85.3 for SW and 26.4 for WpW transduced cells 
(Figure 4.20b), although the very low sample number for SW prevents any meaningful 
conclusions being drawn.
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Figure 4.20 Quality of reconstitution of podosomes in macrophages
Peripheral blood derived macrophages transduced with a) EGFP-WASp and b) WASp 
were stained with phalloidin to visualise F-actin and therefore podosomes. Positive 
transduced cells had the number of podosomes per cell scored and plotted. Each point 
represents a single cell. CEWW = CMV EGFP-WASp, WpW = 500bp endogenous 
promoter WASp, SW = SFFV WASp. * p <0.001, ** p <0.02 students T test
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The distribution of podosomes was measured by calculating the percentage within 
defined groups to determine if there is a normal range of podosome number. Cells 
transduced with CEWW had a near normal distribution with an increase in the 51-100 
group, probably accounting for the increase in the average number of podosomes per 
cell (Figure 4.21). Cells transduced with SW had a distribution that was higher than 
normal showing most of the cells in the two highest groups, but the low sample number 
negates the significance of this (Figure 4.21). The distribution of podosomes in cells 
transduced with WpW showed an increase in cells with low numbers of podosomes 
compared to normal, indicative of a lower level of expression (Figure 4.21).
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Figure 4.21 Distribution of Podosome Number per cell
Peripheral blood derived macrophages were transduced with a) EGFP-WASp (CEWW) 
or b), c) WASp (SW and WpW) and were scored into groups according to podosome 
content. For transduced and WASp+/+ macrophages cells only the cells with podosomes 
were included whereas all cells are included for WASp-/- cells.
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4.3 Discussion
The aims of this chapter were to develop VSV-G pseudotyped self-inactivating HIV-1 
derived lentiviral vectors for use in reconstitution in vitro of primary murine WASp KO 
and human WASp null cells. The data obtained could then be used to help select a 
vector suitable for use in an in vivo gene therapy model. Vectors were developed 
containing EGFP, EGFP-WASp or WASp as the transgene, under the internal control of 
either strong viral promoters or putative endogenous promoter sequences with or 
without the WPRE sequence. This would enable a comparison between the 
constitutively active promoters and high level WASp expression, and a possibly more 
normally regulated level of WASp expression, from the endogenous promoter 
sequences. Firstly EGFP-WASp expression from vectors under the control of SFFV and 
CMV promoters was tested in 3T3 cells. 3T3 cells were easily transduced and expressed 
high amounts of the fusion protein. The expression pattern in these cells was similar to 
that previously seen (Chapter 3). Additionally there was co-localisation of EGFP-WASp 
and F-actin, with disruption of the cytoskeleton and aggregates of F-actin, also observed 
previously in this study, and has been seen when WASp is expressed in other adherent 
cells (Symons et al., 1996).
Vectors containing viral promoters for EGFP-WASp expression allowed infection and 
high-level transduction of murine primary bone marrow derived dendritic cells (Figure 
4.4). These cells had their podosomes restored to 60-65% of normal showing that 
upwards of 80% of transduced cells were able to restore podosomes. These cells had 
podosomes at leading edges, had F-actin and EGFP-WASp co-localised within the 
podosome and although often no ring of vinculin was visible there was definite co­
localisation, suggesting normal podosome assembly. Similar levels of podosome
141
Chapter 4
numbers per cell with a normal distribution were obtained with both viral promoters 
(Figures 4.6 +4.7) suggesting a high level of reconstitution.
Although obtaining viral titers calculated from infection efficiency is a widely used and 
reproducible method of titering, it was not possible to use this method for viral vectors 
containing WASp alone due to unreliable intracellular WASp staining. In addition with 
endogenous promoters there was no expression in non-haematopoietic cells (Martin et 
al., 2005). A molecular titre, obtained by real-time quantitative PCR upon infected cells, 
was the best method for obtaining a reliable viral titer. Although titers obtained by this 
method are generally higher than infectious titres (Table 4.1) (Sastry et al., 2002a) and 
are subject to a reliable standard curve, a direct comparison between vectors is 
obtainable and allows similar quantities of virus to be added to cells, therefore allowing 
accurate comparisons between vectors.
Putative endogenous promoter containing vectors allowed reconstitution of WASp KO 
dendritic cells. When the WPRE was not present the level of reconstitution was lower 
with the 500bp endogenous promoter compared to the SFFV LTR. The quality of the 
reconstitution however was better and had a more normal distribution. When the WPRE 
was introduced and the 1600bp endogenous promoter was also compared there was little 
difference between the promoters ability to reconstitute podosomes. Similarly there was 
little difference in the quality of reconstitution and distribution of podosomes in murine 
dendritic cells.
When human primary macrophages were infected they too were able to have their 
podosomes restored when either viral promoters or endogenous promoter sequences 
were used. Furthermore the podosomes formed were very similar to those observed in 
normal macrophages being formed at leading edges and showing co-localisation of F-
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actin and EGFP-WASp. Although there is very high sequence homology between the 
murine sequence 5’ of the start codon of WASp and the human sequence, the use of the 
500bp endogenous promoter lead to podosome numbers that were lower than that seen 
in normal which was not observed in murine dendritic cells. It could be a possibility that 
there are other sequences, such as those found in the 1600bp promoter that are 
important for either cell specific expression or for species specific expression as there is 
little homology further upstream of the 500bp fragment used. This was also without the 
inclusion of the WPRE, which was shown to improve the quality of reconstitution in 
murine dendritic cells (Figure 4.14) compared to vectors lacking the WPRE (Figure 
4.9).
Endogenous promoters may be a suitable alternative to viral promoters for use in a 
clinical gene therapy vector, where good efficient transduction and expression is 
obtained and is comparable to the levels obtained from viral promoters. There have been 
some problems associated with the use of viral LTRS namely the risk of insertional 
mutagenesis. It has been shown in animal models that multiple insertional events can 
lead to leukaemia (Modlich et al., 2005) (Li et al., 2002) where high doses of virus are 
used and where there are multiple insertional events around proto-oncogenes and 
signalling genes. In addition the leukaemia associated with the SCID-X1 trial in France 
was associated with insertional mutagenesis of the LMO-2 gene (Hacein-Bey-Abina et 
al., 2003a; Hacein-Bey-Abina et al., 2003b). Lentiviral vectors, as do some retroviral 
vectors have the ability to insert multiple copies into each cell (Woods et al., 2003) 
increasing the risk of insertional mutagenesis. The use of self-inactivating vectors 
reduces this risk as there is a lack of enhancer elements in the integrated viral LTR 
(Zufferey et al., 1998) as well as reducing the possibility of replication competent 
retrovirus. As WASp is normally highly restricted to the haematopoietic lineage the use
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of endogenous promoter sequences (either the 500bp or 1600bp fragment) in a viral 
vector may reduce the potential risk of complications from abnormal regulation of 
cellular expression.
This data represents the first case of WAS reconstitution in myeloid cells in vitro using 
lentiviral vectors. Previous retroviral in vitro work has focused on B cell lymphoblastic 
cell lines (Candotti et al., 1999) and particularly primary T cells with both retroviral and 
lentiviral vectors (Wada et al., 2002; Strom et al., 2003b; Strom et al., 2003a; Dupre et 
al., 2004).
Although the endogenous promoter sequences work well in the myeloid lineages in 
vitro it remains to be seen if they are capable of expression in pluripotent stem cells and 
allow expression in multiple lineages of the immune system in an in vivo setting.
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CHAPTER 5
RECONSTITUTION OF A 
MURINE MODEL OF WAS 
USING LENTIVIRAL VECTORS
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5.1 Introduction
We have made lentiviral particles with different internal promoters capable of 
transducing cell lines and primary cells in vitro and have shown successful 
reconstitution of dendritic cells in vitro with WASp using these lentiviral vectors 
(Chapter 4). The next step was to test the vectors ability to reconstitute a WAS KO 
murine model. This involves transduction ex vivo of murine stem cells followed by 
injection into lethally irradiated recipients to restore a normal phenotype again using 
podosome recovery as a tool to measure transduction. Using a modified retroviral 
protocol (Chapter 3), lineage negative cells were transduced ex vivo and transplanted 
into lethally irradiated recipients (Biffi et al., 2004). In this way we were able to 
optimise a lentiviral infection protocol capable of high levels of transduction. It was 
hoped that an improved level of transduction of murine stem cells could be obtained 
with lentiviral vectors over that previously seen with oncoretroviral vectors and lead to 
stable long term recovery of WAS.
Reconstitution of podosomes and number of podosomes per cell were used as a proxy 
measurement of efficiency of transduction in addition to the levels of EGFP (where 
present). Reconstitution in T cells was also measured by recovery of a proliferation 
response when stimulated.
5.2 Results
5.2.1 Reconstitution of WAS KO mouse model Using CMV and SFFV 
containing vectors
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The basic protocol used in the generation of an in vivo model is outlined in Figure 5.1. 
Briefly bone marrow derived lineage negative murine stem cells were harvested from 
the bone marrow, infected ex vivo in the presence of cytokines overnight and infused 
into a lethally irradiated recipient to allow the donor cells to repopulate the 
haematopoietic system. After a period of incubation, ranging from 6 weeks to 5 months, 
the mice were sacrificed and the lymphoid organs analysed for the presence of 
transgene and for reconstitution of function.
M ouse BM reconstitu tion  using  Lentivirus
Harvesting of lin-ve or 
lineage negative cells
O /N  pre-stimulation 
(SCF/  Flt3-L/ IL-6) with 
virus added
in vitro
Flow cytometry 
to determine 
levels of gene 
marking
Lethal irradiation 
split dose (1000 
RADS)
in vivo (6+ weeks)
cells injected for 
engraftment in bone 
marrow, Flow 
cytometry analysis after 
minimally 6 weeks
Figure 5.1 Ex vivo Transduction Protocol
Cartoon depiction of the transduction protocol. Lineage negative cells were 
harvested and cultured with virus overnight in the presence of cytokines. The 
cells were washed and infused back into lethally irradiated recipients and 
allowed to engraft for at least 6 weeks before mice are sacrificed. A sample was 
kept in culture for 72 hours to be analysed by flow cytometry for EGFP levels.
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5.2.2.1 Transduction efficiency of Lineage Negative stem ceils
There was successful gene marking in lineage negative cells when EGFP and EGFP- 
WASp containing vectors were used (Figure 5.2). When vectors containing the CMV 
promoter were used at an MOI of 100 the efficiency of transduction was up to 70% for 
EGFP and 10% for EGFP-WASp, determined by flow cytometry. The efficiency of 
transduction was improved when vectors containing an SFFV LTR as the internal 
promoter were used. The efficiency of transduction ranged from 1-66% for EGFP and
1-45% for EGFP-WASp (Figure 5.2) again using an MOI of up to 100. Representative 
flow cytometry plots showing the MFI of EGFP expression in lineage negative cells 72 
hours post infection are shown in Figure 5.3.
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Figure 5.2 Transduction levels of Lin negative cells
Bar chart of EGFP transduction levels 72 hours post infection, measured by flow 
cytometry. Each point represents an individual experiment. CEW = CMV EGFP, 
CEWW = CMV EGFP-WASp, SEW = SFFV EGFP, SEWW = SFFV EGFP-WASp
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Figure 5.3 Flow cytometry plots of transduced cells
Representative plots for a) SEW and b) SEWW showing transduction levels 
based on EGFP expression. The EGFP levels are determined after gating for 
the live cells (Gl) judged by the forward (FSC) and side scatter (SSC).
5.2.1.2 Bone marrow reconstitution levels
Mice were analysed after a period of 2-9 months and the levels of transduction were 
firstly determined by EGFP levels, measured by flow cytometry in the bone marrow. 
Mice reconstituted with CEW (5/5) had low levels of EGFP present up to 8 months 
whereas CEWW (6/6) infected cells had no EGFP positive cells in the bone marrow 
(Figure 5.4) In contrast EGFP levels in mice infected with SEW showed 14/18 mice 
positive for EGFP with levels of EGFP in the bone marrow ranging from 1-66% in the 
positive mice (Figure 5.4). 8/13 mice reconstituted with SEWW were positive for 
EGFP. The positive mice 5 months (6/6) (Figure 5.4) and 9 months (2/4) (data not 
shown) post transplant had high EGFP transduction levels in the input cells compared to 
3/3 negative with low level EGFP input transduction. The levels of transduction seen in 
the bone marrow of SEWW mice was generally lower than that seen for SEW. In
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addition the transduction levels were reduced from that observed in the infused lineage
negative cells (Figure 5.4).
80 i
60
a.
LL
o©
*£ 40 
©
©a
20
0
CEW CEWW SEW SEWW
Figure 5.4 Levels of Bone marrow Transduction in Reconstituted mice
Bone marrow was removed 6 weeks to 5 months after transplantation and the level 
of transgene expression determined by flow cytometry for EGFP expression. CEW 
(n=5), CEWW (n=6), SEW (n=18), SEWW (n=9). Each point represents an 
individual mouse.
%
5.2.1.3 Secondary lymphoid organ reconstitution levels
CEW but not CEWW mice had EGFP detectable in the peripheral blood, 2-8%, spleen
2-5% and the thymus 0.1-3.4% (Figure 5.5a). EGFP was detectable in both SEW and 
SEWW transduced mice, with EGFP levels highest when SEW was used compared to 
SEWW. EGFP levels in peripheral blood was 42-67% and 8-18%, spleen 27-44% and 
10-20% and thymus 18-35% and 0-10% for SEW and SEWW respectively (Figure 
5.5b).
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Figure S.5 Transduction levels in secondary lymphoid tissues
3-8 months after engraftment peripheral blood (PBL), spleen (SPL) and thymus (THY) 
single cell suspensions from transduced mice were analysed for the presence of EGFP by 
flow cytometry. Each point represents a mouse, a) CEW n=5, CEWW n=6, b) SEW (n=3) 
SEWW (n=6). * p< 0.005 THY compared to PBL and SPL, ** p<0.5 students T test PBL 
compared to SPL and THY.
5.2.1.4 Lineage Analysis
In order to confirm a lineage negative multipotent murine haematopoietic stem cell had 
been transduced an analysis of the different lineages was performed. The presence of 
transduced lineage positive cells up to 5 months post infusion can only be due to 
transduction of multipotent cells that have engrafted and repopulated the haematopoietic 
system.
151
Chapter 5
5.2.1.5 Peripheral Blood
Peripheral blood leukocytes from transduced mice were subdivided based upon their 
forward and side scatter profiles into lymphocyte (L), monocyte (M) and granulocyte 
(G) populations allowing the EGFP levels in each lineage to be determined (Figure 
5.6a). The ratio of transduced lineage cells for each lineage was calculated for CEW 
(Figure 5.6b) SEW and SEWW transduced mice (Figure 5.6c). When the levels were 
compared the highest levels of transduction were seen in the myeloid lineages with the 
lymphoid compartment greatly reduced for all mice analysed (Figure 5.6b+c).
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Figure 5.6 Determination of lineage transduction in peripheral blood
a) The lymphocyte (L), monocyte (M) and granulocyte (G) populations of peripheral 
blood from transduced mice were distinguished by their forward and side scatter in able 
to determine transduction levels in multiple lineages, b) + c) Bar chart showing the 
relative proportion of transduced cells determined for each lineage. CEW (mouse 1-5), 
SEW (mouse 1-3), SEWW (mouse 1-6)
5.2.1.6 Spleen
Splenocytes from CEW, SEW and SEWW transduced mice were stained with B220, 
CD1 lb and CD3 antibodies labelled with PE to distinguish B cells, myeloid cells and T
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cells respectively, to determine if there was multi-lineage transduction. Flow cytometry 
revealed that for all transduced mice there were EGFP positive cells in all populations 
observed (Figures 5.7a,b +c). When the ratios of each lineage in the transduced 
population were compared the levels were evenly spread in mice transduced with CEW, 
with all populations transduced. In SEW and SEWW transduced mice there was 
generally higher EGFP expression in the myeloid lineage, and although there were often 
high levels of EGFP seen in B cells, the levels were lowest in the T cell compartment 
(Figure 5.7c). This corresponds well with previous data showing an increase in 
expression in myeloid cells with the SFFV LTR (Baum et al., 1995).
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Figure 5.7 Flow cytometry of Splenocytes from Transduced Mice
a) Splenocytes from transduced mice were stained for the lineage markers B220, CDllb 
and CD3 labelled with PE. Representative flow cytometry plots are shown from SEW 
and SEWW transduced mice, b) Bar chart showing the relative proportion of transduced 
cells for each lineage in splenocytes determined from flow cytometry data above in CEW 
(mouse 1-5) and c) SEW (mouse 1-3) and SEWW (mouse 1-6) transduced mice. No data 
was obtainable for SEWW5 due to sample contamination.
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5.2.1.7 Reconstitution of Podosomes
Bone marrow cells from reconstituted mice were differentiated into dendritic cells in 
vitro, to count podosomes. After 7 days in culture the dendritic cells were sorted on the 
basis of EGFP and plated onto fibronectin coated coverslips. After fixing and staining 
with phalloidin to reveal the F actin, confocal images were captured to enable the 
percent of cells with podosomes, and the number of podosomes per cell to be 
determined. Dendritic cells from normal mice had 65% with podosomes. Dendritic cells 
from SEW transduced mice had 5% with podosomes compared with 12-23% in SEWW 
transduced mice (Figure 5.8).
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Figure 5.8 Percent of murine derived bone marrow cells with podosomes
Bone marrow derived dendritic cells were positively sorted for EGFP and plated onto 
coverslips for 24 hours to allow cells to adhere. Cells were fixed and counterstained 
with rhodamine phalloidin to visualise F-actin. Confocal images of the cells were 
obtained and maximal projections of 6-12 z sections were used to score for the presence 
or absence of podosomes on the basal surface. Each bar represents an individual mouse 
with 50-100 cells counted for each. Error bar shown is +1SD
When the number of podosomes per cell was counted there was an average of 22 per 
cell for SEWW transduced cells. This is lower than the value of 31.4 seen in dendritic 
cells from normal mice (Figure 5.9) but higher than that seen in SEW transduced and 
untransduced mice.
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Figure 5.9 Podosomes per cell
Cells were stained with phalloidin to visualise actin and therefore podosomes. 
Positive cells had the number of podosomes per cell scored and plotted. Each point 
represents a single cell. Values are pooled from similar treated mice in one 
experiment. (EGFP n=3, EGFP-WASp n=4). P value from students T test.
A representative confocal image (Figure 5.10a-c) of an SEWW transduced dendritic 
cell shows EGFP-WASp located in podosomes and co-localisation with F-actin in the 
podosomes (Figure 5.10b arrows). Further confirmation of the normal structure of the 
podosomes was seen by the vinculin staining in and around the podosomes (Figure 
5.10c).
Figure 5.10 Confocal Image of Murine Dendritic Cell
Bone marrow dendritic cells from EGFP-WASp transduced mice were positively 
sorted on the basis of EGFP before being plated onto coverslips overnight. Cells were 
fixed and counterstained with rhodamine phalloidin to visualise F actin and vinculin. 
Arrows show the presence of podosomes. Images are maximal projections of 12 z 
sections.
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5.2.1.8 Integrated Viral Copy Number and Human WASp Expression 
Levels
It is important to determine if the expression levels are dependant upon copy number 
and if the MOI used generates high copy numbers. In retroviral vectors each additional 
integration event has an increased risk of insertional mutagenesis (Li et al., 2002; Baum 
et al., 2003; Modlich et al., 2005), therefore high or therapeutic expression levels from 
few integration events is preferential.
5.2.1.8.1 Copy Number
Quantitative real time PCR was used to determine the copy number of integrated viral 
genomes within the bone marrow, spleen and thymus. Dilutions of the lentiviral plasmid 
SEWW were used to produce a standard curve against which copies of integrated 
genomes could be measured and quantified. In addition to be able to quantify the 
number of mouse genomes and therefore cells in the reaction a plasmid containing the 
mouse titin gene (a gift from Anne Galy, Genethon, France) was diluted to give another 
standard curve against which cell number could be calculated. Using this method the 
value for the viral genomes can be divided by the number of cells to give the copy 
number per cell.
In mice transduced with SEW the copy number was 5.4-8.7 for bone marrow, 5 for 
spleen and 1-4 for thymus (Figure 5.11). The decrease in copy number in thymus 
compared to spleen correlates well with the decreased EGFP levels, determined by flow 
cytometry, seen in these organs (Figure 5.5b). The copy number in bone marrow, 
spleen and thymus was 3.2-5.3, 3.5-9, and 3-3.5 in SEWW transduced mice (Figure 
5.11) apart from one outlying value in the spleen of 95, which was probably due to
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contamination. The copy number was lower than that seen in SEW transduced mice but 
correspondingly, the expression levels of EGFP-WASp were also lower. Unlike the 
values obtained from SEW transduced mice there was little corresponding reduction in 
copy number observed in the spleen and thymus compared to bone marrow, even 
though the EGFP levels were also reduced in the thymus (Figure 5.5b).
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Figure 5.11 Real Time PCR on DNA to determine copy number
DNA from bone marrow (BM), spleen (SPL) and thymus (THY) from experiment 6 
had the number of integrated viral genomes quantified by real time PCR. Each point 
represents an individual mouse taken from one experiment where the MOI was the 
same for SEW (n=3) and SEWW (n=6). P value is a students T test comparing values 
from BM to THY for both SEW and SEWW values.
5.2.1.8.2 Expression Levels
The expression level of human WASp was also calculated by quantitative real time 
PCR. Unfortunately there was no cell line or primary cell standard to which the 
transduced murine cells could be compared, as human WASp is not normally expressed 
in murine cells and the PCR is specific for human WASp. However the samples could 
be compared to each other, as they are all internally controlled using murine PGK 
expression. It is for this reason that all the values are compared to the levels seen from 
one SEWW transduced bone marrow sample (in this case mouse SEWW 1) chosen 
randomly.
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The levels of human WASp expression were highest in the bone marrow, with some
reduction in the spleen for half the samples (Figure 5.12). The expression levels in the 
thymus were lower than those observed in the bone marrow confirming the reduced
EGFP expression noticed by flow cytometry (Figure 5.12).
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Figure 5.12 Expression of human WASp in murine bone marrow
Total RNA was collected from cell pellets from experiment 6 and the cDNA made by 
reverse transcription. Quantitative PCR was performed on the cDNA to determine the 
levels of human WASp expression compared to the ubiquitous murine protein PGK. A 
reference was needed and SEWW 1 was used by which all other samples were 
compared. Expression levels are measured on the Y axis by fold increase from the 
reference.
5.2.1.9 T cell Proliferation Assay
Splenic lymphocytes were incubated in the presence of anti CD3 antibody at increasing 
dilutions to measure the stimulatory capacity of the transduced T cells. Normal control 
murine T cells were able to respond strongly to all concentrations of CD3 antibody 
giving a high stimulation index. Mice transduced with EGFP responded weakly in 
comparison (Figure 5.13). There was stimulation in two mice transduced with EGFP- 
WASp at an anti CD3 antibody concentration of lug/ml above that observed in EGFP 
transduced cells. At the higher concentration of 3ug/ml 3 mice responded above that of
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EGFP transduced controls (Figure 5.13), whereas the highest concentration of 15ug/ml 
showed little or no stimulation.
T cell proliferation
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Figure 5.13 Splenic T cell proliferation in transduced mice
10 splenic lymphocytes from normal (■ ), sew (■ ), and seww (■ ) transduced 
mice were incubated in 96 well plates coated with anti CD3 antibody at lug, 
3ug and 15ug/ml for 72 hours. The last 18 hours of which was in the presence 
of tritiated thymidine. The thymidine incorporation measured in stimulated 
cells compared over unstimulated cells obtained a stimulation index, sew n=3, 
seww n=6.
5.2.2 Reconstitution using endogenous promoter sequences
Lineage negative stem cells were harvested and transduced ex vivo overnight in the 
presence of cytokines, as previously described (Figure 5.1), at an MOI of 100, as 
determined from molecular titers, with lentiviral particles encoding for human WASp. 
WASp was under the transcriptional control of three different promoters, an SFFV 5’ 
LTR, and a 500bp (Hagemann and Kwan, 1999) or 1600bp (Petrella et al., 1998) 
fragment of the endogenous WAS promoter sequence. Vectors and titers were obtained 
in collaboration from Anne Galy (Genethon, Evry, France). Transduced cells were
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infused into lethally irradiated recipients and allowed to repopulate the haematopoietic 
system. Mice were culled 5 months post injection and efficiency of transduction 
measured by restoration of podosomes in bone marrow dendritic cells, expression of 
human WASp and T cell proliferation.
5.2.2.1 Im m unoblot o f spleen lysates from transduced mice
Lysate for each sample equating to lx l0 6 splenic leukocytes was resolved by SDS- 
PAGE and the presence of human WASp was probed for using an anti WASp antibody. 
In control mice and those transduced with SEW there was no detectable levels of human 
WASp, however, with the exception of one sample (sww 1) there was human WASp 
detectable in lysates from all mice transduced with vectors containing human WASp 
(Figure 5.14) albeit at low levels. When the loading was checked by probing with an 
anti p actin antibody it was found to be similar for all samples loaded onto the gel 
(Figure 5.14).
Figure 5.14 Immunoblot of splenic lysates from transduced mice
Lysates were prepared from spleens from mice transduced with WASp, EGFP and 
untransduced. The proteins were separated by SDS-PAGE and probed for the 
presence of human WASp using an anti WASp antibody. SEW = SFFV EGFP, 
SWW = SFFV WASp, 0.5WpWW = 500bp endogenous promoter WASp, 1.6 
WpWW = 1.6 Kb endogenous promoter WASp.
The blot was also probed with an anti P actin antibody to check the loading was 
consistent between samples.
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5.2.2.2 Podosome recovery in murine dendritic cells
Bone marrow derived dendritic cells were plated onto fibronectin coated coverslips and 
allowed to adhere for 24 hours. The cells were fixed and the F-actin visualised using 
rhodamine phalloidin. Confocal images were captured and the images used to determine 
the percentage of cells positive for the presence of podosomes determined. Dendritic 
cells from normal mice had podosomes present in 60-72% compared to 4-9% for mice 
transduced with SEW (Figure 5.15). Cells from mice transduced with WASp had 
podosomes present in all vectors although podosome levels could not be determined in 
4 samples as the cells failed to adhere to coverslips. Cells transduced with 0.5WpWW 
had podosomes present in 24-30%, 1.6WpWW 26-27% and SWW 7-35% (Figure 
5.15), which represents correction up to 50% of that observed in normal.
Figure 5.15 Percent of murine dendritic cells with podosomes
Murine bone marrow derived dendritic cells were plated onto fibronectin 
coated coverslips for 24 hours to allow cells to adhere. The cells were then 
fixed prior to staining with phalloidin to visualise the F actin. Confocal images 
were obtained and maximal projections of 8-10 sections were used to score for 
the presence or absence of podosomes on the basal surface. Each bar 
represents a mouse where 50-100 cells were counted.
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To determine the quality of reconstitution the number of podosomes per cell was 
counted as described earlier. In cells containing podosomes the average number of 
podosomes per cell in normal mice was 31.9 compared to 12.9 in knockout mice. The 
average number per cell was 20.32, 22.62 and 30.6 for 0.5WpWW, 1.6WpWW and 
SWW, respectively (Figure 5.16). This shows that all three vectors are capable of 
transducing WASp knockout cells to restore podosomes to a level above that seen in 
knockout mice.
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Figure 5.16 Number of podosomes per cell in dendritic cells
Cells were stained with phalloidin to visualise actin and therefore podosomes. 
Positive cells had the number of podosomes per cell scored and plotted. Each 
point represents a single cell. Values are pooled from similar treated mice in one 
experiment. (0.5WpWW n=2, 1.6WpWW n=2, SWW n=4). * p<0.01, ** 
p<0.001 students T test. Values are compared to -/-.
Representative confocal images (Figures 5.17) of control untransduced, SEW, SWW, 
0.5WpWW and 1.6WpWW transduced dendritic cells show podosomes present (marked 
by arrows) in all cell populations transduced with WASp but not EGFP. No vinculin 
staining was performed on these samples.
162
Chapter 5
EGFP ACTIN
+/+
SEW
SWW
wpww0.5
wpww 1.6
Figure 5.17 Confocal images of bone marrow dendritic cells
Bone marrow dendritic cells from normal, EGFP transduced and WASp transduced 
mice under the control of different promoters were plated onto fibronectin coated 
coverslips overnight. Cells were fixed and counterstained with rhodamine phalloidin 
to visualise F actin. Images shown are maximal projections of 6-12 z sections 
showing EGFP where present and F actin. +/+ = Svl29 control, SEW = SFFV EGFP 
WPRE, SWW = SFFV WASp WPRE, wpw0.5 = 500bp Wiskott promoter WASP 
WPRE. wpwl.6 = 1600bp Wiskott promoter WASP WPRE. Scale bar is lOum.
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5.2.2.3 Integrated Viral Copy Number and Human WASp Expression 
Levels
As described earlier the copy number of viral genomes in the bone marrow spleen and 
thymus were determined by quantitative real time PCR using the same standards as 
previously described.
5.2.2.3.1 Copy Number
In mice transduced with SEW the copy number was 0.6-1.2 for bone marrow, 1-2.2 for 
spleen and 0.3-1.2 for thymus (Figure 5.18). The copy number for cells transduced with 
WASp was higher than that seen for EGFP in bone marrow, spleen and thymus. The 
copy number in the bone marrow was 2.6-10, 2.5-8 and 1.9-3.4 for SWW, 0.5WpWW 
and 1.6WpWW respectively (Figure 5.18a). In the spleen the copy number was 4.8-10, 
6.6-10 and 3.9-5.6 for SWW, 0.5WpWW and 1.6WpWW (Figure 5.18b). Finally, in the 
thymus the copy number was 1.4-8.4, 2.2-4.2 and 2.2-4.8 for SWW, 0.5WpWW and 
1.6WpWW (Figure 5.18c). The copy number values obtained for each organ was 
similar regardless of which promoter was included although the copy number was 
highest in the spleen. This was also seen with SEWW transduced mice (Figure 5.11)
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Figure 5.18 Integrated viral genome copy number
Quantitative real-time PCR was used to determine the total number of integrated viral 
copies in the murine genome in the bone marrow (a), spleen (b) and thymus (c). Values 
are corrected for the level of chimaerism based on percent Y chromosome levels. Each 
point represents one mouse, sew = SFFV EGFP, sww = SFFV WASp, 0.5wp = 500bp 
wiskott promoter WASp, 1.6wp = 1600bp wiskott promoter WASp. n=4 for all groups. 
*p<0.01, **p<0.05 students T test compared to values obtained in the spleen.
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5.2.2.3.2 Expression Levels
The expression level of human WASp in the bone marrow and spleen was calculated by 
quantitative real time PCR. There was no cell line or primary cell standard to which the 
transduced murine cells could be compared so the bone marrow from mouse SWW1 
was used as a reference to which all subsequent expression increases or decreases were 
obtained. In the bone marrow (Figure 5.19) there was some variability between samples 
ranging from 1-1000 fold increase in human WASp expression, whereas the spleen 
showed a lot less variation of 0.5-10 fold (Figure 5.19). The expression levels in the 
thymus were not determined. Use of all three promoters, lead to expression of WASp, 
with the average expression level highest for 0.5WpWW and lowest for 1.6WpWW.
Bone marrow Spleen
Figure 5.19 Human WASp expression levels
Quantitative PCR was performed on the cDNA reverse transcribed from the 
mRNA to determine the levels of human WASp expression compared to the 
ubiquitous murine protein, PGK. SWW1 BM was used as a reference by 
which all other samples were compared. Expression levels are measured on 
the Y axis by fold increase from the reference
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5.2.2.4 T cell Proliferation Assay
Splenic lymphocytes were incubated in the presence of anti CD3 antibody at increasing 
dilutions to measure the stimulatory capacity of the transduced T cells. Normal control 
T cells were able to respond strongly to all concentrations of CD3 antibody giving a 
high stimulation index in 3 out of 4 mice (Figure 5.20). Mice transduced with EGFP 
responded weakly in comparison (Figure 5.20). There was stimulation in two mice 
transduced with SWW at all anti CD3 antibody concentrations above that observed in 
EGFP transduced cells. There was a slight increase in stimulation at the lowest CD3 
dose in 1 mouse transduced with 0.5WpWW which was not seen at higher doses. No 
mice treated with 1.6WpWW showed a stimulation increase above SEW treated mice 
(Figure 5.20).
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Figure 5.20 Splenic T cell proliferation in transduced mice
105 splenic lymphocytes from normal (b ), sew (■ ), sww ( ■ ), 0.5Wp (□ ) 
and 1.6Wp ( □ ) transduce mice were incubated in 96 well plates coated with 
anti CD3 antibody at 3ug, 15ug and 30ug/ml for 72 hours. The last 18 hours 
of which was in the presence of tritiated thymidine. The thymidine 
incorporation measured in stimulated cells compared over unstimulated cells 
obtained a stimulation index allowing comparison between mice.
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5.3 Discussion
The aim of this chapter was to successfully treat a murine model of Wiskott-Aldrich 
syndrome by efficiently transducing lineage negative stem cells ex vivo with EGFP- 
WASp or WASp using lentiviral vectors which could then repopulate a lethally 
irradiated recipient. Benefits of our lentiviral system over a retroviral protocol are firstly 
they are self inactivating due to a U3 deletion in the 3’ LTR. This should decrease the 
risk of insertional mutagenesis, a problem which has occurred with SCIDX1 gene 
therapy trials in Paris (Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 
2003b). Additionally as an internal promoter is required this can be optimised 
depending upon the level of expression required (Zufferey et al., 1998). We have 
utilised several promoters, a CMV promoter, a viral 5’ LTR and two novel endogenous 
WAS promoter sequences, to try to optimise a gene therapy protocol which can then be 
transferred to a clinical setting.
When vectors containing EGFP and EGFP-WASp and the promoter was either CMV or 
an SFFV 5’LTR, there was transduction of lineage negative cells that was as high as 
70%. Upon analysis there was recovery of EGFP for both CMV and SFFV promoters. 
(Figure 5.4). However there was only EGFP-WASp detectable from SFFV containing 
vectors. This is in contrast to our previous work in vitro in DCs where the CMV 
promoter has been shown to be very effective at correcting a WASp null phenotype 
(Chapter 4). It has been reported that in haematopoietic cells and long term in vivo 
expression there is suppression of the CMV promoter (Liu et al., 1992; Scharfmann et 
al., 1991) and other promoters which has been associated with de novo methylation of 
the areas flanking the integration site (Jahner and Jaenisch, 1985; Challita and Kohn, 
1994b). CMV mediated expression may also be dependant on cell cycle phase (An et
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al., 2000) and is particularly low in T cells (Brightwell et al., 1997). For SFFV treated 
mice, recovery of EGFP transduced cells was similar to that seen in the input 
population, whereas the transduction levels in the bone marrow of EGFP-WASp 
transduced mice was markedly reduced. It is unclear why this should be the case as it 
has been reported there is a homing advantage in stem cells with WASp (Lacout et al., 
2003) and somatic mosaicism has been observed in patients with spontaneous reversion 
mutations (Wada et al., 2001; Wada et al., 2003; Wada et al., 2004). One theory is that 
there is not sufficient selective pressure for T cell development in this model so a 
selective advantage is not seen. When cells from spleen, lymph nodes and thymus were 
analysed there was a reduction of EGFP and EGFP-WASp levels compared to the initial 
transduction levels, particularly in the thymus, supporting the lack of T cell 
development theory. Previous work with retroviral constructs showed lower initial 
transduction levels and little or no transduced cells in secondary lymphoid organs. This 
suggests, to gain complete reconstitution of the immune system, high transduction 
efficiency is required and the lentiviral vectors tested in this study may be better. In 
addition to multi-organ reconstitution with EGFP-WASp transduced cells, there was 
multi-lineage reconstitution with EGFP positive B, T and myeloid cells in the peripheral 
blood and spleen, which was not seen in cells transduced with EGFP-WASp using a 
retrovirus. Myeloid cells and B cells were the main cell types transduced with little T 
cell transduction. Addition of WASp has been shown to have selective advantages for T 
compared to B cells both in human (Konno et al., 2004) and mouse (Snapper et al., 
1998), but this was not seen in this study. However higher levels of EGFP-WASp 
expression were generally seen in the spleen and peripheral blood compared to bone 
marrow which was not seen with EGFP transduced mice. Splenocytes also had a higher 
average copy number. Quantitative real-time PCR did not show increased expression of
168
Chapter 5
WASp in spleen compared to bone marrow (Figure 5.12), but the system assumes that 
the level of house keeping gene is the same between bone marrow, spleen and thymus, 
which may not be the case.
Bone marrow derived dendritic cells from SFFV EGFP-WASp transduced mice had 
podosomes present in 12-23% of cells showing normal patterns of assembly. This is 
only a quarter of the level of podosomes seen in normal cells even though greater than 
90% of the DCs were EGFP positive. The quality of the reconstitution was lower than 
that seen in vitro (Chapter 4) and in retrovirally transduced cells (Chapter 3) with the 
average number of podosomes per cell not as high as that seen in normal, although it 
was above that seen in untransduced cells. Although not as high as normal the levels 
may be sufficient for at least partial correction of the disease as it has been shown in 
that the mild version of Wiskott-Aldrich syndrome, XLT, there are reduced numbers of 
podosomes (Linder et al., 2003).
The reasons for the decreased levels of transduction after 5 months are unclear. It may 
be dependant on expression levels obtained initially, and data using EGFP suggests the 
higher the initial input transduction levels the greater the thymic reconstitution. The 
experimental duration may also be important but there may have been irreversible 
damage to the thymic microenvironment. It has been shown that the interaction of 
thymic epithelial cells is crucial in T cell development (Klug et al., 1998). Thymic 
development is abnormal in human X-linked SCID (Hale et al., 2004) and WASp has 
been shown to be important in T cell development (Zhang et al., 2002). Older patients 
submitted to a gene therapy protocol failed to engraft (Thrasher et al., 2005) compared 
to high levels of success with younger patients (Gaspar et al., 2004; Hacein-Bey-Abina 
et al., 2002; Cavazzana-Calvo et al., 2000a) suggesting time of transplant could be
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crucial. This does not explain why untransduced CD3 positive cells are present in the 
spleen however.
A T cell proliferation assay showed that there was some lymphoid reconstitution of 
function. The apparent reduction in T cell reconstitution, determined by lower EGFP- 
WASp levels in the thymus, was shown further however where only 2 mice were able to 
respond to a CD3 stimulus. Strangely cells from mice that were able to respond to CD3 
did not have the highest expression levels, as determined by PCR or by flow cytometry.
Further in vivo experiments using WASp as the transgene in place of EGFP-WASp 
were performed. In addition to the SFFV 5’LTR which we have shown to be successful 
in vivo, we utilised two endogenous WAS promoter sequences found 5’ to the WAS start 
codon to see if they would be able to express WASp at sufficient levels to reconstitute 
then WAS phenotype. This would enable a gene therapy protocol to be developed that 
did not use a vector containing a constitutively active strong promoter but instead use an 
endogenous sequence that may provide more regulated normal expression and possibly 
only in haematopoietic cells (Martin et al., 2005). Lineage negative cells were 
transduced as previously described and infused into lethally irradiated recipients. After 
5 months there was expression of human WASp, determined by western blot, in almost 
all samples utilising the SFFV 5’LTR, the 500bp endogenous promoter and the 1600bp 
endogenous promoter.
Recovery of podosomes in bone marrow dendritic cells was again used to determine the 
success of the reconstitution. As there was no EGFP it was not possible to select for the 
transgene positive populations however there were still high levels of podosomes 
compared to EGFP transduced that were approximately a third of that seen in normal
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controls. There was a comparative level of podosome recovery in mice reconstituted 
with all three vectors used. Additionally the quality of the reconstitution determined by 
podosome number per cell was high, again with all three vectors able to achieve average 
podosome numbers higher than knockout or EGFP transduced controls. Although the 
0.5kb and 1.6kb containing promoter WASp transduced cells had the greatest number of 
cells with podosomes it was the SWW transduced cells that had the most podosomes per 
cell.
Expression levels measured by quantitative PCR did not necessarily correlate with 
podosome numbers. In the bone marrow the average expression level was highest for 
cells transduced with 0.5WpWW, although SWW and 1.6WpWW were very similar. 
However the percent of cells with podosomes was increased in the cells that had high 
expression levels determined by real time PCR. The copy number was similar for cells 
transduced with all three vectors for all lymphoid tissues, with the highest levels found 
in the spleen. This was also seen in SEWW transduced cells, suggesting a possible 
maturation advantage for cells containing an integrated copy. There was no correlation 
between high copy number and high human WASp expression levels in the bone 
marrow, although there did seem to be an increase in expression with an increase in 
copy number in the spleen particularly for SWW and 0.5WpWW transduced cells. As 
mentioned, there is no standard to which the expression levels can be compared, due to 
human WASp being expressed in murine cells, so whether these levels are similar to 
that seen in normal haematopoietic cells remains to be seen.
A T cell proliferation assay in response to CD3 stimulation was performed on splenic 
cells and there was little stimulation above EGFP transduced cells in most of the 
samples tested. The mouse that did respond well was SWW 2, which did have a high
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copy number and the highest expression levels determined by PCR. Furthermore the 
band exposed by western blot from sample SWW was visibly one of the strongest. 
Again the reasons for this lack of T cell reconstitution is unknown but as the mice were 
analysed 5 months after infusion with transduced cells it may be factors other than time 
constraints.
In conclusion, further to our successful reconstitution of murine WAS KO dendritic 
cells in vitro, we have successfully performed long term reconstitution of a murine 
WAS KO model using lentiviral vectors encoding EGFP, EGFP-WASp and WASp. 
This was under the transcriptional control of the retroviral SFFV 5’ LTR and 
endogenous promoter sequences that are found upstream of the start codon of WASp. A 
CMV promoter containing vector was not able to reconstitute EGFP-WASp in the 
mouse model.
When WASp was used the reconstitution in vivo determined by the presence of 
podosomes was about a third of normal for all vectors used and the quality of 
reconstitution determined by podosome number was high suggesting that where there is 
reconstitution it will be of sufficiently high enough levels to be therapeutic.
The reconstitution with vectors containing endogenous vector sequences is encouraging 
as more normally regulated WASp may lead to a more normal recovery. This will allow 
a gene therapy trial that does not contain a viral promoter and therefore the enhancers, 
able to act upon other genes, found in viral LTRS. This should make the vector safer 
without compromising the efficacy of the treatment.
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CHAPTER 6
DISCOVERY OF A NOVEL 
ACTIVATING MUTATION IN 
WAS RESULTING IN X-LINKED 
CONGENITAL 
NEUTROPAENIA
173
Chapter 6
6.1 Introduction
Recently a patient with severe neutropaenia, monocytopaenia and a reversed CD4/CD8 
ratio was found to have a mutation of the WAS gene that lead to a substitution in the 
WAS protein at L270P in the Cdc42 binding domain. Apart from the neutropaenia it 
was discovered that the mutation caused actin to be polymerised in vitro constitutively, 
independent of the normal regulation seen for wild type WASp (Devriendt et al., 2001). 
The mutation causes the amino acid lysine (L), which has a small side chain to be 
replaced with proline (P), which has a large side chain and is often found at helical 
turns. In the predicted tertiary protein structure this would prevent the basic C-terminus 
from folding into the pocket created by the alpha helices as this side chain is on the 
inner face of the a-helix. The constitutive actin polymerisation seen is thought to be due 
to incorrect folding of WASp preventing the inactive confirmation. This leads to a 
constitutively active WASp and the disease phenotype seen. This mutation could 
increase the further understanding of the regulation of WASp within cells and the 
neutropaenia and monocytopaenia associated with the unregulated expression may 
suggest toxicity associated with uncontrolled expression or activation of WASp.
6.1.1 Discovery of an activating mutation in WASp
A patient presented at Great Ormond Street Hospital (GOSH) with severe neutropaenia, 
monocytopaenia and lymphopaenia with a reversed CD4/CD8 ratio. When exons 8 and 
9 (the Cdc42 binding domain) of the WAS gene were sequenced, a novel mutation was 
found. This was T36201C, which causes the amino acid substitution I294T. The 
mutation was checked to see if it was a naturally occurring polymorphism and was 
found not to be present in 100 normal individuals either European or African (the
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patient is of African extraction)(P.Anclif, in press). Additionally, the mother was a 
carrier of the mutation and showed apparent non-random X-inactivation in T cells and 
neutrophils (P.Anclif, in press), which has been seen in female carriers of classical WAS 
mutations.
The mutation leads to a replacement in the Cdc42 binding domain of a neutral amino 
acid, isoleucine (I), with the polar amino acid threonine (T). This is thought to interfere 
with the folding of the C-terminus into the pocket created by the alpha helices of the 
Cdc42 binding domain. Additionally it is on the direct opposite side of the pocket as the 
previously seen mutation L270P (Figure 6.1) suggesting the mutation may have a 
similar effect and cause constitutive actin polymerisation. The aims of this chapter were 
to investigate the constitutively active WASpE94T patient cells and the consequences of 
overexpression of WASp12947 in cell lines to elucidate the mechanisms behind the 
patient phenotype.
6.2 Results
6.2.1 Characterisation of patient with WASpI294T
6.2.1.1 Macrophage morphology
Peripheral blood macrophages were seeded onto glass coverslips fixed and the F-actin 
visualised with rhodamine phalloidin to determine any abnormalities in the actin 
cytoskeleton. Normal macrophages (Figure 6.2a) have podosomes present at a leading 
edge lamellopodium. Macrophages from classical WAS patients do not have podosomes 
and patients with less severe mutations, designated to have XLT, have reduced numbers 
(Linder et al., 1999; Linder et al., 2003). Macrophages from the I294T mutant had 
podosomes. However these podosomes were brighter than those seen in normals and
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Figure 6.1 Solution structure of the autoinhibited conformation of WASp
The C terminus of WASp (orange) sits in the pocket formed by the a-helices of 
the GBD domain (green). The positions of the activating mutations of WASp 
I294T and L270P are shown in red and yellow respectively.
Image modified from: A.S.Kim, L.T.Kakalis, N.Abdul-Manan, G.A.Liu & 
M.K.Rosen
Ref:- MMDB Id: 13302 PDB Id: 1EJ5
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were not distributed inside the cell in a normal manner. The podosomes were present in 
ring like structures (Figure 6.2b) similar to those observed in sealing zones in 
osteoclasts and in multiple clusters (Figure 6.2c). The rest of the cell had very low level 
of F-actin staining compared to normal and was difficult to visualise. The macrophages 
were stained for vinculin (Figure 6.2d) to determine if this was normal. There was 
positive staining around the actin core of the podosomes, even when in multiple 
clusters, showing normal assembly.
Figure 6.2 Macrophages from a patient with mutant WASp have abnormal 
cytoskeletal structure.
Cultured peripheral blood derived macrophages from a normal donor and 
L94TWASp were stained with rhodamine-phalloidin. (A), normal macrophages 
typically form clusters of podosomes behind the leading edge of the cell (arrow). 
(B,C) Patient macrophages exhibited a loss of polarisation and unusual podosome 
distribution, often in multiple clusters or ring structures reminiscent of osteoclast 
sealing zones (arrows). (D) Staining with anti-vinculin (FITC) antibody revealed a 
ring of vinculin around an actin core typical of a normal podosome structure. Scale 
bar is 8 um.
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The presence and distribution of podosomes and general cell morphology was analysed. 
Although when podosomes were seen they were brighter, there were actually fewer 
cells with podosomes in the patient than in normal (Figure 6.3a) and there were more 
cells with multiple clusters of podosomes (Figure 6.3b) than normal. In the patient 
almost 10% of the cells had podosomes in a ring structure (Figure 6.3c), which was 
hardly ever seen in normal. Podosomes are dynamic structures that are rapidly 
assembled and disassembled in response to various stimuli (Linder et al., 1999). Using 
interference reflective microscopy podosome dynamics were assessed. The turnover of 
podosomes in I294T macrophages was increased compared to normal (P Ancliff, in 
press) suggesting abnormal actin regulation.
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Figure 6.3 Quantification of cytoskeletal structures in patient macrophages
(a) The percent of cells with podosomes (b) the number of clusters per cell and (c) the 
percent with osteoclast like sealing zones was quantified from confocal images of 
macrophages stained with rhodamine phalloidin. (d) Cell shape was assessed on 3 
characteristics of rounded, polarised and other (where large multiple processes were 
observed see Figure 2b+c).
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Next, the cell shape was characterised into 3 categories (Figure 6.3d). Normal 
macrophages were either rounded, or polarised with a definite leading edge. In contrast 
although some patient macrophages were polarised or rounded, the predominant shape 
was an abnormal one with large and frequent protrusions (Figure 6.2b and 6.2c). This 
abnormal macrophage spreading, elongation and dispersion was further quantified using 
delineated images captured in Adobe Photoshop ® using a Mathematica notebook. 
I294T macrophages showed less elongation, more spreading and increased dispersion 
due to the membrane protusions, compared to normal control (P Ancliff, in press). This 
is in contrast to WASp null patient macrophages, which have increased elongation and 
reduced dispersion.
6.2.1.2 Granulocyte phagocytosis in WASPI294T patient
Whole blood was incubated with fluorescently labelled opsonised E.Coli and the level 
of phagocytosis in the granulocytes determined by flow cytometry by measuring the 
percent of fluorescently positive cells. Normal granulocytes phagocytosed the E.Coli 
efficiently by 10 minutes with 90% of granulocytes positive (Figure 6.4a). 
Granulocytes from the patient had very much reduced phagocytosis with only 6% 
positive at the same time point.
6.2.1.3 Oxidative burst response in WASP12947 patient
Whole blood was collected and the oxidative burst of neutrophils in response to 
different stimuli was measured. The oxidative burst was measured by the oxidation of 
non-fluorescent dihydroxyrhodamine (DHR) to fluorescent rhodamine by free radicals 
released by the cell. PMA was used to check responsiveness and to obtain a maximal 
response. Both control and patient cells were able to generate an oxidative burst in
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response to PMA (Figure 6.4b). However when the physiological stimuli E.Coli and f- 
met-leu-phe (fMLP) were used there was a clear difference between normal and patient 
with the patient cells unable to generate a response. This shows that although the patient 
cells can generate an oxidative burst, they are unlikely to due to an inability to respond 
to a physiological stimulus.
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Figure 6.4 Phagocytosis and oxidative burst defects in patient neutrophils
(a)Whole blood incubated with opsonised E.Coli for 10 minutes at 37°C 
revealed a defect in phagocytosis compared to normals, (b) Although oxidative 
burst responses, measured by rhodamine release from DHR, could be seen with 
PMA, the physiological stimuli of fMLP and E.Coli failed to elicit as strong a 
response in patient cells.
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6.2.1.4 Viability of haematopoietic cells
6.2.1.4.1 CH-11 mediated apoptosis levels in peripheral blood
The mononuclear cell fraction of Ficol separated whole blood was incubated for 48 
hours in the presence of IL-2 and PHA before induction of FAS restricted apoptosis 
using the anti CD95 antibody CH-11. The level of apoptosis and cell death after 48 
hours in the cells from the patient was measured by flow cytometry (Figure 6.5a). 
Annexin and PI staining revealed the level of apoptosis was higher in the I294T mutant 
compared to control although the level of cell death at this time point is similar. The 
33% apoptosis seen was over twice the average of 15% seen in 33 controls (Figure 
6.5b).
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Figure 6.5 Increased levels of apoptosis in cultured lymphocytes
(a) Ficolled peripheral blood was incubated with CH-11, an anti CD95 
antibody and the levels of apoptosis determined by annexin V and PI staining.
(b) There was an increase in apoptosis compared to those obtained from 33 
control individuals (range 5.8-36.2 with SD 6 .8 )
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6.2.1.4.2 Spontaneous apoptosis levels in whole bone marrow
Spontaneous apoptosis in freshly derived bone marrow was measured by staining with
Annexin and cell surface markers before measuring levels of fluorescence within 15
minutes. The cells were gated on their surface markers (Figure 6.6a) and the apoptosis
measured. When compared to normal (Figure 6.6b) the levels of apoptosis were
approximately 4-fold higher in CD34+ (14% and 52%), CD15+ (5% and 15%) and
CD33+ (15% and 53%). These data suggest an increased propensity for apoptosis,
which is particularly noticeable in precursor and myeloid cells, and may be the
underlying reason for the neutropaenia and monocytopaenia.
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Figure 6.6 Spontaneous apoptosis in fresh bone marrow is increased in patient 
cells
(a) Whole bone marrow was collected and stained for the lineage markersCD15, 
CD33 and CD34, annexin and 7AAD to determine apoptosis levels within bone 
marrow lineages, (b) Apoptosis is increased, particularly in the more primitive bone 
marrow precursor populations.
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6.2.2 Generation of a lentivirus encoding EGFP-WASpI294T
In order to further characterise the I294T mutation and the effect of this mutation in cell 
culture with regards to toxicity of WASp expression, a HIV-1 based lentiviral vector 
was constructed that encoded for the mutant protein as a fusion with EGFP. We have 
previously shown an ability to express a fusion of EGFP and WASp in different cell 
types after infection with a lentiviral vector and for the fusion to act normally in human 
macrophages and murine dendritic cells (Chapter 4). Transduction with a lentivirus 
encoding EGFP-WASp allows some degree of regulated expression, by incorporating 
different promoters with varying strengths, varying the MOI and selection of EGFP low 
fluorescent cells, whilst being able to follow the expression using flow cytometry and 
confocal microscopy. Using site directed mutagenesis, the I294T mutation was 
introduced (by Phil AnclifF, UCL Haematology Dept) into a wild-type EGFP-WASp 
fusion (Chapter 4) to make an EGFP-WASpI294T fusion construct (Figure 6.7a). 
Mutation of WAS was confirmed by a Ddel digest of the EGFP-WASp fragment. The 
mutation created an additional Ddel site created by the T to C substitution and was 
visible when separated on an agarose gel (Figure 6.7b, marked by an asterisk). 
Lentiviral particles were generated using the CEWWI294T construct, as previously 
described, and an infectious titer obtained on 293T cells. To confirm expression of a 
full-length protein, 3T3 cells were plated onto glass coverslips and infected at an MOI 
of 10 ensuring virtually 100% infection. After 48 hours the cells were fixed in PFA and 
counterstained with rhodamine phalloidin to visualise the F-actin. The pattern of EGFP 
expression was cytoplasmic with exclusion from the nucleus (Figure 6.7c) and there 
was considerable co-localisation with actin mimicking the pattern previously seen with 
wild-type EGFP-WASp suggesting normal protein expression.
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An immunoblot was performed on cell lysates from infected 293T cells and probed for 
WASp. Cells infected with CEW did not have WASp (Figure 6.7d). However cells 
infected with either CEWWwt or CEWWI294T had protein that was consistent in size 
with a fusion of EGFP and WASp. There was a slight mobility shift in EGFP- 
WASp12941, which has been seen in westerns from patient samples (personal 
communication, P. Ancliff), suggesting the presence of EGFP had no deleterious effect.
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Figure 6.7 Creation of a lentiviral vector containing EGFP-WASp
(a) The I294T mutation was created by insertional mutagenesis using PCR with 
primers containing the mutation in the lentiviral vector, (b) Creation of the mutation 
was confirmed by digestion of the EGFP-WASp fragment with Dde-I revealing an 
extra band at 200bp ( ) when run on a 1% agarose gel. (c) Infection of 293T cells 
with virus containing EGFP-WASp12941 (green) lead to an expression pattern similar 
to that previously seen for EGFP-WASp^ 1 with predominantly cytoplasmic 
expression and co-localisation with F-actin (red), (d) An immunoblot probed with 
anti WASp antibodies confirmed a 90kDa protein was being made, although a subtle 
mobility shift was noticeable in EGFP-WASpI294T lysates.
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6.2.2.1 Infection of Bad macrophages with lentiviral vectors
B ad macrophages are an M-CSF dependant murine macrophage cell line derived from 
splenic adherent cells transformed with SV40 DNA mutated in the origin of replication 
(Schwarzbaum et al., 1984). As they are a haematopoietic cell line, WASp activity, and 
therefore mutant WASp activity, may be revealed in a more physiological manner. B ad 
cells maintained in culture with lOng/ml M-CSF were plated on coverslips and 
transduced at an MOI of 40 and incubated for 72 hours to allow maximal expression. 
After 72 hours there was greater than 95% transduction efficiency with CEW and 
CEWWi294T (Figure 6.8a,b). The gross morphology revealed with F-actin staining 
showed that Bac-1 macrophages do not normally assemble podosomes (Figure 6.8c). 
However when they were transduced with vectors containing EGFP WASp12947 
podosomes were formed (Figure 6.8d,e,f). Apart from those seen at a leading edge, 
podosomes were often in multiple clusters and occasionally in ring like formations 
(Figure 6.8g,h,i) similar to that observed in patient macrophages. EGFPWASp12941 
localised to the podosome structures (Figure 6.8d,e) and their nature confirmed by their 
localisation to the lower surface of the cell and a characteristic ring of vinculin around 
the actin core (Figure 6.8e,f). The frequency of podosome assembly was quantified by 
counting random fields of 100-150 cells. Overall 9% of CEWWI294T transduced Bac-1 
macrophages had podosomes compared to just 1% of CEWW ^ (Figure 6.8j). This 
ability to generate podosomes is indicative of an ability to stimulate actin 
polymerisation. This was confirmed in an in vitro actin polymerisation assay where 
WASp coated Sepharose beads were able to polymerise actin when incubated in cell 
extracts from U937 cells. This could be blocked with cytochalasin D confirming it is 
newly formed F-actin and not monomeric G-actin (P.Ancliff in press) formed by 
WASp12947
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Figure 6.8. EGFP-WASp12941 induces the formation of podosomes in Bac-1 
macrophages.
A, B Efficiency of transduction observed by EGFP expression was greater than 
95% for each well, as shown for vectors encoding EGFP (A) and EGFP-WASp12941 
(B). C. Bac-1 macrophages do not normally assemble podosomes (stained with 
rhodamine phalloidin). D, E & F. Cells transduced with vectors encoding EGFP- 
WASp1-941 assemble podosomes, in which EGFP (D) localises to the podosome 
actin (stained with rhodamine phalloidin) core (E). The nature of podosomes was 
confirmed by a characteristic ring of vinculin (anti-vinculin Cy5) surrounding the 
actin core (F). G, H & I. The distribution of podosomes mimics that of primary 
cells from WASpL94r mutant cells, forming multiple clusters and ring formations 
(stained with rhodamine phalloidin). J. Percentage of transduced macrophages with 
one or more podosomes according to mutant inserted.
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6.2.2.2 V iability o f transduced  HT1080 cells is dim inished
Over a 15-day period the EGFP levels, DNA levels and cell viability were measured in 
transduced HT1080 cells. Cells infected with CEW or CEWWwt maintained their 
EGFP levels (Figure 6.9) although cells infected with CEWWwt exhibited some 
variation in the transduction levels over time. In contrast cells infected with CEWWI294T 
reduced significantly in number from 31% to 7% at an MOI of 1 and from 90% to 38% 
at an MOI of 10, being outgrown by untransfected cells at both MOI’s tested (Figure 
6.9).
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Figure 6.9 Infection of HT1080 cells leads to inhibited growth of EGFP- 
WASp12941 expressing cells
HT1080 cells were transduced with lentiviral vectors encoding EGFP (CEW), EGFP' 
WASpWT (CEWW) and EGFPWASp,294T (CEWW,294T), at a multiplicity of infection 
of 1 and 10. Percentage of EGFP positive cells were scored at 3,6,10,15 days 
(represented by vertical bars) after transduction by flow cytometry, and were stable 
throughout the observation period for EGFP and EGFP-WASpwl with no observable 
toxicity. In contrast, cells transduced with EGFP-WASp12941 were steadily outgrown 
by non-transduced cells, indicating an inhibitory effect on cell growth even at low 
copy number. Bars represent the average of 6 - 8  experiments with standard deviation. 
T-Test *p = 0.018, **p = 0.00001.
187
Chapter 6
The viability of the HT1080 cells was measured by staining with Annexin to determine 
apoptosis levels and 7AAD to measure total cell death. Once again high levels of 
transduction was seen 3 days post infection, which diminished over time by 15% for 
C E W W ^ and by over 30% for CEWW12941 (Figure 6.10a). Cells transduced with CEW 
did not have high levels of apoptosis either at the beginning of the culture period or at 
the conclusion (Figure 6.10b), which was mirrored by a low level of cell death
\W 'T
throughout the experiment (Figure 6.10c). Cells transduced with CEWW had 
elevated levels of apoptosis early after infection followed by increased cell death by day 
10 (Figure 6.10b+c) and corresponded with a slight drop in EGFP levels (Figure 
6.10a). However, cells transduced with CEWWI294T had extremely elevated levels of 
apoptosis early in the experiment that decreased as the number of transfected cells 
diminished. The levels of 7AAD rose during the duration of the experiment. This shows 
although both CEWW^T and CEWWI294T transfected cells became apoptotic and then 
died, the effect was much more pronounced in CEWWI294T cells (Figure 6.10b,c).
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Figure 6.10 Apoptosis levels in transduced HT1080 are increased
HT1080 cells infected with EGFP, EGFP-WASp™7  and EGFP-WASp12947 
harvested from culture and counterstained with Annexin V PE and 7AAD to determine 
apoptosis and cell death levels, (a) EGFP levels were monitored and Annexin (b) and 
7AAD (c) levels determined from the EGFP positive populations using flow cytometry.
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6.2.3 Cloning of VCA domain deleted lentiviral constructs
The “verprolin cofilin acidic” or VCA domain at the c-terminus of WASp is where 
monomeric actin and ARP2/3 bind, leading to initiation of new F-actin in response to 
stimuli (Higgs et al., 1999; Symons et al., 1996). In order to confirm whether the 
cellular defects seen and death of transfected cells were due to unregulated activation of 
the actin cytoskeleton, VCA deletion mutants of wild-type WASp and I294TWASp were 
constructed. The CEW W ^ and CEWW12941 vectors were digested with EcoRI, the 
relevant fragments purified from an agarose gel and re-ligated, thus removing a 231 bp 
fragment, whilst keeping the N-terminal EGFP in frame to maintain the fusion. This 
corresponds to the terminal 77 amino acids, which make up the VCA domain (shown in 
Figure 6.11a) and resulted in viral vectors that encoded a truncated version of EGFP- 
WASp (Figure 6.11b). The cloning was confirmed by digestion with EcoRI (Figure 
6.11c) revealing the missing band on an agarose gel. These A-VCA mutant vectors were 
used to make lentivirus as described earlier and an infectious titer obtained on 293T 
cells. The pattern of EGFP expression in those cells was similar to that previously 
observed in 3T3 cells and other adherent cells transduced with wild-type full-length 
EGFP-WASp i.e. cytoplasmic with nuclear exclusion (data not shown).
Cell lysates from transduced 293T cells were run on an immunoblot and probed for 
WASp. As previously seen in 293T cells, cells transduced with CEW did not express 
WASp and those transduced with CEW W ^ and CEWW12941 expressed a 95kDa fusion. 
Cells transduced with both the A-VCA vectors expressed a truncated protein that was 
approximately 75kDa in size (Figure 6.11d). Interestingly the mobility shift seen with 
full length EGFP-WASpI294T was still visible in the AVCA mutant.
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Figure 6.11 Creation of VCA deleted mutants of EGFP-WASp lentiviral 
constructs
(a) Digestion of EGFP-WASp* 7  and EGFP-WASpI294T with EcoRI allowed the 
deletion of the actin binding C-terminal VCA domain thus creating lentiviral 
constructs without the actin-binding domain, (b) Cartoon depiction of constructs 
created, (c) Digestion with EcoRI shows the loss of a 200bp band (*) which is the 
VCA domain, (d) Immuno-blot from lysates of HT1080 cells infected with EGFP, 
EGFP-WASp, EGFP-WASp12947, A-VCA EGFP-WASp and A-VCA EGFP-WASp12947 
probed with an anti WASp antibody. A smaller band corresponding to the deletion 
mutants was seen. Interestingly the mobility shift was seen for both full length and 
deletion mutants. Comparable loading was checked by probing for p-actin.
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6.2.3.1 Viability of A-VCA domain mutant transduced cells is 
maintained
HT1080 cells were transduced at an MOI of 10 with CEW, CEWWwr, CEWWI294T, 
A-VCA CEWW™1, and A-VCA CEWW12941 and the viability of the transduced cells 
followed over 15 days. As previously seen, the EGFP levels were maintained in cells 
transduced with CEW (Figure 6.12). The EGFP levels diminished slightly whilst 
showing large variability in those cells transduced with CEW W ^. Cells transduced 
with CEWW12941 diminished over time whereas the cells transduced with the A-VCA 
mutants, although variable between experiments, maintained their EGFP levels in a 
pattern similar to that seen for CEW W ^ (Figure 6.12). There was some diminishment 
of EGFP levels with the A-VCA mutants, but crucially for A-VCA CEWWI294T, the 
EGFP levels were similar to that of CEWW™7 and A-VCA CEW W ^. This shows that 
the VCA domain is required for the loss of EGFP seen in EGFP WASp12941 transfected 
cells, although may not be solely responsible. The reduced level of EGFP loss seen with 
wild-type WASp and A-VCA mutants may be due to effects exerted by other portions of 
the WASp protein, or due to the fusion with EGFP.
The viability of the A-VCA vector transduced HT1080 cells compared to full length 
vectors was measured over the 15 day period, using apoptosis and cellular death 
markers as described previously. At day 3 levels of apoptosis and cell death were 
comparable in cells transduced with all vectors (Figure 6.13b+c). By day 10 however, a 
time point where the EGFP population was diminishing in the CEWWI294T population 
with a corresponding increase in cell death, the levels of apoptosis and cell death in A-
WTVCA mutants was comparable or lower than CEWW showing the cells were mainly 
healthy and maintaining their viability (Figure 6.13b+c).
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Figure 6.12. The VCA domain of mutant WASp is responsible for the toxicity 
seen in transduced HT1080 cells
HT1080 cells were transduced with lentiviral vectors encoding EGFP (CEW), 
EGFP-WASp'”  (CEWW) and EGFP-WASp12941' (CEWW12941), both with and 
without the VCA domain at a multiplicity of infection of 10. Percentage of EGFP 
positive cells were scored at 3,6,10,15 days (represented by vertical bars) after 
transduction by flow cytometry, and were stable throughout the observation period 
for EGFP and EGFP-WASp T with no observable toxicity. In contrast, cells 
transduced with EGFP-WASpI294T were steadily outgrown by non-transduced cells, 
indicating an inhibitory effect on cell growth (representative of 2-4 independent 
experiments). This effect is dependent on an intact VCA domain as EGFP was 
maintained if the VCA domain was removed. T-test *p = 0.001
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Figure 6.13 Apoptosis levels in VCA deletion mutant transduced HT1080 cells 
are not increased
HT1080 cells transduced with EGFP, EGFP-WASp* 1  and EGFP-WASp12941 both 
with and without the VCA domain were harvested from culture and counterstained 
with Annexin V PE and 7AAD to determine apoptosis levels, (a) EGFP levels were 
monitored and Annexin (b) and 7AAD (c) levels determined from the EGFP positive 
populations using flow cytometry. Graphs are representative of 2-4 experiments.
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6.2.4 Cloning of lentiviral vectors containing an SFFV internal promoter
In order to determine cell sensitivity to the activating mutant form of WASp, lentiviral 
vectors were cloned that contained an SFFV 5’LTR as the internal promoter in place of 
the CMV promoter previously used (Figure 6.14a). Although the SFFV promoter has 
been shown to generate high expression levels in myeloid (Eckert et al., 1996; Baum et 
al., 1995) and haematopoietic stem cells (Demaison et al., 2002), cell lysates from 
SEWW12947 and A-VCA SEWW12947 transduced HT1080 cells showed a decrease in 
protein expression compared to CEWW12947 and A-VCA CEWW12947 transduced cells 
(Figure 6.14b) at both an MOI of 1 and 10.
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Figure 6.14 Cloning of mutant WASp vectors with an SFFV LTR
(a) EGFP-WASp12947 and EGFP-WASP12947 A-VCA was introduced into a HIV-1 
derived self-inactivating lentiviral vector containing an SFFV 5’ LTR as an internal 
promoter in place of the CMV previously described, (b) An immunoblot probing for 
WASp in transduced HT1080 cells revealed similar sized bands from vectors containing 
different promoters but reduced levels in cells transduced with SFFV containing vectors. 
Re-probing for P-actin was a loading control.
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6.2.4.1 Viability of HT1080 cells after transduction with SFFV containing vectors.
HT1080 cells were transduced with SEW, SEWW12941 and A-VCA SEWW1294T and the 
viability determined by EGFP levels as described earlier. EGFP levels were maintained 
in SEW and A-VCA SEWW12941 transduced cultures at both MOIs tested over a 28 day 
period (Figure 6.15). Cells transduced with SEWWI294T at a low MOI also maintained 
their EGFP levels. Upon transduction with a higher MOI there was death of transduced 
cells with 10% of transduced cells dying (Figure 6.15). This cell death was at a greatly 
reduced rate and level to that observed previously with vectors containing a CMV 
promoter.
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Figure 6.15 Infection of HT1080 cells with SFFV vectors shows less inhibited growth 
of EGFP-WASpl294T expressing cells
HT1080 cells were transduced with lentiviral vectors encoding EGFP (SEW) or 
EGFP WASp12941 (SEWWI294T) with and without the VCA domain at a multiplicity of 
infection of 1 and 10. Percentage of EGFP positive cells were scored at 2-28 days 
(represented by vertical bars) after transduction by flow cytometry, and were stable 
throughout the observation period for EGFP with no observable toxicity. At low doses 
there was no toxicity seen with EGFP-WASp12947 but was seen at high doses although at a 
much reduced level and rate than previously seen with CMV containing vectors. This 
indicates the inhibitory effect of I294T is dose dependant. \ 9 5
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The viability of transduced cells was again measured by annexin and PI staining to 
determine the levels of apoptosis and cell death. There was little detectable difference in 
Annexin or PI levels between samples at both MOIs tested (data not shown). Thus the 
cell death observed in SEWW12947 transduced cells by loss of EGFP was small and 
undetectable compared to SEW and A-VCA SEWW12941 transduced cells, again 
different to that previously observed in CEWW12941 cells.
6.2.5 WASpI294T induces genomic instability and polyploidy
Cytogenetic analysis of bone marrow samples on three separate occasions from the 
index patient revealed variable abnormalities including loss of heterozygosity, inversion 
of 7q, and on one occasion high hyperdiploidy (P Ancliff, personal communication). It 
is hypothesized that n94TWASp was responsible for this instability. Infection of HT1080 
cells with CEW, CEWW™7 and CEWW12941 at an MOI of 1 and 10 (infectious titer 
determined on 293T cells) followed by measurement of the DNA content was used to 
determine if there were any abnormalities arising from EGFP-WASp12947 expression.
6.2.5.1 Levels of DNA in transfected cells
The amount of DNA in transduced and untransduced cells was measured using 
multicycle software with flow cytometry. The DNA content of cells transduced with 
CEW or CEW W ^ was relatively stable over the 15-day experiment period and 
remained similar to that of untransduced cells in the same culture (Figure 6.16). The 
percentage of cells with a DNA content of 4n or more in the cells transduced with 
CEWW12947 increased for the duration of the experiment (see Figure 6.16 inset for 4n+ 
determination) at an MOI of both 1 and 10 relative to untransduced cells in the same 
culture (Figure 6.16). In fact there was a 6-fold increase in the percent of cells with 4n
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or more DNA levels in the cells transfected with EGFP-WASp1297 compared to 
untransfected cells. This effect was more pronounced in the cells infected at an MOI of 
10 (Figure 6.16). Using linear gates to quantify the percent of cells at each stage in 
mitosis the percent of cells with 4n as well as an increase in 4n can be seen (Figure 
6.17a).
Samples from the cultures were obtained and cytospun onto slides. These were stained 
histochemically and visualised by light microscopy. Cultures transduced with CEW or 
CEWWwt showed predominantly cells with single nuclei. In contrast cells transduced 
with CEWW12941 showed a high number of cells with multiple nuclei (Figure 6.17b) 
confirming the results obtained by flow cytometry.
Untransduced 
CEW moi 1 I 
CEW moi 10 I
CEWW*t moi 1 I 
CEWW"1 moi 10 I
CEWW12947 moi 1 I 
CEWW,294T moi 10 I
0 2 4 6 8 10 12 14
Percent of cells with 4n+
Figure 6.16 Analysis of DNA content in EGFP+ and EGFP- cell populations
HT1080 cells were transduced with lentiviral vectors encoding EGFP, EGFP-WASp^1 
and EGFP-WASp12941 at an MOI of 1 and 10. The cells were ethanol fixed before 
staining with PI and the cellular DNA content of EGFP+ and EGFP- cells measured by 
flow cytometry. Multicycle software (see inset) was used to determine the relative 
DNA content at day 2 and day 8. Cells transduced with EGFP-WASp12941 showed an 
increase in their DNA content compared to EGFP or EGFP-WASpWT.
gfp -ve 
gfp +ve
cm Com
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CEWWI294T moi 10
EGFP-ve EGFP+ve
control CEW
CEWW CEWWI294T CEWWi294T zoom
Figure 6.17 Increase of cellular DNA and multi-nuclear cells during mitosis
(a) Using linear gates the number of cells with 4n and greater than 4n (red arrow) 
DNA in CEWW2941 transduced HT1080 cells was measured by flow cytometry. 
The increase in the 4n EGFP+ve population was confirmed by histochemically 
stained cytospins (b). An increase in the number of cells with multiple nuclei is 
clearly visible in the CEWW,294T transduced cell population
6.2.5.2 Abnormal Cytokinesis is Observable in HT1080 cells
To assess why cells were appearing with multiple nuclei after a short period of culture 
HT1080 cells were transfected at an MOI of 10 with CEW, CEWW^ and CEWWI294T 
and after 24 hours, transferred to coverslips at a low density of 103 per coverslip. They 
were then allowed to proliferate for a further 24 hours so cytokinesis could occur,
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before being fixed and stained for actin and microtubules. Cells infected with CEW 
grew normally and cells undergoing cytokinesis could be spotted due to the presence of 
a contractile actomyosin ring where the daughter cell is being cleaved off (Figure 
6.18a). This ring was seen at a frequency of 12% (Figure 6.18b) for CEW transduced 
cells. However this was impaired in cells transduced with CEWW^T (6%) and virtually 
absent in cells transduced with CEWWI294T (0.6%) (Figure 6.18b). With this lack of 
actomyosin ring a corresponding disrupted pattern of actin staining compared to CEW 
transduced cells was seen (Figure 6.18a) showing the effect EGFP-WASpLQ4T was 
having^ipon the cells.
CEW
CEWWI294T
b
Figure 6.18 Loss of actin contractile rings in dividing HT1080 fibroblasts
HT1080 cells were transduced with EGFP, EGFP-WASpWT or EGFP-WASpI294T, 
plated at low density onto glass coverslips and allowed to grow overnight. The 
transduced cells (green) were stained for F-actin (white/red) and tubulin (blue) and 
images captured by confocal microscopy, (a) Contractile rings in dividing cells can be 
seen in EGFP transduced cells (arrow) but are lost in EGFP-WASpI294T transduced cells 
with a corresponding increase in cortical F-actin.(b) The total percent of cells with 
contractile rings is reduced for both EGFP-WASpWT and EGFP-WASp12947 compared to 
EGFP alone. Total cells counted was 150-200
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6.3 Discussion
In this chapter a novel mutation of WASp has been investigated that does not lead to a 
classical WAS phenotype. In fact this mutation led to disruption of the auto inhibited 
confirmation and consequently to dysregulation of actin polymerisation. In patient 
primary macrophages this manifests itself as increased clusters and abnormal 
distribution of podosomes that have increased levels of F-actin judged by fluorescence 
intensity of confocal images. This dysregulation of actin is further shown by the lack of 
phagocytosis and oxidative burst in granulocytes upon physiological stimulation. The 
loss of the protein tertiary structure can be attributed to the introduction of a polar side 
chain into the alpha helix of the C-terminus that would normally fit into the 
hydrophobic core of the GBD of WASp. A phosphomimicking mutant Y291EWASp 
(Cory et al., 2002) and the recently discovered L270pWASp (Devriendt et al., 2001) are 
adjacent and opposite respectively to ° 94TWASp and have similar properties of 
instigating actin dysregulation. This suggests the disruption of the auto inhibited 
confirmation may be similar to Y291 phosphorylation which has been shown to be 
important in the direct regulatory function of WASp (Cory et al., 2002).
A lentivirus containing wild-type EGFP-WASp was mutated to contain EGFP- 
WASp12947 and a pattern of expression similar to wild type was seen in non- 
haematopoietic cell lines. A western blot of transfected cell lysate revealed a mobility 
shift on SDS-PAGE with C94TWASp, which has also been seen in patient cells. It is 
unclear as to why this shift occurs but it may be due to post-translational modifications 
at sites previously unavailable in an autoinhibited WASp or directly related to the 
presence of the threonine, which can be glycosylated.
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The dysregulation of actin is shown in vivo through the formation of podosomes in 
EGFP-WASp12941 transduced Bac-1 macrophages, which do not normally make 
podosomes. Furthermore they are formed within the cells in a manner similar to that 
presented in primary macrophages, with multiple clusters and ring like structures. This 
could be occurring because the active confirmation favoured by I294TWASp is making 
Y291 more accessible to kinases and phosphatases, thus enhancing the effect of WASp 
through Cdc42, which has been shown to be important in podosome assembly and 
disassembly (Bums et al., 2001b; Linder et al., 1999).
12947WASp results in monocytopaenia and neutropaenia and bone marrow cells fail to 
proliferate in vitro (P.Ancliff, in press). In addition we have seen an increase in 
spontaneous apoptosis in bone marrow, in both mature and progenitor populations and 
in inducible apoptosis in peripheral blood lymphocytes compared to normal. This shows 
that dysregulation of the actin cytoskeleton has an adverse effect on cell survival.
The adverse effect of K94TWASp on cell survival is further supported by the cell death 
seen in HT1080 cells at high and low MOI’s when a strong promoter is used. Over a 14- 
day period untransduced cells outgrew the transduced cells and when apoptosis 
measured in the EGFP positive population, it was increased.
To confirm the cell death seen was due to actin dysregulation a further modification was 
made to remove the VC A region of WASp. When expressed in cells the mobility shift 
on SDS-PAGE was still seen showing any modifications that result in the shift are not 
in the VC A domain. The EGFP expression in A-VC A CEWWI294T transduced cells was
n r r
maintained at a similar level to that seen with CEWW transduced cells throughout the 
15 day experiment and there was no corresponding increase in apoptosis or cell death
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showing the actin dysregulation is responsible for the apoptosis. Transduction with 
vectors utilising an SFFV promoter, which was shown by immunoblot to give reduced 
expression in HT1080 cells also lead to cell death but at a much reduced level and rate. 
This suggests that the level of expression of EGFP-WASPI294T within the cell is critical 
to induce the deleterious effect.
A low level of toxicity was seen in HT1080 cells transduced with EGFP-WASp^1 but
WTwas not reproducible. We have previously shown overexpression of EGFP-WASp 
has been associated with toxicity in transduced human dendritic cells and macrophages 
where the actin cytoskeleton has been severely disrupted (Chapter 3 and 4). This was 
not reduced upon removal of the VC A domain, therefore there may be other 
physiological activators and adaptors e.g. PIP2 , Nek, Hck, Cdc42, WIP, important in the 
regulation of WASp, which are contributing to the adverse effect of WASp over 
expression. Again this seems to be expression related as the lower levels seen when an 
SFFV promoter was used did not have the same effect.
To try and determine the underlying reason for the deleterious effect of WASp12941 in 
patient primary cells and overexpression of EGFP-WASp12941 in transduced HT1080 
cells analysis of the DNA content of the cells was performed. Cytogenetic abnormalities 
detected in bone marrow samples from the patient are indicative of genomic instability. 
This effect is replicated by the emergence of polyploidy, loss of heterozygosity and 
amplification of Rb in mutant lymphoblastoid cell lines (P. Ancliff, personal 
communication). In addition the polyploidy observed in HT1080 cells expressing 
EGFP-WASpI294T also suggests genetic instability. This may be a reason why there is 
neutropaenia and monocytopaenia in the patient.
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Cytokinesis requires the regulated assembly of a contractile ring of actin and myosin 
that cleaves the cell in two (Glotzer, 2001). In fission yeast Schizosaccharomyces 
pombe, this forms in the middle of the cell early in mitosis and contracts after anaphase. 
The equatorial location of the actomyosin ring is maintained by late-mitotic 
microtubular structures. If these are disrupted, the position of the ring drifts resulting in 
asymmetric cell division and genomic instability (Pardo and Nurse, 2003). Also in 
yeast, it is believed that the cortical actomyosin ring plays an important role in the 
establishment of spindle orientation through interaction with astral microtubules that 
form on the spindle pole bodies before ring formation (Gachet et al., 2001). 
Pharmacological inhibition of actin polymerisation, results in activation of a mitotic 
checkpoint that ensures that mitotic spindles are correctly orientated before anaphase is 
allowed to take place (Gachet et al., 2001). These findings in yeast therefore point to a 
mechanism for growth arrest and genomic instability in cells that have dysregulated
T T Q /IT  TOO/ITactin dynamics through expression of WASp in primary cells and EGFP-WASp 
in culture.
The actin polymerising activity in the actomyosin ring is highly dynamic, resulting in 
continuous assembly and disassembly, and in fission yeast depends on the Arp2/3 
complex forming, Cdcl2, profilin and WASp (Pelham and Chang, 2002). In WASp 
mutant yeast cells (wsp\&), the closure of the actin ring is significantly reduced. In 
EGFP-WASp12947 transduced HT1080 cells undergoing cell division there is a loss of 
the actomyosin ring corresponding with an increase in the cell ploidy. It is therefore 
likely that dysregulated WASp activity could compromise cytokinesis either directly by 
disturbing normal ring formation, or indirectly by depletion or sequestration of critical 
substrates for actin polymerisation in cytoskeletal structures. One of these substrates
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could be Cdc42. WASp and Cdc42 interact in the activation of WASp (Aspenstrom et 
al., 1996; Kolluri et al., 1996; Symons et al., 1996) and the transduction of signals from 
the cell surface. Recently it has been shown that over expression of Cdc42 in cells in 
culture leads to polyploidy and growth arrest (Muris et al., 2002) mimicking what has 
been observed here.
Insights into problems associated with overexpression of mutant WASp and to some 
extent wild-type WASp are useful for elucidating viable gene therapy protocols. When a 
protein with the complexity of WASp is restored into the haematopoietic compartment, 
there may be a higher degree of regulation needed than for other primary 
immunodeficiencies such as X/SCID where expression from a viral promoter does not 
seem to have any deleterious effects (Cavazzana-Calvo et al., 2000a; Gaspar et al.,
2004). The complexity of the effects WASp can exert can be seen in HT1080 cells. 
Expression from a CMV promoter can lead to cell death, but this is not seen when an 
SFFV promoter is used.
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Discussion
Gene therapy for primary immundeficiencies using retroviral vectors has moved from 
the laboratory to the clinic in the past few years with great success for SCID-X1 
(Cavazzana-Calvo et al., 2000a; Hacein-Bey-Abina et al., 2002; Gaspar et al., 2004) and 
ADA-SCID (Aiuti et al., 2002)(Gaspar et al ASGT 2005). The success of SCID-X1 is 
thought in part to be attributable to the massive selective advantage for cells containing 
a functional common y chain (Stephan et al., 1996), in addition to advances in vector 
design and transduction protocols.
Wiskott-Aldrich syndrome is thought to be a good candidate for gene therapy due to the 
poor prognosis with a mismatched bone marrow transplant (reviewed in (Thrasher and 
Kinnon, 2000b)) and the reported selective advantage seen when somatic mosaicism 
occurs in patients (Wada et al., 2001; Wada et al., 2003; Wada et al., 2004) and in 
competition assays in a murine model (Strom et al., 2002). In fact using retroviral 
vectors we (Chapter3) and others (Klein et al., 2003; Strom et al., 2003b) have shown 
successful correction of a murine model with WASp expression.
Clinical gene therapy trials have not been without problems. Insertional mutagenesis, a 
predicted but thought to be rare possibility, has occurred leading to complications in 3 
patients treated for SCID-X1 (Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 
2003b). In fact it has now been established that retroviruses prefer to integrate close to a 
gene transcriptional start site (Wu et al., 2003) and the number of insertional events 
have been linked to the frequency of mutagenic events in murine models (Modlich et 
al., 2005). In addition it has failed where older patients have been treated (Thrasher et
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al., 2005) which has been postulated to be linked to patient age and an effective thymic 
microenvironment.
Problems with oncoretroviral gene therapy also include the well documented need for 
mitosis before any insertions can occur in the genome (Miller et al., 1990b). This was 
the rationale behind the development of lentiviral vectors, mainly based upon HIV-1. 
Lentiviral based vectors have been modified to be self-inactivating, thus removing 
enhancer regions thought to be important in insertional mutagenesis (Zufferey et al., 
1998), and reduces gene silencing (reviewed in (Ellis, 2005), although recently full 
length transcripts were detectable by PCR (Logan et al., 2004b). Elements have been 
included in the vectors to increase expression and insertion into non-dividing cells and 
have internal promoters to enhance gene expression. Unfortunately they have a 
propensity to integrate into active genes (Schroder et al., 2002; Mitchell et al., 2004) 
compared to transcription start sites for MLV based retroviruses. This may cause 
problems similar to that seen in the Paris clinical trial (Hacein-Bey-Abina et al., 2003a; 
Hacein-Bey-Abina et al., 2003b) Interestingly avian sarcoma viral vectors do not show 
any propensity to insert either in active genes or at transcription start sites (Mitchell et 
al., 2004), possibly increasing the safety of such vectors. Other viral vectors able to 
integrate into non-dividing cells are proving to be efficient delivery vectors. These 
include EIAV (O'Rourke et al., 2005; Siapati et al., 2005) and foamy virus (Hirata et al., 
1996; Josephson et al., 2002; Leurs et al., 2003). The insertion patterns of these vectors 
need to be investigated to determine if active genes or transcriptional start sites are also 
preferred. It may be decided that site directed or site specific integration into a piece of 
redundant DNA is required. This has been demonstrated using bacteriophage 
recombinases (Groth et al., 2000) and work is on-going using site specific
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endonucleases, homologous recombination and AAV and is reviewed in (Glover et al.,
2005).
We have shown successful transduction and correction of WAS knockout dendritic 
cells, macrophages and murine stem cells, capable of reconstituting a murine knock out 
model, with lentiviral vectors (Chapters 4+5), to levels similar to that observed in other 
groups (Charrier et al., 2005; Dupre et al., 2004), lending much promise to the 
development of a clinical trial for WAS utilising lentiviral vectors. The use of 
endogenous WAS promoter sequences to express WASp in a lentiviral gene therapy 
model has been shown (Chapters 4 + 5), and compares favourably with reconstitution in 
T cells shown with the 1.6Kb promoter (Dupre et al., 2004) and the 500bp promoter 
(Martin et al., 2005) and with expression derived from a viral LTR in this study. In this 
study the protein expression levels, determined by EGFP, was always lower than that 
seen for EGFP alone. This could be due to high level expressing cells dying, leaving 
low level expressers as viable. In fact some toxicity was seen when normal cells 
containing WASp had EGFP-WASp introduced (Chapter 3), and toxicity from the 
I294T mutant WASp was increased with expression levels (Chapter 6). The presence of 
EGFP tagged onto WASp cannot be excluded from being the cause of problems 
associated with high level expression, therefore use of an IRES sequence to separate 
expression of WASp and a marker gene may be useful to exclude this possibility. More 
normally regulated WASp expression levels may be attained by these endogenous 
sequences reducing toxicity associated with high level expression. WASp expression is 
restricted to the haematopoietic lineage (Derry et al., 1994; Stewart et al., 1996), which 
is thought to be dictated by regulatory elements found upstream of WAS and within the 
sequences used as promoters in this study (Hagemann and Kwan, 1999; Petrella et al.,
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1998). Haematopoietic restricted expression is an attractive proposition for 
immunodeficiencies as expression of haematopoietic-specific genes in non- 
haematopoeitic tissue may result in undesired side effects leading to insertional 
mutagenesis (reviewed in (Baum and von Kalle, 2003). Although expression can be 
attained from both the 500bp and 1.6 Kb WASp promoters, further investigation into 
the active elements within the 1.6Kb sequence and transcription factors responsible for 
the haematopoietic restricted expression is required. A transgenic mouse model where 
EGFP is expressed under the control of the 500bp or 1.6Kb promoter sequence would 
reveal expression temporally and spatially, thus helping with the understanding of 
expression patterns and whether or not the promoters are actually haematopoietic 
specific.
In this study, recovery of podosomes was used as a measurement for efficiency and 
efficacy of WASp reconstitution based upon podosome recovery when WAS is 
microinjected into WASp null dendritic cells (Bums et al., 2001b) and the findings by 
Linder et al that XLT patients with a lower level of WASp have podosomes present but 
in reduced numbers (Linder et al., 2003). Other groups have also used podosome 
recovery (Charrier et al., 2005) but many have focused upon recovery of T cell function 
using recovery of T cell proliferative responses and CD3 capping (Wada et al., 2002; 
Klein et al., 2003), IL-2 secretion (Strom et al., 2003a) or immunity to viral infections 
(Strom et al., 2003b). Although some T cell proliferative recovery was observed in this 
study further study of the immune system recovery is needed to determine if gene 
therapy for WAS is a future clinical treatment.
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WASp is linked to actin dynamics, therefore podosome turnover in reconstituted cells 
may reveal whether actin dynamics are normalised. Chemotaxis is defective in WAS 
null cells in vitro (Badolato et al., 1998; Zicha et al., 1998) and in vivo (de Noronha et 
al., 2005; Snapper et al., 2005), therefore recovery of chemotaxis when WASp is 
introduced would show effectiveness of gene transfer. In addition the recovery in vivo 
of splenic and lymph node architecture, shown to be defective in WASp mice (de 
Noronha et al., 2005), would be indicative of normal migration, immune friction and 
ability to respond normally to antigen. The inability to mount a normal inflammatory 
response in WASp KO mice could be exploited using contact sensitivity to DNFB (Del 
Prete et al., 2004) or inability to class switch in response to low concentrations of 
dextran (Westerberg et al., 2005). Another defect, phagocytosis, could be measured in 
vitro using immunoglobulin coated beads (Lorenzi et al., 2000a) or in vivo using 
apoptotic cells (Leverrier et al., 2001b). An increase in inflammation or phagocytosis in 
reconstituted mice would suggest successful recovery of phenotype.
Due to the complex interactions of WASp within cells, regulation of expression is 
important. Insights into the effects of WASp over expression have been seen in our 
studies on a novel I294T mutant of WASp, utilising the lentiviral gene delivery system. 
Dysregulation of the actin cytoskeleton in patient cells, caused by the mutant WASp 
expression, lead to severe neutropaenia and monocytopaenia, a lack of immune cell 
function, increased apoptosis and genomic instabilities including polyploidy. In HT1080 
cells expression of mutant WASp lead to death of transduced cells, actin dysregulation, 
increased apoptosis and defects in cytokinesis, leading to polyploidy, mimicking the 
patient symptoms. Interestingly there was some death associated with high level 
expression of wild-type WASp in HT1080 fibroblasts (Chapter 6) but was not
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reproducible. Furthermore it was not seen when a SFFV promoter was used. This is 
thought to be due to lower levels of protein expression. Further work is needed to fully 
elucidate the mechanism through which the mutant WASp exerts its cellular effects and 
the effects of protein concentration. Removal of the VC A domain and with it the actin 
polymerisation domain abrogated the toxicity of the I294T mutant WASp. This may not 
be the best control however as removal of the entire domain also would affect the 
folding of the protein and therefore the auto inhibition. An improved method for 
removal of the actin polymerization ability could be through the mutation of amino acid 
470 in WASp. It has been shown that the point mutation of L470A abrogates actin 
polymerisation ability by not allowing the ARP2/3 complex to undergo a 
conformational change upon binding to WASp (Goley et al., 2004; Rodal et al., 2005). 
WASp folding should still be normal with this mutation therefore showing if the I294T 
mutant exerts all its effects through excess actin polymerisation, in addition to 
determining whether possible toxicity due to overexpression of wild-type WASp is also 
due to excess actin polymerisation.
As WASp is haematopoietic restricted, repetition of the I294T WASp experiments on a 
haematopoietic cell line e.g. U937 or Jurkats, would be useful to see if the same effects 
would be observed. In addition primary cells such as CD34 stem cells could be 
transduced and the effects on cell division, apoptosis and genomic stability measured. It 
would be predicted to exert the same cytokinesis defects in haematopoietic cells. It has 
been shown WIP is tightly involved in the regulation of WASp expression (Ramesh et 
al., 1997; Stewart et al., 1999; Luthi et al., 2003), preventing degradation of WASp by 
calpain (Shcherbina et al., 2001) thereby controlling the cellular level of WASp. This 
may prevent over expression in haematopoietic cells negating the effect of the auto­
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active WASp. The interaction of the mutant WASp with cellular binding partners also 
needs to be investigated, especially Cdc42 as there has been some recent data on levels 
of Cdc42 during cytokinesis and the effects of increasing or reducing the levels during 
cytokinesis (Oceguera-Yanez et al., 2005). The sensitivity of cells to WASp expression 
levels is interesting as it may be pertinent to gene therapy protocols. High level 
expression may not be the most efficacious in the long term, further increasing the 
potential of endogenous promoter sequences which may give a more normal protein 
expression level.
Further investigation into mutant WASp could be performed in vivo. This includes 
transducing lineage negative stem cells and infusing into lethally irradiated recipients in 
a manner similar to the gene therapy protocol described in Chapter 6. Pressure upon 
transduced cells to divide to repopulate the murine haematopoietic compartment may 
lead to genomic instabilities, seen in the patient. Alternatively the transduced cells may 
disappear altogether due to toxicity, as seen in the HT1080 fibroblasts. Generation of a 
knock in mutant model where I294T WASp is expressed in the place of wild-type may 
also further elucidate the effects of the mutant upon cell division and its subsequent 
immunological phenotype.
The future prospects for retroviral gene therapy look bright. However there are some 
areas where improvements need to be made and are currently being investigated.
Improved vector design is one such area. SIN vectors for retroviral vectors are most 
likely to be developed for clinical use before the use of lentiviral vectors. They are 
thought to be safer due to the loss of enhancer activity, although full length genomic
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transcipts are detectable (Logan et al., 2004a), and may also reduce silencing (reviewed 
in (Ellis, 2005). Silencing of integrated virions occurs in both retrovirally and 
lentivirally transduced cells leading to increased copy number to gain sufficient cellular 
expression levels and with it an increased risk of insertional mutagenesis based upon a 
multiple hit theory. Use of c/s-elements such as locus control regions (LCRs), chromatin 
insulators and scaffold/matrix attachment regions (SMARs) are being investigated for 
their ability to reduce silencing. LCRs upstream of the B-globin cluster have been used 
in vitro (Lotti et al., 2002) and in vivo (May et al., 2002), in lentiviral vectors, to show 
antisilencing effects. Insulators protect gene expression from neighbouring enhancers or 
silencers (reviewed in (Burgess-Beusse et al., 2002) thus preventing positional effects of 
the integrated virion. S/MARs are mammalian origins of replication that also have some 
insulating activity (reviewed in (Conese et al., 2004). They have been used successfully, 
in a nonviral setting, to enhance persistence of gene expression over long periods of 
time (Ehrhardt et al., 2003) by replicating when there is cell division. Incorporation of 
these elements into lentiviral vectors, including non-integrating lentiviral vectors, 
already shown to allow long-term expression in non-dividing tissues (Yanez-Munoz et 
al., 2006) may improve expression from low integrated copies of virus and non­
integrated virus thus reducing the chance of insertional mutagenesis.
Improvements in the purification and time to transduce stem cells, and the mechanisms 
behind successful bone marrow repopulation may also improve and increase the safety 
of gene therapy protocols as fewer cells may be needed to be transduced and infused 
into the recipients.
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In conclusion, Wiskott-Aldrich syndrome is a good candidate for correction by gene 
therapy, but further investigation into the possible detrimental effects of high level 
expression is needed. In addition lentiviral vectors have been shown to be excellent 
gene delivery vehicles and should be considered for future clinical trials in place of 
oncoretroviral vectors. Their capacity to include complex regulatory elements and 
internal promoters, possibly endogenous, should allow tighter regulation of expression 
thus improving the safety concerns following mutagenic events with existing 
oncoretroviral trials.
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Appendix
Amp
FL3/41.5RI:0.5:RIWASp
4748 bp
Sac II
Pst I
WASP
\
Hind III
Eco RV
Eco R I
PolvA
Pst I 
E c o r i
Appendix 1 FL3/41.5RI:0.5RI. Plasmid containing WASp cDNA. 
(gift from J.Derry)
EGFP
CMV
Kanamycin(R)
pEGFP-C2
4735 bp
I
Bam h i
Appendix 2 pEGFP-C2 (Clontech)
Appendix
pBluescript SK (+)
2958 bp
Hid III
EcoRl
BarrHl
pEGFP-C2-WASPmcs
6483 bp
Kanamycim
SV40 ori
A D D endix  4  nBluescrint
I 
I 
I
ColEl origin
Ncol
Ncol
CMV nromoter
Nhel
Ncol
EGFP
Smnl
WASP
Xhol
Sma I
SV40 DolvrA^
Hincll
Sac I 
SacI 
PolyA Signal 1
EcoRl
BanHl
Appendix 3 pEGFP-WASp-C2 Xbal
fl origin
Ampicillin
beta-Galactosidase
Xhol
Hinc II
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Beta-Lactamase
Pst I —
EBV EBNA-1
Cla I
PINCO
12886 bp
5’ LTR
PSI packaging signal
“ I 
Pst I 
gag MLVMO 
MLVMO
R n r ^ i  I
ECO RI
promoter
Hudin
F.CtFP
3’ LTR
POK1
Po/ I
Puromycin 
Puromvcin N-Acetvltransferase
Appendix 5 PINCO-EGFP retroviral construct
Beta-Lactamase 5* LTR
gag MLVMO
EBV ORI P pol MLVMO
hCMV promoter
Hind III
EGFPPINCO-EGFP-WASP
14524 bp
EBV EBNA- WASp
Xho I
Not I
PGK1 3 'LTR
Puromycin N-Acetyltransferase 
Puromycin
Appendix 6 PINCO-EGFP-WASp retroviral construct
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T73~ 
WPRE
Cld
EGFP
K n d
HIV-1 3’ del U3 LTR
ampicillin (R)
cPPT
p’HRsincpptCEW
9662 bp
HIV-1 5’ LTR
rep on
SV40 promoter-enhancer
gpt (OFR-frame shift)
Appendix 7 CMV EGFP WPRE Lentiviral construct
Cla I
WPRE
EGFP
Bamm
3’ SFFV LTR
EcoRl
cPPT
HIV-1 3’ del U3 LTR
ampicillin (R)
p’HRsincpptSEW
9662 bp
rep on
HIV-1 5’ LTR
<
* SV40 promoter-enhancer
2 Dt (OFR-frame shift)
Appendix 8 SFFV EGFP WPRE lentiviral construct
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Hin dm WPRE 
Eco RI \
Eco R I 
WASP 
EGFP
Kpn I 
LTR-HIVdelU3
Hid III
r —RI
Hin dill oHR'SINcnot CEWW
11369 bp
Hin dUI
cPPT
Hin dill
ampicillin (R)
ren on
^ ^ S V 4 0  promoter-enhancer 
Hin dill 
gpt (OFR-frame shift)
Hin dill
HIV-1 5’ LTR
Appendix 9 CMV EGFP-WASp WPRE lentiviral construct
Hin dill WPRE 
Eco RI \ Kpn I
£coRI LTR-HIVdelU3
WASP 
EGFP
Hidlll
SFFV LTR
EcoRl
Hin dill
Hin dill
cPPT
Hin dill
ampicillin (R)
pHR'SINcppt SEWW
11369 bp
ren on
'^ ^ S V 4 0  promoter-enhancer 
Hin dill 
gpt (OFR-frame shift)
Hin dill
HIV-1 5’ LTR
Appendix 10 SFFV EGFP-WASp WPRE lentiviral construct
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EcoRl
gaattcaattcgggattacaggtgtgagctattgtccccagccaaaaggaaaagttttactgtagtaacccttccggact
agggacctcgggcctcagcctcaggctacctaggtgctttagaaaggaggccacccaggcccatgactactccttgc
cacagggagccctgcacacagatgtgctaagctctcgctgccagccagagggaggaggtctgagccagtcagaag
gagatgggccccagagagtaagaaagggggaggaggacccaagctgatccaaaaggtgggtctaagcagtcaag
tggaggagggttccaatctgatggcggagggcccaagctcagcctaacgaggaggccaggcccaccaaggggcc
cctggaggacttgtttcccttgtcccttgtggttttttgcatttcct^tecctt^ctgctcattgcggaagttcctcttcttacc
ctgcacccagagcctcgccagagaagacaagggcagaaagggatcc
Appendix 11 Sequence of PCR product for 500bp wiskott promoter.
Bam h i  
WASp promoter
Eco RI 
Hin dm
cPPT
Hin dill
dill
Hin dill
EGFP
Kpn I
LTR-HIVdelU3
Hin dill
pHR’SINcppt-WpE 
9064 bn
ampicillin (R)
HindlU
LTR HIV-1
rep
f ... SV40 promoter-enhancer
\  Hi dill
gpt (OFR-frame
Appendix 12 Wp-EGFP lentiviral construct
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Hirdm
EcoRl
WASP
F™RT
BanH I
WASd Dromoter
Eco RI
Hin dill
cPPT
Hin dill
Hin dill
:pnl
LTR-HIVdelU3
H i n d  I I I
pHR’SINcppt-WpW
9896 bp
Hin dill
LTR HIV-1
\ ampicillin (R)
rep
^  SV40 promoter-enhancer
Hin dill 
gpt (OFR-frame shift)
Appendix 13 Wp-WASp lentiviral construct
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